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General Remarks on Experimental Data 
 





C NMR spectra were recorded at 400 MHz on a Bruker AV 400 
instrument at 298K unless otherwise stated. Chemical shifts () are reported in parts per 
million from low to high field and referenced to residual solvent. Coupling constants (J) are 
reported in hertz (Hz). Standard abbreviations indicating multiplicity are used as follows: b = 
broad, s = singlet, d = doublet, dd= doublet of doublet, t = triplet, q = quartet, m = multiplet, J 
= coupling constant). Flash column chromatography was carried out using Kiesegel C60 
(Fisher Scientific) as the stationary phase. Analytical TLC was performed on aluminium-
backed sheets pre-coated with silica 60 F254 adsorbent (0.25 mm thick, Merck, Germany) 
and visualized under UV light. Mass spectrometry was carried out by the mass spectrometry 
services at the University of Edinburgh and at the EPSRC National Centre, Swansea. Size 
exclusion chromatography was performed using Toyopearl HW-405 (Tosoh, Japan) with 
methanol/chloroform in a 1:1 v/v ratio as the eluent. Unless otherwise stated, all reactions 
were run under an atmosphere of N2. Prior to use, isophthaloyl dichloride was purified by 
recrystallization from hexane; p-xylylenediamine was purified by distillation under reduced 
pressure. Analytical RP-HPLC was carried out on a Gilson instrument composed of 306 
pumps, 811C dynamic mixer (100 µL), 806 manometric module and an Applied Biosciences 
759A UV detector with a Phenomenex C18 (2) Luna column (2 x 250 mm, 5 µm, 100A). 
Preparative RP-HPLC was carried out on a Gilson instrument composed of 306 pumps, 811C 
dynamic mixer (1.5 ml), 806 manometric module and a 118 UV detector with a Spherisorb 
ODS2 column (21.2 x 250 mm, 5 µm, 100A). LCMS was carried out on a Finnigan Mat 
system composed of an LCQ mass spectrometer, P4000 pumps, and a UV2000 UV detector 
with a Phenomenex C18 (2) Luna column (2 x 250 mm, 5µ, 100A). Chromatograms were 





Layout of this Thesis 
 
During this thesis we tried to design, synthesise and analyse some novel devices for the 
selective delivery of peptides. These systems are based on the enzyme-activated anticancer 
prodrugs developed by Prof. Gesson in Poitiers and the peptide rotaxanes developed by Prof. 
Leigh in Edinburgh. The innovative rotaxanes we constructed are devised to protect and 
selectively release a peptide in response to an enzyme-specific stimulus for the targeted 
therapy of cancer. In Chapter 1 we tried to expose the main synthetic strategies aimed at 
improving the stability and permeation features of biologically active peptides. We examined 
some prodrug approaches and particularly the tumour-activated prodrugs (TAPs), largely 
investigated for use in anticancer chemotherapy. TAPs are generally three-part molecules 
composed of trigger, spacer and effector units. We also presented the original methodology 
developed by Prof. Leigh, namely the hydrogen bond-directed assembly of peptide rotaxanes, 
to protect a peptide thread from external environment. Finally we presented our project which 
consists of a combination of the peptide prodrug and rotaxane approaches. Therefore, based 
on the knowledge of both research groups we tried in Chapter 2 to develop some model 
systems in order to study the influence of the rotaxane architecture upon prodrug molecules. 
The first step towards such rotaxane-based peptide prodrugs relied on the efficient design of a 
spacer which has to be bulky enough to work as a stopper for the macrocycle. Much of the 
work presented in this chapter is based on the design and synthesis of such self-immolative 
units. We then explored the response of our model rotaxanes under the action of the activating 
enzyme. After this detailed study, in Chapter 3 we applied our concept to the biologically 
active peptide Met-enkephalin. In this chapter we presented a comparison between a rotaxane 
prodrug of Met-enkephalin and its non-interlocked derivative. Thus both compounds were 
successfully synthesised and evaluated to release the free peptide after enzymatic activation. 
The protective effect of encapsulating the peptide within a rotaxane assembly was also studied 
in human plasma and with different proteases. Finally, in Chapter 4, we introduced the 
construction of a rotaxane-based molecular machine programmed to synthesise a short peptide 
unit from the amino acids carried on its thread. We synthesised with success a one-station 
model rotaxane to study the catalyst effect of the macrocycle. Unfortunately this model 
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Over the past few decades peptides and proteins have received considerable attention 
not only in terms of their chemistry but also for their roles in various biological processes and 
their potential use as tools to explore new prospects in chemotherapy. It is now possible that 
in the close future peptides and their derivatives will play a significant role in the field of 
medicinal chemistry. Nevertheless to reach this point, extended bioavailability strategies and 
site-selective delivery methods constitute a fundamental prerequisite. Indeed, while a few are 
already approved for medical use, peptide drugs have been applied in a very limited extent 
since they are highly unstable via oral administration and are mainly unable to cross the cell 
layers. As a result most of these therapeutics are currently administered by the parenteral 
route (intravenous or subcutaneous), which represents obvious drawbacks considering patient 
acceptability and compliance in the course of long-term treatments. Moreover parenteral 
formulations are still not efficient enough to assure the peptide a prolonged time of action. 
Therefore the design of oral delivery strategies represents a major challenge for peptide-based 
therapy. Modern techniques using special formulation, encapsulation, conjugation and other 
delivery devices offer promising outlooks but are still at a development stage. The 
incorporation of unnatural amino acids, the introduction of totally modified subunits, the 
derivatisation into cyclic structures and other chemical alterations of the original bioactive 
peptide represent some of the most advanced synthetic techniques towards the improvement 
of peptide pharmacological applications. Thus this peptidomimetic approach currently 
appears as one of the most encouraging strategies but requires a significant knowledge to 
rationally manipulate the peptide architecture without losing its unique activity corresponding 
to a unique conformation. Alternatively, another ongoing approach that does not alter the 
peptide structure is to temporary derivatise it into a biologically inactive prodrug, which after 
a selective activation would release the parent peptide.  
 
In this chapter we will try to review some of the different chemical strategies aimed at 
improving peptide delivery focusing mainly on the area of anticancer chemotherapy and 
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Conventional cancer chemotherapy has historically been developed by delivering 
small molecules to target and damage malignant DNA replication. Until the twentieth century 
and the beginning of modern science and medicine, most therapeutics was provided by plants 
and minerals. The use of natural products to fight disease and particularly cancer, which is far 
from being a modern age disease, has a rich ancient history.
1
 However the rise of modern 
organic chemistry and the still-increasing knowledge of malignant growth enabled the first 
efforts towards the design and synthesis of new highly potent anticancer drugs.
2
 In fact, most 
of the current pharmaceuticals are directly inspired from naturally occurring structures, nature 




The modern era of cancer chemotherapy started serendipitously by the discovery of the 
potential antitumour effects of mustard gas, a chemical warfare used during World War I. The 
successive endeavour to design more active compounds led to the development of the “first” 
anticancer chemicals: mustine 1.1 (a.k.a. mechlorethamine) and other nitrogen mustard 
derivatives (Scheme 1.1).
6
 This marked the beginning of contemporary chemotherapy and 
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1946: mechlorethamine
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Still in clinical use today
Chlorambucil
Aromatic mustards are less electrophilic 
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Can be administered orally
Melphalan
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selectively absorbed by 
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A prodrug of nitrogen mustard
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Scheme 1.1 | Nitrogen mustards: drug design and targeted strategy. (Adapted from ref. 2) 
 
                                                 
1
 Heller, J. R. Bull. N. Y. Acad. Med. 1962, 38, 348-359. 
2
 Neidle, S.; Thurston, D. E. Nature Rev. Cancer 2005, 5, 285-296.  
3
 Clardy, J.; Walsh, C. Nature 2004, 432, 829-837. 
4
 Mann, J. Nature Rev. Cancer 2002, 2, 143-148. 
5
 Itokawa, H.; Morris-Natschke, S. L.; Akiyama, T.; Lee, K.-H. J. Nat. Med. 2008, 62, 263-280. 
6
 Gilman, A.; Philips, F. S. Science 1946, 103, 409-436. 
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To date DNA alkylating agents, antimetabolites, tubulin-binding drugs and topoisomerase 

































































Figure 1.1 | Examples of current anticancer drugs 
 
Despite the great advances achieved during the last decades and the wide chemical arsenal 
available for the treatment of cancer, the main drawback still remains the lack of selectivity of 
anticancer chemotherapy. Indeed, being incapable of differentiating rapidly dividing healthy 
cells from tumour cells, most of the current antiproliferative drugs frequently induce side 
effects. As a result, the amount of drug that can be administered is usually insufficient to 
deliver a lethal concentration at the tumour site and hence, in most of the cases, only allows 
the prevention of its growth. Another dramatic consequence is the emergence of cancer 
resistance to chemotherapy.
8
 Combination of anticancer agents without overlapping toxicity is 
currently used to overcome and bias such behaviour. An understanding of the biochemistry of 







                                                 
7
 Médicaments antitumoraux et perspective dans le traitement des cancers, in Traité de chimie thérapeutique, 
Volume 6, Edition TEC and DOC, Edition Médicales Internationales, 2003. 
8
 Kruh, G. D. Oncogene 2003, 22, 7262-7264. 
9
 Fojo, T.; Bates, S. Oncogene 2003, 22, 7512-7523.  
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In the early twentieth century the revolutionary “magic bullet” concept introduced by the 
pioneering work of Ehrlich, the father of chemotherapy, highlighted the potential of targeted 
toxicity which would allow the lethal delivery of cytotoxic agents within malignant cells.
10
 
Since then, the design of drugs and prodrugs directed towards specific toxicity expanded by 
progressively understanding the unique features of cancer cells (e.g. tumour hypoxia, tumour 





Molecularly targeted therapy, the new generation of anticancer drugs designed to interact with 
tumour specific hallmarks, offers the prospect of differentiating healthy cells from malignant 
cells and therefore to conquer cancer.
12
 Even though new biological targets are still being 
discovered (e.g. mutant kinases, the tumour micro-environment, cancer stem cells, 
telomerases, HDACs)
13
 there is still a need to identify/create smart drugs acting only at 
tumour sites and to develop effective tumour-activated prodrugs, making the visionary “magic 




Cancer development is clearly associated with genetic alterations and instability: proto-
oncogenes, tumour suppressor and DNA damage repair genes have all been associated with 
most human malignancies. The resulting mutated genes induce continuous proliferation, 
usually considered as a kind of cellular immortality. Furthermore, regulatory proteins are also 
affected, thus being incapable of restoring or killing the expressed malignant proteins. Cancer 
is consequently a strongly developed and complex disease involving defensive as well as 
aggressive biological tools to overcome cellular processes and death (e.g. autoemission of 
growth signals, induction of angiogenesis, extended proliferation, resistance to inhibiting 






                                                 
10
 Stern, F. Angew. Chem. Int. Ed. 2004, 43, 4254-4261.  
11
 Denny, W. A. Eur. J. Med. Chem. 2001, 36, 577-595. 
12
 Vamus, H. Science 2006, 312, 1162-1165. 
13
 Sawyers, C. Nature 2004, 432, 294-297. 
14
 Strebhardt, K.; Ullrich, A. Nature Rev. Cancer 2008, 8, 473-480. 
15
 Hanahan, D.; Weinberg, R. A. Cell 2000, 100, 57-70. 
CHAPT. 1 | STRATEGIES FOR PEPTIDE-BASED CHEMOTHERAPY 
6 
 
As a result mutated proteins represent serious targets for peptide-based therapy.
16
 Further 
determination of the critical interacting region may allow the development of effective small 
peptidic fragments to specifically restore the disrupted protein functions, offering the 
possibility to jam the mechanism of cancer survival without any DNA-based methods.
17
 
Indeed reconstitution, replacement or inhibition of disregulated proteins might be 
accomplished by specific transduction, thus delivering peptides to tumours may allow cell 
biology modulation at the protein level.  
 
By comparison with “small” molecules, peptide therapeutics have shown extremely limited 
clinical development because of their associated physiological drawbacks. Following even 
oral or parenteral administration, peptides have to overcome diverse physical and biochemical 
barriers. Typically, peptide oral bioavailability ranges from 1 to 2 % with in vivo half-lives 
inferior to 30 minutes.
18
 The main reasons for the low bioavailability of peptide drugs are 




However peptides have the great potential to be highly selective powerful drugs, thereby 
considerably decreasing the risks of systemic toxicity.
20
 Peptides with anticancer use or 
potential have recently been reviewed and classified according to their biological mechanism 
of action: enzyme inhibitors, protein-protein interaction inhibitors, receptor-interacting 
peptides and nucleic acid-interacting peptides.
21
 The wide diversity of peptides presented in 









                                                 
16
 Borghouts, C.; Kunz, C.; Groner, B. J. Peptide Sci. 2005, 11, 713-726. 
17
 Wadia, J. S.; Dowdy, S. F. Adv. Drug Deliv. Rev. 2005, 57, 579-596. 
18
 Lee, V. H. L.; Yamamoto, A. Adv. Drug Deliv. Rev. 1990, 4, 171-207. 
19
 Gangwar, S.; Pauletti, G. M.; Wang, B.; Siahaan, T.; Stella, V. J.; Borchardt, R. T. Drug Discovery Today 
1997, 2, 148-155. 
20
 Mendoza, F. J.; Espino, P. S.; Cann, K. L.; Bristow, N.; McCrea, K.; Los, M. Arch. Immunol. Ther. Exp. 2005, 
53, 47-60. 
21
 Janin, Y. L. Amino Acids 2003, 25, 1-40. 
22
 Kieber-Emmons, T.; Murali, R.; Greene, M. Curr. Opinion Biotech. 1997, 8, 435-441. 
23
 Meloen, R.; Timmerman, P.; Langedijk, H. Molecular Diversity 2004, 0, 1-3. 
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I. Strategies to enhance peptide delivery 
 
”the less peptide character in a drug candidate, the more stable it is likely to be towards 
protease cleavage” [Borchardt, R. T. et al. Adv. Drug Deliv. Rev. 1997, 27, 235-256.] 
 
As briefly mentioned, peptide drugs need to overcome several barriers before properly 
reaching their target. Rapid degradation by proteases and low membrane permeability are 
essentially the main drawbacks restricting the direct pharmacological use of native peptides. 
Considering the extraordinary potential of this class of natural molecules, a great amount of 
research has been developed in order to enhance peptide stability and permeation. The 
knowledge acquired over the years now allows the design of new peptide-like candidates and 
other delivery systems to be constructed to overcome the challenge of peptide oral 
bioavailability. These strategies can be classified into three general categories: 
peptidomimetics, cyclic peptides and prodrugs.  
 
The purpose of these strategies is to protect the peptidic bond from enzymatic cleavage in 
order to enhance its biological stability. From a mechanistic point of view, the enzymatic 















































tetrahedral intermediate  
 
Scheme 1.2 | Schematic protease catalytic mechanism 
 
Manifold modified peptides have been prepared in order to access enhanced biostability, 
preventing the protease recognition process. Structural alterations are also well recognised to 
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generate the fundamental changes in peptide conformation responsible for improved 
penetration and stability.
24
 Amongst the best examples are cyclic peptides which exhibit 




Nowadays, the conception and synthesis of peptidomimetics have attracted major 
attention and the term “peptidomimetics” itself is often associated with confusion since 
extensive works has been carried out in this subject area. Peptidomimetics are “nonpeptidic” 
compounds designed to translate the functional and topographical information carried by 
bioactive peptides into small biologically stable organic molecules. A scheme has even been 
published classifying peptidomimetics in three different categories: peptide backbone 
mimetics (type I), functional mimetics (type II) and topographical mimetics (type III).
25
 
Curiously, type I peptidomimetics are slightly modified peptide derivatives while for 
mimetics of type II and III, the peptide structure is hardly recognisable.  
 
Globally, the successful design of all three types of peptidomimetics closely depends on the 
careful appreciation of the essential requirements needed to maintain the biological activity of 
the parent peptide. Furthermore the structural knowledge of the peptide target (i.e. a receptor 
or an enzyme) is also of fundamental importance. As a consequence, modern techniques such 
as Structure-Activity Relationship (SAR), combinatorial chemistry, NMR, X-Ray 
crystallography and computational modelling are commonly used to rationally assist the 
conception of peptidomimetics.
26
 Accordingly, the artificial peptide should present a superior 
biological index, demonstrating either agonist or antagonist activity. 
 
I.1.1. Backbone modification 
 
From the straightforward protease mechanism depicted in Scheme 1.2, it can be 
expected that chemical modifications of the amide linkage or near to the peptidic bond such as 
Cα-alkylation, N-alkylation (peptoids), or use of D-amino acids may hinder enzymatic 
hydrolysis (Scheme 1.3).   
                                                 
24
 Pauletti, G. M.; Gangwar, S.; Siahaan, T. J.; Aubé, J.; Borchardt, R. T. Adv. Drug Deliv. Rev. 1997, 27, 235-
256. 
25
 Ripka, A. S.; Rich, D. H. Curr. Opin. Chem. Biol. 1998, 2, 441-452. 
26
 Gante, J. Angew. Chem. Int. Ed. 1994, 33, 1699-1720. 






































use of D-amino acid
 
 
Scheme 1.3 | Examples of investigated chemical peptide backbone modifications 
 
Modification of the amide bond has been extensively studied and a large number of surrogates 
are now reported: reduced amide bond, depsipeptide (ester linkage), hydroxyethylene, 











































Reduced amide bond Depsipeptide Hydroxyethylene
X = O: Phosphinate
X = CH2: Phosphonate































Figure 1.2 | Examples of investigated peptide bond surrogates 
 
For instance one of the most current and significantly studied alternatives is the use of 1,4-
substituted 1,2,3-triazoles as peptide bond mimetics. Indeed, these kinds of motifs are readily 
accessible via the powerful Copper-Catalyzed Azide-Alkyne Cycloadditions (CuCAAC), 
a.k.a. the Huisgen 1,3-dipolar cycloaddition updated by Meldal and Sharpless.
28,29
 1,2,3-
Triazoles are quite appealing for peptide chemists since their stereoelectronic similarity with 
amide bonds is quite remarkable (Scheme 1.4).  
                                                 
27
 Gautier, A.; Pitrat, D.; Hasserodt, J. Bioorg. Med. Chem. 2006, 14, 3835-3847. 
28
 Tornoe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem., 2002, 67, 3057-3064. 
29
 Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem. Int. Ed. 2002, 41, 2596-2599. 








































Scheme 1.4 | Peptidotriazoles as peptidomimetics (X-ray from ref. 30) 
 
As depicted in the excellent review by Angell and Burgess the reaction has been widely used 
not only to join peptide fragments together, thus forming acyclic or cyclic triazole-based 





I.1.2. Secondary structure mimetics 
 
Particular efforts have been undertaken to prevent the protease recognition process by 
controlling peptide conformation.
31
  Restricting peptides in one particular conformation might 
be more efficient than locally replacing a functional group, though this is not so simple since 
even modifying a single functional group may also result in a dramatic modification in 
regards to the peptide conformation. However the idea here is to closely imitate a desired 
conformation by introducing a synthetic module to achieve considerably reduced protease 
affinity as well as enhanced membrane permeation of a parent peptide. The incorporation of 
such modules (also called scaffolds or foldamers), special building blocks locally restricting 
peptide conformational freedom, has largely been explored however the list is too exhaustive 
to be discussed here.
32
 Not only do foldamers improve bioavailability by inducing significant 
changes in the peptide three-dimensional structure, they have also contributed to 
understanding and enhancing peptide selective binding to biological receptors. In this case the 
peptidomimetic is designed to retain the biologically-active conformation of a natural ligand 
or peptide inhibitor. 
 
                                                 
30
 Angell, Y. L.; Burgess, K. Chem. Soc. Rev. 2007, 36, 1674-1689. 
31
 Stigers, K. D.; Soth, M. J.; Nowick, J. S. Curr. Opin. Chem. Biol. 1999, 3, 714-723. 
32
 Hanessian, S.; McNaughton-Smith, G.; Lombart, H.-G.; Lubell, W. D. Tetrahedron 1997, 53, 12789-12854. 
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Among the various conformational features displayed by peptides and proteins, β−turns are 
certainly one of the most biologically-relevant structural motifs found in these therapeutic 
derivatives. Consequently the development of β−turn rigid scaffolds has been widely 


















































Figure 1.3 | Examples of β−turn mimetics 
 
I.1.3. Functional and topographical peptidomimetics 
 
Type II peptidomimetics are rationally designed to precisely adjust the essential 
peptide side chains responsible for biological activity into a rigid scaffold. These unnatural 
frameworks present interesting oral bioavailabilities since most of the original peptide bonds 
are depleted in the final architecture. For instance the RGD motif has been converted into the 































Scheme 1.5 | A RGD peptidomimetic 
 
                                                 
33
 Sewald, N.; Jakubke, H.-D. Peptides: Chemistry and Biology, Wiley-VCH, 2002. 
34
 Alig, L.; Edenhofer, A.; Hadvary, P.; Huerzeler, M.; Knopp, D.; Mueller, M.; Steiner, B.; Trzeciak, A.; 
Weller, T. J. Med. Chem. 1992, 35, 4393-4407. 
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The use of a rigid backbone is generally warranted to prevent the hydrophobic collapse effect. 
This effect refers to the conformational change observed when organic molecules containing 
hydrophobic groups enter an aqueous environment. In fact, within unrestricted molecular 
structures those functionalities tend to associate due to intramolecular hydrophobic interaction 
and finally form biologically inactive conformations.  
 
Topographical mimetics can be regarded as the perfect peptidomimetics. These compounds 
have clearly no obvious relationship with the corresponding natural peptide ligand and are 
rationally designed (or the result of large screening methods) to perfectly fit a target protein 
binding domain. The term limetics (a contraction of ligand mimetic)
35
 was also coined to 
characterise this type of molecules as the only common thing they share with the parent 
peptide is their common target. As a result topographical peptidomimetics possess the 
necessary pharmacophoric elements flanked in a rigid backbone that perfectly directs the 
orientation of these biologically relevant elements.  
 
Morphine 1.3 is, unknowingly, a famous type III peptidomimetic (Figure 1.4). Indeed this 
non-peptidic molecule was found to agonise the effect of the endogenous β−endorphin 
peptide on opioid receptors. Tifluadom 1.4 is also a selective agonist of opioid receptor which 
















Figure 1.4 | Non-peptide mimetics 
 
This approach has been used, for instance, to prepare mimetics of inhibitors of the angiotensin 
converting enzyme (ACE), a zinc metalloprotease (Scheme 1.6). Starting from the 
nonapeptide teprotide, a natural inhibitor of ACE isolated from snake venoms, it was first 
observed that the C-terminal fragment Ala-Pro 1.5 already inhibited ACE, albeit weakly.  
                                                 
35
 Veber, D. F. In Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium; 
Smith, J. A.; Rivier, J. E., Eds.; Escom: Leiden, 1992, 3-14. 
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This dipeptide was then transformed to α-methylsuccinylproline 1.6, the carboxyl group 
being expected to coordinate the Zn ion. Satisfied in that reasoning, the carboxyl group was 
finally replaced by the more effective Zn-ligating thiol function to lead the first rationally 
developed inhibitor of ACE, captopril 1.7, currently used to treat hypertension.
36
 This was 





















Scheme 1.6 | Development of ACE inhibitors 
 
I.2. Cyclic peptides  
 
Cyclic peptides are covalently constrained peptides. Demonstrating increased stability, 
enhanced bioavailability and receptor selectivity, cyclopeptides have become increasingly 
important towards the development of peptide-based drugs. This growing interest is further 
explained by the high potential exhibited by a large variety of cyclic peptides. For instance, 


















































Figure 1.5 | Examples of biologically relevant cyclic tetrapeptides 
                                                 
36
 Ondetti, M. A.; Rubin, B.; Cushman, D. W. Science 1977, 196, 441-444. 
37
 Turbanti, L.; Cerbai, G.; Di Bugno, C.; Giorgi, R.; Garzelli, G.; Criscuoli, M.; Renzetti, A. R.; Subissi, A.; 
Bramante, G.; DePriest, S. A. J. Med. Chem. 1993, 36, 699-707. 
38
 Katsara, M.; Tselios, T.; Deraos, G.; Matsoukas, M.-T.; Lazoura, E.; Matsoukas, J.; Apostolopoulos, V. Curr. 
Med. Chem. 2006, 13, 2221-2232. 
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Strained peptides and particularly cyclic analogues have been shown to present enhanced 
bioavailability due to a reduced hydrophilic nature, hence being more easily absorbed via the 
transcellular pathway. In agreement with the fact that the cell membrane consists of a 
complex lipid bilayer matrix, hydrophobicity has been traditionally accepted as the most 
important requirement for peptide absorption. However, it has been demonstrated that a 
compromise needs to be found for optimal transcellular internalization. Schematically in the 
transcellular route, peptides have to pass from an aqueous media to a hydrophobic 
environment, the energetic barrier to this diffusion process being the desolvatation energy. 
Cyclic peptides have a decreased hydrogen bonding capacity as a result of intramolecular 
hydrogen bond formation, therefore energy transfer is less expensive and internalisation 
favoured.  
 
Nevertheles cyclic peptides are not totally conformationally locked but take the best structure 
to accord with their surroundings, and the notion of “membrane-induced conformational 














Scheme 1.7 | Schematic representation of conformational basis of membrane  
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I.3. The prodrug approach  
 
As first defined by Albert in 1958, prodrugs are therapeutic agents which are inactive 
per se but are transformed into one or more active metabolites in vivo.
40
 As outlined here, the 
aim of a prodrug strategy is to modify drugs into inactive derivatives showing enhanced 
pharmaceutical and pharmacokinetic (the ADME profile: Absorption, Distribution, 
Metabolism, Elimination) releasing the active parent species after enzymatic or chemical 
activation.
41
 Thus prodrug derivatisation provides a solution to the many drawbacks 
associated with drug formulation and delivery (e.g. poor aqueous solubility, chemical 
instability, oral absorption, pre-systemic metabolism, toxicity…) but one of the most 
appealing aspects of prodrugs is that they could make the ultimate targeted delivery possible, 












enzymatic / chemical transformation
any limitations of a parent drug (aqueous solubility, chemical instability,
oral absorption, pre-systemic metabolism, toxicity...)
 
 
Scheme 1.8 | Illustration of the prodrug concept 
 
Indeed, with regards to anticancer chemotherapy, prodrugs have been widely investigated to 
overcome these barriers and to target therapy, leading to the so-called Tumour-Activated 
Prodrugs (TAPs) (see Chapter II).  
 
                                                 
40
 Albert, A. Nature 1958, 182, 421-423. 
41
 Testa, B. Biochem. Pharma. 2004, 68, 2097-2106. 
42
 Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Nature Rev. Drug 
Disc. 2008, 7, 255-270. 
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The field of prodrugs in chemotherapy is quite vast so we will discuss only the appropriate 
area of prodrugs of peptides.  
 
I.3.1. Prodrugs to improve bioavailability 
 
With regards to peptide therapeutics, various prodrug approaches have been 
considered to improve formulation and delivery.
43
 Masking N-positive and/or C-negative 
terminal charges of peptide backbone is for instance commonly explored to reduce 
susceptibility to exopeptidases and improve permeability properties.  
 
Indeed Borchardt et al. investigated aminopeptidase resistant peptides using bioreversible 
linkages: N-termini were attached to an auto-immolable spacer moiety which can be activated 








































Scheme 1.9 | Biocleavable aminopeptidase resistant peptides 
 
Following the initial enzymatic activation, the fast hydroxy amide lactonisation primed by the 
unmasked phenol allow the release of the parent amine. It is worth mentioning that this 
cyclisation step is facilitated by the presence of a conformational “trimethyl lock”.  
 
                                                 
43
 Oliyai, R. Adv. Drug Deliv. Rev. 1996, 19, 275-286. 
44
 Amsberry, K. L.; Borchardt, R. T. Pharm. Res. 1991, 8, 323-330. 
45
 Amsberry, K. L.; Gerstenberger, E.; Borchardt, R. T. Pharm. Res. 1991, 8, 455-461. 
46
 Nicolaou, M. G.; Yuan, C.-S.; Borchardt, R. T. J. Org. Chem. 1996, 61, 8636-8641. 
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Later on, this two-step process has successfully been used to prepare a prodrug of the 
pentapeptide Leu-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH). The self-immolative prodrug 
system was able to release the peptide in presence of Pig Liver Esterase, however permeation 
across Caco 2 cells was not improved and the prodrug was shown to have as poor stability as 
Leu-enkephalin itself in cell culture models. An enhanced susceptibility to endopeptidase 
activity was invoked to explain this limited bioavailability. 
 
Bundgaardt and Rasmussen also constructed aminopeptidase resistant enkephalin prodrugs by 
condensing their N-terminal part with aldehydes and ketones, leading to a series of 4-
imidazolidinones (Scheme 1.10). This derivatisation was effective in improving the metabolic 
stability of enkephalins. Furthermore the kinetics of the non-enzymatic hydrolysis, while 
being slow, could be controlled by tuning the carbonyl subsituents R1 and R2 to favour 























Scheme 1.10 | 4-imidazolidinone masked Met-enkephalin 
 
In the same way, Bundgaard and Rasmussen also reported the synthesis and evaluation of 
carboxypeptidase resistant peptides by forming N-α-hydroxyalkyl prodrug derivatives 
(Scheme 1.11).
48
 Prepared by hydrolysis or aminolysis of N-acyl-5-oxazolidinones, the 
prodrug was demonstrated to display a greater stability than the parent peptide against 
carboxypeptidase A, an enzyme hydrolysing the C-terminal amide of peptides. 
 
                                                 
47
 Rasmussen, G. J.; Bundgaard, H. Int. J. Pharm. 1991, 76, 113-122. 
48
 Bundgaard, H.; Rasmussen, G. J. Pharm. Res. 1991, 8, 313-322. 










































Scheme 1.11 | N-α-hydroxyalkyl peptide prodrugs 
 
The same strategy is applicable for the synthesis of endopeptidase (e.g. trypsin, chymotrypsin) 
resistant peptides by reversibly alkylating the susceptible endo peptide bond. However the 
poor stability of such derivatives led to the development of the more stable N-acyloxyalkyl 
derivative (Scheme 1.12).
49
 Unfortunately, this attempt was proved to be unfruitful as the 





















































Scheme 1.12 | N-acyloxyalkyl peptide prodrugs 
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Formation of ester derivatives (the most common prodrug approach) from residual peptide 
carboxylic acids, alcohols or phenols was also shown to benefit bioavailability due to 
increased lipophilicity, rapidly releasing the parent drug after enzymatic ester bond 
hydrolysis.
50
 For instance the pivaloyl ester of desmopressin 1.9, a synthetic analogue of 
vasopressin, demonstrated higher stability and transport across Caco-2 cells.
51
 Similarly, the 
Angiotensin Converting Enzyme inhibitor enalapril 1.10 is a commercially available prodrug 











































Figure 1.6 | Ester prodrugs of peptides 
 
I.3.2. Bioreversible cyclic peptides 
 
Reversible modifications of the peptide backbone are unambiguously one of the most 
interesting alternatives for improved peptide delivery. The more promising “bioreversible 
cyclic peptides” have harnessed considerable attention. As mentioned previously, cyclic 
peptides are good candidates for enhanced peptide delivery strategies and a prodrug approach 
restricting temporary a bioactive peptide into a cyclic conformation is obviously attractive. 
 
Within this framework Borchardt et al. developed an esterase-sensitive cyclic prodrug by 
linking both C- and N-terminal of the peptide to a spacer unit (Scheme 1.13). With this design 
the authors anticipated that enzymatic cleavage of the ester functional group followed by fast 
intramolecular cyclization should lead to the release of the parent peptide.  
 
                                                 
50
 Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. J. Med. Chem. 2004, 47, 2393-2404. 
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Scheme 1.13 | Bioreversible cyclic peptides 
 
Therefore Borchardt and co-workers constructed various types of esterase-sensitive spacers to 
study the cyclisation and release of linear bioactive peptides (Figure 1.7). As expected the 
prodrugs were found to be resistant to both amino- and carboxypeptidases. Furthermore, the 
cyclic structure conferred the peptide an enhanced hydrophobicity as a consequence of 


















Figure 1.7 | Examples of bioreversible cyclic peptides 
 
For instance, the phenylpropionic acid-based cyclic prodrug of the H-TrpAlaGlyGlyAspAla-
OH model peptide displayed an enhanced profile and in vitro studies demonstrated the great 
potential of such derivatisation. Indeed, transport experiments revealed that the cyclic prodrug 
is permeable across Caco-2 cells while the linear peptide is rapidly metabolised at the apical 





                                                 
52




prodrug Phenylpropionic acid-based 
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In the same manner a cyclic prodrug of the opiod peptide DADLE was constructed using a 
coumarinic spacer.
53
 Indeed the cis double bond of the coumarinic derivative also affords a 
favourable conformation lock for the lactonisation release mechanism. 
 
The concept of bioreversible cyclic peptides reinforces the idea that restricting peptide 
conformational freedom decreases the susceptibility to proteolytic degradation and more 
importantly increases the permeation potential due to reduced hydrogen bonding capacity to 




II. Tumour-activated prodrugs 
 
The concept behind such an approach is to selectively activate a non-toxic prodrug 
within the tumour, resulting in the site-controlled release of the parent drug and therefore 
limited systemic toxicity. Activation of those prodrugs can be achieved in multiple ways 
considering cancer hallmarks (e.g. pH differences, tumour hypoxia, selective enzyme 
expression, tumour-specific antigens).
55
 Therefore achieving an appropriate prodrug approach 
may allow the tumour-directed delivery of most anticancer drugs and consequently overcome 
systemic toxicity due to non-selective interactions. Accordingly, design of efficient selective 
drug delivery systems has an important initial requirement: the knowledge of the biochemical 
cancer hallmarks that can allow differentiation between malignant and healthy cells and in 
this way carry out the desired toxicity-selectivity. Thus the prodrug monotherapy (PMT) 
approach aims at selectively activating prodrugs of anticancer agents using the features 
particular to the tumours. Alternative strategies are the two-steps targeting approaches (the so-
called DEPT: Directed-Enzyme Prodrug Therapy) which involve the preliminary targeting of 
an enzyme to the tumour cells (see II.2.). 
 
Although the design of Tumour-Activated Prodrugs (TAPs) is slightly different from the 
classic prodrug molecules described previously, it schematically remains simple: the TAP is 
usually a three-part modular molecule comprising trigger, spacer and effector units (Scheme 
1.14).  
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Scheme 1.14 | General scheme for targeted prodrug design 
 
The trigger is designed to target cancer cells and to cause the prodrug activation. The drug is 
generally linked to the trigger through a spacer unit. In some cases TAPs can be simply two 
part trigger-drug conjugates however the size of the drug often restrict the recognition of the 
trigger motif. Accordingly a self-immolative spacer is introduced to simultaneously enhance 
trigger accessibility and reduce drug toxicity. Therefore the liberated spacer-drug intermediate 
undergoes further spontaneous degradation ideally liberating the parent drug at the initial site 
of activation. The choice of the self-immolative spacer is of fundamental importance and 




II.1. Prodrug monotherapy (PMT) 
 
 As already mentioned PMT aims at designing anticancer prodrugs that are directly 





Hypoxia is a unique physiological phenomenon observed in solid tumours due to their 
imperfect neovascularisation. Thus oxygen deficiency in solid tumours results in the enhanced 
activity of reducing enzymes, such as nitroreductase, which can be used for the selective 
activation of anticancer prodrugs.
58
 Nitroaromatics are generally the most representative 
examples of bioreductive prodrugs. For instance the nitrogen mustard prodrug 1.11 was 
shown to rapidly release the parent drug after action of nitroreductase (Scheme 1.15).
59
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Scheme 1.15 | Nitroreductase-activated prodrug 
 
Moreover the selective expression of receptors at the tumour surface also constitutes a way to 
selectively deliver antitumour agents.  Once identified, the ligand to these receptors can be 
attached to a cytotoxic agent to form a conjugate that would be targeted to the tumour. 
 
Finally some enzymes, such as β-glucuronidase, were found to be present in elevated level in 
and around tumour tissues.  
 
II.1.1. Glucuronylated prodrugs 
 
Since the last ten years glucuronylated prodrugs have been widely investigated for the 
selective chemotherapy of cancer. In fact Gesson et al. demonstrated that active β-
glucuronidase, an endogenous enzyme hydrolysing β-glucuronides, is liberated in necrotic 
areas surrounding tumours.
60
 On the other hand, in normal tissues this enzyme is exclusively 
located in lysosomes. 
 
Therefore the elevated tumour β-glucuronidase extracellular activity allowed its development 
in the PMT strategy. In this approach β-glucuronidase activates the glucuronylated prodrug 
into highly toxic agent specifically at the tumour site. More interestingly in normal tissues, the 
intracellular location of β-glucuronidase limits the risk of non-selective drug release since the 
highly hydrophilic nature of glucuronylated prodrugs reduces their ability to penetrate cells. 
 
                                                 
60
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Koch, M.; Monneret, C. Cancer Res. 1998, 58, 1195-1201. 
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To date numerous glucuronylated prodrugs have been constructed and evaluated to 
















































































SN-38 (camptothecin derivative) prodrug
Gadolinium contrast agent prodrug 
for detection of β-glucuronidase
 
 




Among the various glucuronylated prodrugs developed over the years, HMR 1826 is probably 




II.1.2. HMR 1826 
 
HMR 1826, a prodrug of doxorubicin developed within Gesson group, is based on the 
self-immolative benzyloxycarbonyl linker attached to the carbohydrate moiety. Following the 
action of β−glucuronidase the released nitrophenol undergoes a spontaneous 1,6-elimination 
to liberate a carbamic acid which spontaneously decarboxylate to yield the parent amine drug 
(Scheme 1.16).  
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Scheme 1.16 | HMR 1826, a glucuronylated prodrug of doxorubicin 
 
Due to its attractive self-immolative properties this elimination-based spacer is still widely 
used for the development of enzyme-responsive prodrugs. Indeed it was demonstrated for 
HMR 1826 that the quinone methide rearrangement of the o-nitrophenol intermediate is 
extremely fast (< 5 min.). A correlation was further established between the phenol’s pKa and 
the kinetics of liberation of the drug. While o-nitrophenol (pKa = 7.2) released the drug 





In vitro experiments established the excellent stability of HMR 1826 in various plasma (mice, 
rat and human) showing a maximum 20% degradation after 50 hours incubation at 37°C.
67
 In 
vivo studies demonstrated that the relatively non-toxic prodrug HMR 1826 is selectively 
activated in tumour necrotic areas due to the liberation of β-glucuronidase in disintegrating 
tumour tissues. Moreover, the excellent tolerance of HMR 1826 allows overcoming the 
problem of dose-limiting cardiac toxicity associated with doxorubicin. In fact in vivo studies 
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Comparison between doxorubicin and HMR 1826 in human lung tumours indicated the 
superior potential of the glucuronylated prodrug approach.
69
 Indeed after perfusion with HMR 
1826 the level of doxorubicin in tumour tissue was about 7-fold higher than after perfusion 
with doxorubicin alone. Moreover doxorubicin showed poor uptake difference between 
normal and tumour lung while co-administration of a specific β-glucuronidase inhibitor (D-
saccharolactone) with HMR 1826 resulted in no drug release. Further in vivo studies revealed 




Figure 1.9 | Comparison of Doxorubicin and HMR 1826 in MX1 breast tumour xenografts 
 
These results were attributed to the increased drug deposition and retention in the tumour 
connected with reduced concentration of the anticancer agent in normal tissues, considerably 
lowering the destruction of normal cells. 
 
II.2. Antibody-Directed Enzyme Prodrug Therapy (ADEPT) 
 
ADEPT is another alternative approach to the differentiation between healthy and 
neoplastic cells.
70
 This two-step drug delivery strategy consists of locating an enzyme at the 
tumour surface that would then activate a related prodrug. First of all an antibody-enzyme 
conjugate targeted against a specific cancer antigen is administered. After a period of time, 
once the level of discrimination is sufficiently significant and the unbound immunoconjugate 
                                                 
69
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removed from the blood circulation, the prodrug is injected and converted by the targeted 



















Scheme 1.17 | Schematic representation of ADEPT 
 
Proposed by Bagshawe in 1987,
71
 the strategy has known many improvements coming about 
with the advances in antibody technology. In the early stages, ADEPT demonstrated 
extraordinary experimental results, however the immune response generated by the murine 
antibody and the bacterial enzyme only allowed a single cycle of therapy.
72
 Progress in the 
preparation of humanised antibodies by recombinant DNA technology now allows the 
preparation of various fusion protein’s that do not present risks due to immune response, 
preserving the protein’s activity (i.e. binding and enzymatic activity). Since these significant 
efforts a multitude of antibody-enzyme/prodrug combination has demonstrated encouraging 
results in preclinical models of human cancers.
73
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For instance, the use of an mAb-β−glucuronidase fusion protein in combination with HMR 
1826 was the first example of the use of a human enzyme in ADEPT.
74,75
 In vivo experiments 
were conducted in nude mice with subcutaneous human colorectal carcinoma xenografts. 
HMR 1826 was injected one week after the administration of the glucuronidase 
immunoconjugate. Pharmacokinetic investigations revealed that the doxorubicin was 
distributed preferentially in intratumoral tissues than in normal tissues, this being a serious 
improvement in comparison with non-targeted doxorubicin.  
 
More recently, Kamal et al. prepared two galactosylated prodrugs of anticancer agents which 
were evaluated in the course of ADEPT and PMT model protocols.
76
 Indeed endogenous β-
galactosidase was demonstrated to be overexpressed in hepatocellular carcinoma cell line 
(Hep G2) thus allowing its use in PMT. Following in vitro studies, the prodrugs were found to 
be good substrates for E. coli β-galactosidase and significantly less toxic than the parent 
drugs. Indeed, the ADEPT and PMT type studies conducted on A375 cell line (presenting no 
β-galactosidase activity) and the Hep G2 cell line revealed an excellent activation factor 
QIC50 (IC50[prodrug]/IC50[prodrug+enzyme]) of the galactosylated prodrugs. Detailed in vivo 
investigations are ongoing. 
 
GDEPT (Gene-Directed Enzyme Prodrug Therapy), also called suicide gene therapy, is 
another valuable alternative to ADEPT.
77
 The only difference in this strategy is the way of 
localising non-endogenous enzymes to tumours. In GDEPT a gene is transfected specifically 
to tumour cells to express the expected enzyme inside the cell, contrary to ADEPT where the 
enzyme is extracellularly located. The difficulty of this approach results in the effective 
intracellular delivery of the gene. Many vectors are currently studied such as virus, bacteria, 
liposomes... which are also being investigated for the genetic therapy of cancer.
78
 The use of 
viruses as transfecting agents led to the Virus-Directed Enzyme Prodrug Therapy (VDEPT). 
In this case, a genetically modified virus (composed of a tissue-specific transcriptional 
regulatory sequence linked to a protein coding domain) is used to express a prodrug-
converting enzyme in infected cells. 
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II.3. Targeted delivery of peptides 
   
 To the best of our knowledge only two enigmatic examples of such an approach have 
been reported concerning peptides, based on the well-known glucuronylated prodrugs. 
Considering this promising approach, Zemlicka and co-workers developed in 2002 a 
glucuronylated prodrug of the Class I Major HistoCompatibility (MHC) peptide GILGFVFTL 
(Figure 1.10).
79
 Although the synthesis turned out to be more complicated than expected, the 









































Figure 1.10 | The first glucuronylated peptide prodrug 
 
Biological studies demonstrated that on the one hand the prodrug has no binding activity on 
T2 human cells defective in MHC I-associated peptide processing (inactivated T cells). On 
the other hand the addition of a large excess of β−glucuronidase resulted in an increased level 
of HLA-A2.1, demonstrating the release of the antigenic peptide and subsequent binding with 
HLA-A2.1 antigen. This example illustrated the validity of the prodrug approach which in this 
case is essential. Indeed systemic delivery of such antigenic peptides to mark tumour cells is 
absolutely inconceivable since such chemotherapy is not able to differentiate cancerous cells 
and would immediately alert the immune system resulting in severe anarchical cellular 
destruction. 
 
A few years later, Jeffrey et al. accomplished a further step forward by using such 
glucuronide-based linkers to construct antibody-drug conjugates.
80
 The cytotoxic peptides 
monomethyl auristatin E and F (MMAE and MMAF) were linked to the self-immolative 
system and a supplementary mAb was attached to target antigen positive tumour cells (Figure 
1.11).  
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MMAF, R = Phe  
 
 
Figure 1.11 | An antibody targeted peptide prodrug 
 
Such devices were designed here to exploit lysosomal β−glucuronidase as a release 
mechanism within antibody-targeted cancer cells. Biological studies revealed that such 
systems are able to specifically release the active drug to the target antigen-positive cells. In 
vivo evaluations in nude mice demonstrated the efficacy of such conjugates as all implanted 
tumours were cured. A non binding antibody prodrug conjugate was also injected to 
demonstrate the specificity of the prodrug system. Indeed, this conjugate displayed no 
antitumour activity as it was not activated in the course of the therapy. 
 
III. Rotaxane-based peptide prodrugs 
III.1. Rotaxanes and other interlocked molecules 
 
Rotaxanes constitute a class of mechanically-interlocked molecular architectures 
consisting of one or more rings trapped around a thread presenting final bulky stoppers 
(Figure 1.12). Although the two components are not covalently connected, rotaxanes are still 
considered as a single molecule since a covalent bond needs to be disrupted to separate the 
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Rotaxanes and other mechanically-interlocked molecules such as catenanes (two or more 
interlocked macrocycles), display a great interest and potential in the construction of synthetic 
molecular machines, as they constitute the central elements of such machinery. However 
before reaching this point much of the research has focused in the straightforward and 
efficient accessibility of such molecules.  
 
Concerning the preparation of rotaxanes, two main synthetic strategies have been commonly 




Scheme 1.18 | The two main synthetic strategies for the preparation of rotaxanes 
 
In the capping approach, the previously formed pseudo-rotaxane is trapped by capping the 
thread ends with two bulky stoppers. In the clipping strategy the macrocycle components 
wrap around the stoppered thread and the final “clipping” ring closing reaction leads to the 
rotaxane. 
 
After the first trivial statistical low-yielding approaches,
81, 82
 molecular templation brought a 
dramatic improvement in the assembly of interlocked molecules and it is today the way of 
excellence for their preparation. Thus using a variety of non-covalent intermolecular 
interactions (ranging from metal-ligand coordination, hydrogen bonding, π-π stacking, 
hydrophobic and electrostatic interactions)
83
 allows the preorganisation of the various 
components of the interlocked target so that the desired final mechanical linking is greatly 
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facilitated. However we will only focus here on the hydrogen bond directed assembly of 
rotaxanes. 
 




 closely followed by Vögtle,
85
 was one of the firsts to access interlocked 













































Scheme 1.19 | The first hydrogen bond-directed amide-based catenanes 
 
Generally to offset the weakness of hydrogen bonds, multiple interaction sites are used to 
maintain the two components together, finally obtaining a high degree of preorganisation 
between the two interlocking parts. Indeed in the examples published by Hunter and Vögtle, 
the templated formation of [2]-catenanes is directed by hydrogen-bonding interactions 
between the carbonyl groups of isophthaloyl units and the NH groups of amides. 
Supplementary π-π interactions between phenyl rings also assist the formation of these 
amide-based catenanes. 
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A few years later, Leigh and co-workers reported the synthesis of a [2]-catenane from the 
reaction of isophthaloyl chloride and p-xylylenediamine at high dilution.
86
 Taking the 
mechanism of this reaction into consideration, the methodology was extended to the 
preparation of [2]-rotaxanes using suitably stoppered diamide threads.
87
 Using a fumaric 
template led to an incredible 97% yield, this success being explained by the quasi-ideal 















































Scheme 1.20 | Leigh’s synthesis of diamide rotaxane by the clipping strategy  
 
Subsequently, Leigh et al. also found that simple peptides could be used as a template for the 
formation of amide-based rotaxanes. In fact the mechanism for the formation of such 
interlocked products relies primarily on the templated assembly of the benzylic amide 
macrocycle around two transoid amide groups. Amides in similar spatial arrangements can 
indeed be found in simple peptides, so peptides may consequently be able to template the 
cyclisation of benzylic amide macrocycles around them to give peptide rotaxanes (Scheme 
1.21).  
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10663. 
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 Gatti, F. G.; Leigh, D. A.; Nepogodiev, S. A.; Slawin, A. M. Z.; Teat, S. J.; Wong, J. K. Y. J. Am. Chem. Soc. 
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Scheme 1.21 | Mechanism of formation of peptide rotaxane 
 
A glycylglycine rotaxane was the first peptide rotaxane to be synthesised using this clipping 
strategy, in 62% yield, leading to the conclusion that such rotaxane encapsulation could be 




“If the hydrogen bond directed synthesis described here can be extrapolated to more complex 
peptides, then temporary housing within a rotaxane superstructure could simultaneously 
provide protection from hostile environments, improved stability, and engineered 
lipophilicity/solubility characteristics.” 
 
Following this first success several dipeptide rotaxanes were constructed varying the amino 
acid residues in order to determine the essential structural requirements for a suitable 
hydrogen-bonding template between appropriately stoppered peptide threads and benzylic 
amide macrocycles.
90, 91
 It briefly appears, because of the evident steric restrictions, that one 
glycine residue is absolutely necessary to efficiently access dipeptide rotaxanes.  
                                                 
89
 Leigh, D. A.; Murphy, A.; Smart, J. P.; Slawin, A. M. Z. Angew. Chem. Int. Ed. 1997, 36, 728-732. 
90
 Asakawa, M.; Brancato, G.; Fanti, M.; Leigh, D. A.; Shimizu, T.; Slawin, A. M. Z.; Wong, J. K. Y. J. Am. 
Chem. Soc. 2002, 124, 2939-2950. 
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The synthesis of longer peptide rotaxanes proved more difficult since, in apolar solvent 
(necessary for using hydrogen-bond template), the peptide thread tends to autosatisfy itself in 
term of hydrogen bonding (folding) preventing good preorganisation with the macrocycle 
precursors. The supplementary lack of solubility also contributes to dramatically decreased 
yields. However, it appears that a single internal template site (i.e. a glycine residue) is able to 
satisfy those structural requirements in longer peptide threads.  
 
A Boc-Leu-enkephalin (Boc-Tyr-Gly-Gly-Phe-Leu-OH) rotaxane was prepared (Figure 
1.13), albeit in 1% yield, and its properties evaluated. It appeared that, contrary to the 
instantaneous degradation of Boc-Leu-enkephalin, the peptide rotaxane was completely 
resistant to proteolytic degradations by several exo- and endopeptidases. Preliminary studies 
at GlaxoSmithKline confirmed that the rotaxane-encapsulated form of Leu-enkephalin does 




































Figure 1.13 | Boc-Leu-enkephalin rotaxane 
 
From that point, the concept of using rotaxanes as peptide delivery agents became extremely 
attractive. Indeed on top of providing a protective shield to the peptide, encapsulation within a 
rotaxane superstructure would allow the modulation of the hydrophilic character of the 
peptidic thread, thus engineering its membrane permeation ability. Indeed Leigh et al. also 
investigated the influence of attaching subtituents to the macrocycle unit and proved that this 





                                                                                                                                                        
91
 Brancato, G.; Coutrot, F.; Leigh, D. A.; Murphy, A.; Wong, J. K. Y.; Zerbetto, F. Proc. Natl. Acad. Sci. USA 
2002, 99, 4967-4971. 
92
 Potok, S. PhD Thesis, University of Edinburgh, 2004. 
Resistant to both endo- and 
exopeptidases 
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Those great results therefore pointed out the difficulty in accessing long peptide rotaxanes. A 
straightforward sequence needs to be developed to magnify the potential of such delivery 
devices, and a convergent approach using preformed rotaxane building blocks seems to be 
appropriate in this case. To remedy this disadvantage, an efficient and versatile methodology 
was developed in the Leigh group to elongate previously-formed peptide rotaxane building 
blocks. The strategy relied on the assembly of a peptide rotaxane bearing a temporary stopper 






Scheme 1.22 | Elongation of peptide rotaxane building blocks 
 
The temporary stopper needs to be carefully designed: it should be bulky enough to lock the 
macrocycle and reactive enough to nucleophilic attack without being displaced by p-
xylylenediamine during the rotaxane formation process. The ideal stopper to fulfil these 
requirements was found to be the 2,6-diphenyl-4-nitrophenyl ester. Accordingly, various 
rotaxanes bearing this activated ester stopper were prepared and successfully elongated with a 
range of C-stoppered peptides.
92 
The encouraging results obtained prompted Leigh et al. to 
explore those conditions in the novel synthesis of the Boc-Leu-enkephalin rotaxane (Scheme 
1.23).  
























































































Scheme 1.23 | Synthesis of Boc-Leu-enkephalin rotaxane via the elongation strategy 
 
The synthesis of Boc-Leu-enkephalin was readily improved, bringing an admirable 
advancement in the preparation of therapeutic mechanically-interlocked nanodevices. 
However, for these devices to be considered as prodrugs, the encapsulated compound needs to 
be released at some point. These kinds of rotaxane-based prodrugs could however be devised 
by using a stimuli-responsive stopper that, once activated and cleaved, would release the 
active thread following the mechanical disassembly of the rotaxane architecture.  More 
interestingly, incorporating a trigger unit at the stopper would be ideal for the development of 
rotaxane-based peptide prodrugs selectively targeting tumour cells.  
 
III.3. Rotaxane-based peptide prodrugs 
 
Our concept consists in associating the targeted delivery system elaborated by Prof. 
Gesson in Poitiers (e.g. HMR 1826) and the supramolecular assembly process developed in 
Edinburgh by Prof. Leigh (e.g. Boc-Leu-enkephalin rotaxane) in order to derivatise bioactive 
peptides into rotaxane-based prodrugs. As a result such anticancer devices would be 
selectively activated at tumour sites (Scheme 1.24). 
 





Scheme 1.24 | Designing novel nanodevices for the selective delivery of cytotoxic peptides 
 
The rotaxane-based peptide prodrugs strictly follow the design of TAPs. The trigger, spacer 
and peptide drug constitute the heart of the molecule. Encapsulation by a well-suited 
macrocycle would afford a protective shield to that heart. Furthermore, the synthetic 
derivatisation of classical prodrug constructions is essential to reach a prodrug thread 
presenting bulky stoppers which would permanently lock the macrocycle around the peptide 
template.  
 
First of all, the trigger moiety is selectively recognised and hydrolysed around tumour cells 
(Scheme 1.25). Such activation may occur even in the course of a PMT protocol (e.g. with 
β−glucuronidase as the activating enzyme) or ADEPT strategy (e.g. β−galactosidase as the 
directed enzyme). The subsequent removal of the polar trigger (e.g. glucuronic acid or 
galactose) should mediate the penetration of the peptide rotaxane across cancer membranes 
(case A).  Self-immolation of the activated spacer should result in the release of the bioactive 
peptide and complementarily in the liberation of the macrocycle.  
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The extracellular release of the peptide is also conceivable (case B). This possibility is quite 
interesting in the case of membrane receptor-interacting peptides since the level of the peptide 























Scheme 1.25 | Mechanism of rotaxane-based peptide prodrugs 
 
Our machine should present limited toxicity regarding healthy cells however, once activated, 
the consecutive release of the parent anticancer peptide should selectively kill tumour cells. 
Consequently this innovative delivery device is designed to overcome the two main 
drawbacks associated with peptide therapy: their rapid degradation by proteases and their 
poor absorption. Furthermore, this rotaxane-based molecular machine also addresses the 
challenge of obtaining more selectivity in anticancer chemotherapy. Indeed being constructed 
upon a prodrug design, the machine should not present any side-effects due to systemic 






1. The trigger is selectively 
recognised and hydrolysed near to 
the tumour cell 
 
2. Penetration into 
the tumour cell 
 
3. Self-immolation  
of the spacer 
 
4. Intracellular release of the 




(e.g. β-glucuronidase in PMT, 
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Based on the knowledge acquired by the two universities over the years we decided to 
construct a model rotaxane-based peptide prodrug to test the validity of such a concept. We 
focused on spacer moieties already developed within Gesson group to prepare simple peptide 
prodrugs. The successful encapsulation of the resulting prodrug using the rotaxane forming 
reaction developed within Leigh group would afford the first peptide rotaxane prodrugs.  
 
Accordingly a careful study of the peptide prodrug and its corresponding rotaxane is 
warranted to comprehend the influence of encapsulating peptides upon their physiological and 
therapeutic properties. The targeted activation of our machine should liberate the fully-
functional peptide at tumour sites, accompanied with the tetraamide macrocycle, for which 
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The work presented in this chapter was done in collaboration with Aurélien Viterisi who 
prepared model peptides 2.2 and 2.33, synthesised macrocycles 2.53 and 2.54 and carried out 
the HPLC purifications of the final prodrugs. He also monitored the enzymatic hydrolysis of 
our prodrug molecules along with the measurement of their water solubility.  
 
 
I. Arymalonaldehyde-based delivery system ....................................................................... 42
I.1. Introduction.................................................................................................................... 42
I.2. The acid-catalysed dimerisation of arylmalonaldehydes ............................................... 43
I.3. Arylmalonaldehyde-based rotaxane prodrug ................................................................. 49
 
II. “Allyl-based” delivery system .......................................................................................... 51
II.1. Synthesis and preliminary enzymatic evaluation of the new “allyl spacer”................. 51
II.2. Synthesis of “allyl-based” model prodrugs .................................................................. 54
II.3. Enzymatic hydrolysis.................................................................................................... 56
II.4. Synthesis of the tunable “allyl-based” rotaxane model prodrugs................................. 58
II.5. Synthesis of the functionalised macrocycles ................................................................ 61
II.6. Water solubility and enzymatic hydrolysis of PEG-grafted rotaxane prodrugs ........... 62
II.6.1 Water solubility ...................................................................................................... 62
II.6.2 Enzymatic hydrolysis ............................................................................................. 63
II.7. Observations ................................................................................................................. 64
 
III. bis-Galactosyl-based delivery system............................................................................. 65
III.1. Introduction ................................................................................................................. 65
III.2. Synthesis...................................................................................................................... 67
III.3. Enzymatic hydrolysis .................................................................................................. 70
 
IV. Conclusion ........................................................................................................................ 72
 
V. Supporting information .................................................................................................... 73
V.1. The acid-catalysed dimerisation of arylmalonaldehydes ............................................. 73
V.2. “Allyl-based” delivery system...................................................................................... 75
V.3. bis-Galactosyl-based delivery system ........................................................................ 102
 
 
CHAPT. 2 | TOWARDS A MODEL ROTAXANE-BASED PEPTIDE PRODRUG 
42 
 
I. Arymalonaldehyde-based delivery system 
I.1. Introduction 
 
Our first attempts to prepare a model rotaxane-based peptide prodrug focused on the 
arylmalonaldehyde spacer which was previously developed within the Gesson group to target 
doxorubicin.
93
 A preliminary enzymatic study conducted with three glucuronylated model 
prodrugs bearing the variously substituted arylmalonaldehydes (NO2, F and Me) revealed that 
















R = NO2, F, Me
β-glucuronidase




























Scheme 2.1 | Arylmalonaldehyde-based glucuronylated prodrugs 
 
CPK models confirmed that nitro-arylmalonaldehyde linker 2.1 is bulky enough to act as a 
stopper and therefore could be used for the investigation of our concept. For a model peptide 
we decided to use the stoppered glycylglycine dipeptide 2.2 (which has been widely applied 
as a template for peptide rotaxane formation),
95
 and to synthesise its rotaxane derivative 2.3. 
The enzymatic hydrolysis of the glucuronide moiety should activate our drug delivery device, 
releasing the model peptide after self-immolation of the arylmalonaldehyde unit (Scheme 
2.2). 
 
                                                 
93
 Papot, S.; Combaud, D.; Gesson, J.-P. Bioorg. Med. Chem. Lett. 1998, 8, 2545-2548. 
94
 Rivault, F.; Tranoy-Opalinski, I.; Gesson J.-P. Bioorg. Med. Chem. 2004, 12, 675-682. 
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 Leigh, D. A.; Murphy, A.; Smart, J. P.; Slawin, A. M. Z. Angew. Chem. Int. Ed. 1997, 36, 728-732. 




















































































Scheme 2.2 | Mechanism of enzymatic release 
 
I.2. The acid-catalysed dimerisation of arylmalonaldehydes 
 
In the synthesis described by Gesson et al., glycosylation of 2-(4-nitrophenyl) 
malondialdehyde 2.1 was conducted in the presence of the protected glucuronyl bromide 
using the classical Koenigs-Knorr reaction. With the aim to reduce the number of steps to 
access compound 2.4 we investigated the acid-catalysed glycosylation of 2.1 directly from the 
fully protected glucuronide. Surprisingly glycosylation of 2.1 in the presence of various Lewis 
acids was not successful while 2.4 was synthesised with excellent yields, selectively in the 






































Scheme 2.3 | Attempted glycosylations of 2-(4-nitrophenyl) malondialdehyde 2.1 
β-glucuronidase 
activation of the rotaxane 
spontaneous 
decomposition 
release of the peptide 
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However, an intriguing main product was isolated from the acid-catalysed glycosylation 
mixture. The straightforward 
1
H NMR spectrum prompted us to envisage the formation of a 
highly symmetric compound, presenting no sugar signals. Accordingly, we decided to study 
the behaviour of arylmalonaldehyde 2.1 under acid conditions (TMSOTf, CH3CN) and could 
rapidly observe the formation of a single apolar product, revealing NMR profiles identical to 
the unknown isolated product. Beside the signals corresponding to aromatic protons, the 
1
H 
NMR spectrum displayed only two singlets at δ 6.08 and 7.35 ppm with a 1:1 intensity which 
indicated the symmetry of the molecule, along with the absence of any aldehyde functionality. 
The 
13
C NMR spectrum revealed no signal downfield from 147 ppm, confirming the absence 
of any carbonyl group. More importantly, the signal at δ 88.3 ppm suggested the presence of 
an acetalic carbon.  
 
Therefore based on those experimental observations, structure 2.5 was proposed, which would 
result from the acid-catalysed dimerisation of arylmalonaldehyde 2.1 (Scheme 2.4). Mass 



























Scheme 2.4 | Structure elucidation 
 
Historically this kind of motif, namely 2,6,9-trioxabicyclo[3.3.1]-nona-3,7-diene (also called 
bridged bis-dioxines), was prepared in 1965 via a platinum (II)-promoted condensation of 
acetylacetone.
96
 To the best of our knowledge only two synthetic methods leading to this 
diene system have been reported. Arnold and Budesinsky observed in 1988 the formation of 
the 4,8-dicarbaldehyde as the dimer product of triformylmethane (Scheme 2.5).
97
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Scheme 2.5 | Dimerisation of triformaldehyde 
 
NMR studies with a chiral shift reagent demonstrated the chirality of such bicyclic structure 
possessing a 2-fold rotational axis as the only element of symmetry.  
 
Later on, Kollenz et al. proposed the unique general synthetic method to access substituted 
trioxabicyclononadienes.
98
 Addition of various aromatic amines to a stable α-oxoketene 










































Scheme 2.6 | The Kollenz method, amine nucleophiles 
 
Kollenz et al. also reported the synthesis of bifunctionalised bis-dioxines using hydroxyl 
nucleophiles.
99
 Indeed, addition of such nucleophiles to the stable α-oxoketene resulted in the 
formation of a stable 1:1 adduct which was further cyclised under acidic conditions to afford 
the difunctional derivative (Scheme 2.7).  
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Scheme 2.7 | The Kollenz method, hydroxyl nucleophiles 
 
Thus considering the few methodologies described to reach such bicyclic core, we envisaged 
to develop a novel and convenient strategy for the preparation of substituted 2,6,9-
trioxabicyclo[3.3.1]-nona-3,7-diene starting from arylmalonaldehydes. Therefore we started 
exploring the behaviour of nitroarylmalonaldehyde 2.1 under various acidic conditions 




















Scheme 2.8 | Investigating conditions 
 
Formation of 2.5 was observed using 0.5 equiv. of BF3.Et2O, ZnCl2, CF3SO3H or TMSOTf. 
The best result obtained with TMSOTf (84% yield) prompted us to investigate the acid 
stoichiometry. However every further attempt to optimise the yield of this reaction failed 
employing either more or less equivalent of the acid catalyst. In the light of these first results, 
those optimal conditions were applied to the variously substituted arylmalonaldehydes 2.6, 
2.7, 2.8, 2.9 and 2.10 (Scheme 2.9).100  
                                                 
100
 The starting arylmalondialdehydes 2.1, 2.6, 2.7, 2.8, 2.9 and 2.10 were either commercially available (2.6 and 
2.8) or prepared in two steps from the corresponding arylacetic acid (2.2, 2.7, 2.9 and 2.10) according to the 
method of Arnold: Arnold, Z. Collect. Czech. Chem. Commun. 1961, 26, 3051. 
entry acid (equiv.) yield 
1 TFA (0.5) - 
2 H2SO4 (0.25) - 
3 BF3.Et2O (0.5) 28 % 
4 TiCl4 (0.5) - 
5 SnCl2 (0.5) - 
6 ZnCl2 (0.5) traces 
7 CF3SO3H (0.5) 65 % 
8 TMSOTf (0.5) 84 % 
9 TMSOTf (1) 55 % 
10 TMSOTf (0.3) 61 % 
11 TMSOTf (<0.3) - 



















Scheme 2.9 | Extending scope 
 
Except for the bridged bis-dioxine 2.15 (R= H), all the expected bicyclic products were 
isolated in moderate to good yields after purification by flash column chromatography (42-
84%). Moreover, in the course of the studies conducted with arylmalondialdehydes bearing an 
electron-donating group (2.8 and 2.9, R= CH3 and R= OMe), we were able to isolate 




C NMR analysis of both 
compounds demonstrated the symmetry of these molecules and further NOESY experiments 




















2.8 - 2.9 2.13 R = CH3 
2.14 R = OMe
H H
NOESY effect
2.16 R = CH3 
2.17 R = OMe  
 
Scheme 2.10 | Arylmalonaldehydes 2.8 and 2.9 under acid catalysis 
 
Accordingly 2.16 and 2.17 were supposed to be reactive intermediates in the formation of 
bridged bis-dioxines (they are quite similar to the intermediate compound proposed by Arnold 
and Budesinsky). Indeed, treatment of 2.16 and 2.17 in the presence of catalytic amount of 
TMSOTf led to the formation of the corresponding trioxabicyclononadienes 2.13 and 2.14 
(Scheme 2.11).  
Arylmalonaldehyde R= Bridged bis-dioxine yield 
2.1 NO2 2.5 84 % 
2.6 Cl 2.11 64 % 
2.7 F 2.12 55 % 
2.8 CH3 2.13 42 % 
2.9 OMe 2.14 50 % 
2.10 H 2.15 7 % 









































Scheme 2.11 | Isomerisation and acid-catalysed cyclisation of 2.16 and 2.17  
 
Such demonstration reasonably allowed the proposal of a general mechanism for the acid 
catalysed dimerisation-cyclisation of arylmalonaldehydes (Scheme 2.12). In the primary step, 
TMSOTf catalyses the dimerisation of the starting arylmalonaldehyde. Subsequent Z-E 
isomerisation of at least one double bond facilitates acid-catalysed intramolecular cyclisation 












































Scheme 2.12 | Postulated mechanism for the formation of bridged bis-dioxines 
 
Since none of these intermediates have been detected with arylmalondialdehydes 2.1, 2.6 and 
2.7 (R= NO2, Cl and F) it may be postulated that the presence of electron-withdrawing para-
substituents on the aromatic ring favours the double bond isomerisation and consequently 
increases the rate of formation of the corresponding cyclic dimers. 
E-E conformation 
= Impossible cyclisation 
E-Z conformation 
= Cyclisation 
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In conclusion, this study allowed the description of new “bridged bis-dioxines” obtained in 
moderate to good yields by dimerization of arylmalondialdehydes in the presence of a 
catalytic amount of TMSOTf. This constitutes a new unexpected methodology for the 




I.3. Arylmalonaldehyde-based rotaxane prodrug 
 
Accordingly, using the original synthesis reported by Gesson et al. we prepared 
intermediate 2.19. The regioselective reduction of α,β−unsaturated aldehyde 2.4 was 
performed using Luche reagent (NaBH4-CeCl3) (93%) and the resulting allylic alcohol 2.18 
was activated with carbonyl diimidazole (83%). 2.19 was finally coupled with glycylglycine 
derivative 2.2 to obtain the model protected prodrug thread 2.20 in a moderate 51% yield 
































































Scheme 2.13 | Preparation of the arylmalonaldehyde-based thread 
 
Thread 2.20 was then submitted to the classical rotaxane-forming reaction conditions. Thus 
2.20 was reacted with p-xylylene diamine (16 equiv.) and isophthaloyl chloride (16 equiv.) in 
chloroform in presence of triethylamine (32 equiv.) at high dilution (Scheme 2.14). 
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 Fernandes, A.; Marrot, J.; Gesson, J.-P.; Papot, S. Tetrahedron Lett. 2006, 47, 5961-5964. 


































































































Scheme 2.14 | Preparation of the arylmalonaldehyde-based rotaxane 2.21 
 
After many efforts the interlocked structure was finally separated from the starting thread and 
could be observed by 
1
H NMR (Figure 2.1). The large shielding effect experienced by the 
glycine protons (H11, H13 and H15) along with the additional macrocyclic protons (HA, HB, HC, 




Figure 2.1 | 
1
H NMR spectra of thread 2.20 and rotaxane 2.21, (400 MHz, 298 K, CDCl3) 
 
Nevertheless, the rotaxane proved to be rapidly degraded and could not be used for further 
experiments. This prompted us to envisage the construction of a new system enabling the 
enzyme-mediated activation of peptide rotaxane prodrugs. One of the crucial points of our 
machines is the design of the spacer unit which must be bulky enough to stop the macrocycle, 
allow a good recognition of the trigger component by the enzyme and lead efficiently to the 
release of the encapsulated peptide after trigger activation.  
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II. “Allyl-based” delivery system 
 
After several unfruitful attempts we managed to design a spacer which seems to fulfil 
our main requirements. This novel unit is directly derived from the HMR 1826 spacer which 
is probably one of the most efficient self-immolative linkers used in prodrug systems to 
date.
102,103
 Therefore the straightforward derivatisation of the 4-hydroxy-3-nitrobenzylalcohol 
(i.e. HMR 1826 spacer) depicted in Scheme 2.15 afforded a valuable solution for the 






















































Scheme 2.15 | Design of a new model rotaxane prodrug based on HMR 1826 spacer 
 
II.1. Synthesis and preliminary enzymatic evaluation of the new “allyl spacer” 
 
“Allyl spacer” 2.23 is quite appealing since it is easily obtained from commercially 































Scheme 2.16 | Preparation of the new “allyl spacer” 
                                                 
102
 Papot, S.; Tranoy, I.; Tillequin, F.; Florent, J.-C.; Gesson, J. P. Curr. Med. Chem. Anti-Cancer Agents 2002, 
2, 155-185. 
103
 Tranoy-Opalinski, I.; Fernandes, A.; Thomas, M.; Gesson, J.-P.; Papot, S. Anti-Cancer Agents Med. Chem. 
2008, 8, 618-637. 
The supplementary allyl group prevents 
the macrocycle from dethreading 
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Allylation of 4-hydroxy-3-nitrobenzaldehyde under the classical Williamson procedure 
afforded allyl ether 2.22 (96%) which was then submitted to various Claisen conditions. The 
best results were obtained heating 2.22 at 160-170°C neat leading to 57% of the expected 
spacer along with the remaining starting allylated phenol. Compound 2.24 was prepared by 
reduction of 2.23 (40%) to serve as a reference for the enzymatic studies. 
 
However before going in depth in the study, a preliminary test had to be carried out: the 
enzymatic recognition of the bis-ortho-substituted phenol glucuronide had to be 
demonstrated. Accordingly the simple glucuronide derivative 2.28 was prepared and 






























































Scheme 2.17 | Synthesis of model glucuronide 2.28 
 
The newly-built spacer 2.23 was glycosylated using Koenigs-Knorr conditions (97%) and 
then reduced to its benzylic alcohol derivative 2.26 (82%). Transesterification of the acetate 
protecting groups (86%) followed by saponification of the methyl ester furnished model 
glucuronide 2.28 (37%).  
 
Glucuronide 2.28 (490 µg) was incubated with bovine liver β−glucuronidase (100 U) in 
phosphate buffer (0.02 M, pH 7.0, 1 mL) at 37°C.  HPLC monitoring showed no reaction at 
all suggesting that the supplementary allyl group prevents the glucuronide from being 
recognised and hydrolysed (Scheme 2.18).  
 












phosphate buffer 0.02 M
pH 7.0, 37°C
NO reaction













Scheme 2.18 | Enzymatic hydrolysis of model glucuronide 2.28 
 
Disposing of a promising rapidly-accessed spacer, we decided to focus our efforts in 
preparing a galactoside derivative of 2.23. Indeed, galactosylated prodrugs can be used in 
ADEPT protocols.
104,105,106 
Furthermore, literature demonstrated that highly substituted 
phenolic β−galactosides are substrates for β−galactosidase.107 Thus treatment of 2.23 with 
per-acetylated galactosyl bromide in the presence of silver (I) oxide afforded β−galactosyl 
2.29 (79%). Reduction of the aldehyde function (87%) and subsequent deprotection of the 
acetyl protecting groups (88%) afforded the desired model 2.31. Incubation of 2.31 (510 µg) 
with Escherichia coli β−galactosidase (40 U) in phosphate buffer (0.02 M, pH 7.0, 1 mL) at 
37°C was followed by HPLC. The later revealed the total disappearance of starting 
































































Scheme 2.19 | Synthesis and enzymatic hydrolysis of model galactoside 2.31 
                                                 
104
 Cheng, H.; Cao, X.; Xian, M.; Fang, L.; Cai, T. B.; Ji, J. J.; Tunac, J. B.; Sun, D.; Wang, P. G. J. Med. Chem. 
2005, 48, 645-652. 
105
 Tietze, L. F.; Major, F.; Schuberth, I. Angew. Chem. Int. Ed. 2006, 45, 6574-6577. 
106
 Kamal, A.; Tekumalla, V.; Krishnan, A.; Pal-Bhadra, M.; Bhadra, U. Chem. Med. Chem. 2008, 3, 794-802. 
107
 Yu, J.; Mason, R. P. J. Med. Chem. 2006, 49, 1991-1999. 
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However these results also depicted the poor affinity of our model galactoside 2.31 for β-
galactosidase. Indeed 1 unit of E.coli β-galactosidase is known to hydrolyse 1 µmol of the o-
nitrophenyl β-D-galactoside model substrate per minute at 37°C. In our case (1.37 µmol of 
2.31 and 40 U of E.coli β-galactosidase) the extremely slow kinetics of the enzymatic 
hydrolysis (30 minutes) demonstrated the dramatic effect of blocking the two o-phenolic 
positions.  
 
Since the nitro function is essential for rapid 1,6-eliminations, modification of meta positions 
of the aromatic ring or functionalisation of the benzylic position obviously appears as 
alternative solutions to introduce a stopper part to the HMR 1826 spacer without altering its 
self-immolative properties.  
 
Nevertheless, considering the many parameters to reach an efficient rotaxane-based delivery 
device we decided to pursue with this spacer in the galactose series even if the preliminary 
enzymatic studies, although demonstrating the complete hydrolysis of the model galactoside, 
were not really encouraging in term of kinetics. In addition, galactoside prodrugs can be used 
in ADEPT protocols and are easier to prepare and to handle in comparison with the 
glucuronylated prodrugs used in the PMT approach. Thus with this model system we can 
study the effect of the macrocycle upon the release of the model peptide along with the 
influence of the stopper on the self-immolative spacer.  
 
II.2. Synthesis of “allyl-based” model prodrugs 
 
 Thus to pursue our investigations we prepared the Gly-Gly-Gly model prodrug thread 
2.35 (Scheme 2.20). Activation of benzylic alcohol 2.30 with p-nitrophenylchloroformate 
(96%) and coupling with the model stoppered tripeptide 2.33 afforded intermediate 2.34 
(85%). Final deprotection of the carbohydrate moiety yielded prodrug 2.35 (64%).  
 
 

























































































Scheme 2.20 | Synthesis of model galactoside prodrug thread 2.35 
 
Rotaxane 2.36 was prepared using the classical hydrogen bond-directed assembly with a 
satisfying 51% yield (confirming that our spacer is an efficient stopper), isolated after 
classical chromatography on silica gel and subsequent size exclusion chromatography. Sugar 


















































































































































Scheme 2.21 | Synthesis of model galactoside prodrug rotaxane 2.37 
 
Comparison of the 
1
H NMR spectra of 2.34 and 2.36 evidenced the formation of the 
interlocked architecture (Figure 2.2).  
 





Figure 2.2 | 
1
H NMR spectra of thread 2.34 and rotaxane 2.36, (400 MHz, 298 K, CDCl3) 
 
Indeed, besides the supplementary protons corresponding to the macrocycle (HA, HB, HC, HD, 
HE and HF), most of the resonances of the stoppered tripeptide (H14, H16, H18, H20 and H21) are 
significantly shifted to higher field in the rotaxane due to the shielding effect of the aromatic 
rings of the macrocycle. The major shifts of the glycine protons H14, H16 and H18 indicate that 
the glycine residues are directly located in the cavity of the macrocycle in the predominant 
structure of 2.36 in CDCl3. Higher field shifts of the spacer protons H7, H8 and H12 are also 
observed while no modifications are noticed for the galactose trigger (H1, H2, H3, H4, H5 and 
H6). This information suggests that the macrocycle is able to shuttle up to the spacer unit and 
then blocked by the nitro- and allyl- substituents, as demonstrated by the CPK models of 
rotaxane 2.36.  
 
II.3. Enzymatic hydrolysis  
 
Enzymatic hydrolysis of prodrug thread 2.35 (0.1 µmol) was conducted with E. coli 
β−galactosidase (10 U) in phosphate buffer (0.02 M, pH 7.0, 500 µL, 5% DMSO) at 37 °C 
(Scheme 2.22).  


















































Scheme 2.22 | Enzymatic release of the model peptide from prodrug thread 2.35 
 
The enzymatic reaction was monitored by HPLC and revealed the release of model peptide 
2.33 in approximately 90 minutes. Thereby HPLC chromatograms displayed the appearance 




Figure 2.3 | Enzymatic hydrolysis of prodrug thread 2.35 
 
These results confirmed that our galactosides are definitively not good substrates for E.coli β-
galactosidase. However, even if the enzymatic hydrolysis occurred over prolonged reaction 
time, we could observe the total release of the peptide, meaning that this simple and easy-





model peptide 2.33,  
prodrug thread 2.35  
and spacer 2.24 
 
Prodrug thread 2.35  
+ E.coli β-galactosidase 
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Unfortunately galactoside rotaxane 2.37 proved to be totally insoluble in phosphate buffer 
(0.02 M, pH 7.0).  Even the addition of up to 50% DMSO was not sufficient to solubilise the 
rotaxane. To overcome this drawback, the functionalisation of the macrocycle unit seems to 
be a good recourse to tune the hydrophilic character of our rotaxane. Indeed Leigh et al. 
recently developed an efficient method for the functionalisation of rotaxanes using the 
Copper-Catalysed Azide Alkyne Cycloaddition (CuCAAC).
108
 Therefore we decided to 







































Scheme 2.23 | The “tunable” model rotaxane prodrug 
 
II.4. Synthesis of the tunable “allyl-based” rotaxane model prodrugs 
 
Rotaxane 2.38 was easily synthesised from thread 2.34 using the classical hydrogen 
bond directed assembly with the isophthaloyl dichloride azido derivative and isolated with a 
63% yield (Scheme 2.24).  
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 Gonzalez Cabrera, D.; Koivisto, B.; Leigh, D. A. Chem. Commun. 2007, 41, 4218-4220. 
Click Chemistry 
 
Try to solubilise the rotaxane 
Sugars, PEGs, carboxylic acids… 






















































































































H NMR spectra of 2.34 and 2.38 also illustrated the formation of the rotaxane (Figure 
2.4). Indeed, apart from the signals corresponding to the sugar, most of the resonances 





Figure 2.4 | 
1
H NMR spectra of thread 2.34 and rotaxane 2.38, (400 MHz, 298 K, CDCl3) 
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Thus rotaxane 2.38 was functionalised via CuCAAC with different alkyne derivatives (2.39 to 
2.42, prepared by Aurélien Viterisi) to afford a small library of protected rotaxane-based 















Scheme 2.25 | “Tuning” model rotaxane 2.38 
 
Rotaxanes 2.43 to 2.46 were isolated in moderate yield (21 to 34%) which is quite unusual for 
this kind of reaction. Even the use of TBTA (tris-(benzyltriazolylmethyl)amine), which is 





To study our concept we initially focused on rotaxanes 2.44 and 2.45, bearing respectively 
PEG and PEG-glucose chains. Removal of the acetyl protecting groups (MeONa, MeOH, 
0°C) of both rotaxane 2.44 and 2.45 afforded the final model rotaxane prodrugs 2.47 and 2.48 
which were further purified by preparative HPLC (Figure 2.5).  
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 Chan, T. R. ; Hilgraf, R.; Sharpless, K. B.; Fokin, V. V. Org. Lett. 2004, 6, 2853-2855. 
alkyne rotaxane yield 
Glucose 2.39 2.43 34% 
PEG 2.40 2.44 24% 
PEG-Glucose 2.41 2.45 21% 





















































































































































































































Figure 2.5 | The PEG-grafted rotaxane prodrugs 
 
II.5. Synthesis of the functionalised macrocycles 
 
For both rotaxanes 2.47 and 2.48 described above, the corresponding macrocycles 
were prepared and isolated by Aurélien Viterisi. These macrocycles would serve as HPLC 
references in the enzymatic hydrolysis studies and also for the eventuality of biological tests.  
 
Accordingly, as the synthesis of such macrocycles is extremely difficult, we opted for a 
rotaxane-derived strategy. Therefore an ester-bearing thread was prepared and interlocked 
with the amide-based macrocyles. The bis-azide rotaxanes were then functionalised and 
finally hydrolysed to release the free macrocycles (Scheme 2.26). 
 
Thus rotaxane 2.50 was prepared by the classical hydrogen bond-directed assembly using 
fumaramide thread 2.49. The fumaramide unit is to date one of the most effective templates 
for the formation of rotaxanes by a clipping reaction.
110
 Therefore bis-azide rotaxane 2.50 was 
isolated in 83% yield and further reacted with alkynes 2.40 and 2.41 via the Copper-Catalysed 
Azide-Alkyne Cycloaddition (CuCAAC) (76% and 81% respectively). Saponification of 
stoppers from rotaxanes 2.51 and 2.52 led to the mechanical disassembly of the interlocked 
architectures to afford the desired PEG and PEG-glucose macrocycle 2.53 and 2.54. 
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 Gatti, F. G.; Leigh, D. A.; Nepogodiev, S. A.; Slawin, A. M. Z.; Teat, S. J.; Wong, J.  K. Y. J. Am. Chem. 
Soc. 2001, 123, 5983-5989. 


























































































































2.51 R = PEG 76%
2.52 R = PEG-Glucose 81%
2.53 R = PEG 90%
2.54 R = PEG-Glucose 25%
2.40 R = PEG
2.41 R = PEG-Glucose
 
Scheme 2.26 | Synthetic route for the preparation of the functionalised macrocycles 
 
II.6. Water solubility and enzymatic hydrolysis of PEG-grafted rotaxane prodrugs 
II.6.1 Water solubility 
 
Water solubility was determined by HPLC for both thread and rotaxane prodrugs 
(Table 2.1). In a typical procedure, a sample of known concentration was injected in HPLC 
and its corresponding peak integrated on the chromatogram. Then a saturated solution of the 
compound was prepared, filtered and injected on HPLC and its signal integrated, giving thus a 
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Compound Solubility in water (at 20°C) 
Allyl thread 2.35 870.0 µmol.L-1 
Allyl rotaxane 2.37 < 0.4 µmol.L-1 
PEG rotaxane 2.47 6.0 µmol.L-1 
PEG-glucose rotaxane 2.48 22 590.0 µmol.L-1 
PEG macrocycle 2.53 17.0 µmol.L-1 
PEG-glucose macrocycle 2.54 170.0 µmol.L-1 
 
Table 2.1 | Water solubility of the “allyl-based” prodrugs and grafted macrocycles 
 
The data revealed that both PEG-grafted rotaxanes 2.47 and 2.48 were more soluble than the 
simple rotaxane prodrug 2.37. We could also notice that rotaxane 2.48 (22 590.0 µmol.L-1) is 
much more soluble than 2.47 (6.0 µmol.L-1) in water. The solubility of 22 590.0 µmol.L-1 is 
strange in comparison with the other systems. Interestingly 2.48 is even more soluble than the 
non-interlocked prodrug 2.35 (870.0 µmol.L-1). Macrocycles 2.53 and 2.54 displayed 
moderate solubility (the simple amide-based macrocycle is almost totally insoluble in water). 
 
II.6.2 Enzymatic hydrolysis 
 
PEG-rotaxane 2.47 (0.1 µmol) was incubated with E. coli β−galactosidase (100 U) in 
phosphate buffer (0.02 M, pH 7.0, 500 µL, 10% DMSO) at 37 °C. HPLC monitoring revealed 
slow and incomplete release of the model peptide (Figure 2.6).   
 
 
Figure 2.6 | Enzymatic hydrolysis of PEG rotaxane 2.47 
HPLC references 
 
model peptide 2.33,  
PEG macrocycle 2.53,  
PEG rotaxane 2.47 and spacer 2.24  
 
PEG rotaxane 2.47  
+ E.coli β-galactosidase 
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The same conditions were applied for the PEG-glucose grafted rotaxane. Therefore enzymatic 
hydrolysis of 2.48 (0.1 µmol) was conducted in the presence of E. coli β−galactosidase (100 
U) in phosphate buffer (0.02 M, pH 7.0, 500 µL) at 37°C. Conversion of 2.48 was monitored 
by HPLC and indicated the complete release of model peptide 2.33 along with the 









Enzymatic hydrolysis of our “allyl-based” model prodrugs reveals several important 
features. First the prodrug thread 2.35 is effectively activated by E. coli β-galactosidase to 
form spacer 2.24 and free peptide 2.33. Nevertheless the enzymatic studies conducted for both 
interlocked and non-interlocked prodrugs unambiguously revealed that our “allyl-based” 
prodrugs are not good substrates for β−galactosidase, resulting in prolonged reaction times to 
release the parent peptide. Thereby while the non-interlocked prodrug 2.35 liberates the 
peptide in approximately 90 minutes, the release of the peptide from PEG-glucose rotaxane 
2.48 was approximately 7 times slower (and even incomplete from PEG rotaxane 2.47 after 





model peptide 2.33,  
PEG-glucose macrocycle 2.54,  
PEG-glucose rotaxane 2.48  
and spacer 2.24 
 
PEG-glucose rotaxane 2.48  
+ E.coli β-galactosidase 
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Although we succeeded in solubilising our prodrug rotaxanes, it appears that the macrocycle 
considerably decreases the kinetics of release of the peptide. The close proximity of the 
macrocycle and the trigger moiety may account for this behaviour. Moreover the additional 
large chains grafted on the macrocycle may also participate in this decrease in activity. At this 
point it appears that, on one hand, the macrocycle has to be moved away from the trigger and 
on the other hand its functionalisation might be accomplished by “clicking” small polar 
molecules able to drive its hydrophilic properties. From that point of view, the carboxylic 
acid-grafted rotaxane 2.46 should be a good candidate that we will need to investigate to test 
the hypothesis of the proximity between macrocycle and trigger. 
 
III. bis-Galactosyl-based delivery system 
III.1. Introduction 
 
In the light of the results described previously we envisaged the design of a new 
rotaxane prodrug system. Indeed, the studies conducted with the “allyl-based" models 
demonstrated that additional modification of HMR 1826 spacer has to be moved away from 
the carbohydrate trigger unit to promote an efficient enzymatic recognition. Thus the 
confinement of the macrocycle unit around the peptide template should make the trigger-
spacer conjugate more accessible for enzymatic activation. Moreover the evidence that water 
solubility constitutes a serious drawback of our delivery device is now clearly obvious. From 
this point of view the bis-galactosylated rotaxane derivative depicted in Scheme 2.27 appears 





























































Scheme 2.27 | Design of a new model rotaxane prodrug based on HMR 1826 spacer 
Additional galactosyl unit to prevent 
the macrocycle from dethreading 
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CPK models demonstrated that the additional sugar appropriately positionned on the spacer 
unit allows containment of the macrocycle away from the o-nitro-galactose trigger. 
Furthermore the presence of two carbohydrate units on the rotaxane should assure good 
water-solubility of the whole device.  
 
In the present case, two possible mechanisms can be invoked for the liberation of the 
encapsulated peptide. Indeed the presence of two galactose triggers on the novel prodrug 
rotaxane allows two potential enzymatic activations. On one hand, hydrolysis of the o-nitro 
galactoside should mediate the release by the classical 1,6-elimination; alternative hydrolysis 















































































































































Scheme 2.28 | Mechanism of enzymatic release 
 
β-galactosidase 
activation of the rotaxane 
1,6-elimination 
release of the peptide 
β-galactosidase 
activation of the rotaxane 
1,4-elimination 
release of the peptide 
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Self-immolative spacers involving 1,4-quinone methide rearrangement have already been 
investigated for application in prodrug systems. For instance Shabat and co-workers recently 
reported the assembly of first-generation bioactivable dendritic prodrugs able to achieve 
multidrug release following successive 1,4-eliminations.
111
 However Gesson and co-workers 



























t1/2 = 216 min. t1/2 = 37 min.  
 
Scheme 2.29 | 1,4- versus 1,6-elimination 
 
In our case the p-nitro galactoside seems to be less prone to enzymatic hydrolysis. The close 
presence of the benzylic amide macrocycle should indeed hinder the β−galactosidase 
approach from this side of the rotaxane, consequently favouring the 1,6-elimination 
mechanism. Furthermore the kinetic difference between 1,4- and 1,6-eliminations should also 




 Regioselective nitration of 3,4-dihydroxybenzaldehyde gave spacer 2.55 (48%) which 
was then bis-galactosylated using Koenigs-Knorr conditions (65%). Reduction of aldehyde 
2.56 (83%), activation of the resulting benzylic alcohol 2.57 with p-nitrophenylchloroformate 
(96%) and coupling with the model stoppered peptide 2.2 (77%) finally afforded thread 2.59 
(Scheme 2.30).  
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Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; 
Bosslet, K. J. Med. Chem. 1998, 41, 3572-3581. 



















































































































Scheme 2.30 | Preparation of the bis-galactosylated thread 
 
Thread 2.59 was then subjected to rotaxane forming conditions and the desired rotaxane 2.60 












































































































Scheme 2.31 | Preparation of the bis-galactosylated rotaxane 2.60 
 
Comparison of the 
1
H NMR spectra between thread and rotaxane clearly illustrates the 
formation of the interlocked architecture (Figure 2.8).  
 





Figure 2.8 | 
1
H NMR spectra of thread 2.59 and rotaxane 2.60, (400 MHz, 298 K, CDCl3) 
 
Indeed, apart from amide protons (i.e. H12 and H14), most of the resonances of the stoppered 
peptide (H11, H13, H15 and H16) are predominantly shifted to higher field. The downfield shift 
observed for amide protons H12 and H14 is due to intermolecular hydrogen bonding to the 
tetraamide macrocycle. Spacer protons H8 and H9 also experience the shielding effect of the 
macrocycle, which is not the case for spacer proton H7. These observations indicate that the 
macrocycle is stoppered by the additional galactose unit and the nitro group, thus favouring 
the enzyme accessibility to the o-nitro trigger. 
 
Finally, both thread 2.59 and corresponding rotaxane 2.60 were deprotected to obtain the 
active prodrug systems 2.61 and 2.62 in 81% and 88% respectively (Scheme 2.32). 
 





































































































































Scheme 2.32 | Preparation of the bis-galactosylated prodrug thread 2.61 and rotaxane 2.62 
 
III.3. Enzymatic hydrolysis 
 
HPLC analysis of the enzymatic hydrolysis of prodrug thread 2.61 (0.5 µmol) in the 
presence of E.coli β−galactosidase (40 U) in phosphate buffer (0.02M, pH 7.0, 1mL) at 37 °C 








model peptide 2.2,  
prodrug thread 2.61  
 
Prodrug thread 2.61  
+ E.coli β-galactosidase 
t = 40 min. 
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We could also observe many additional peaks on the chromatogram. Unfortunately LCMS 
analysis allowed the identification of only one compound which corresponds to the 
nucleophilic attack of the released peptide on the quinone methide intermediate, which could 
















































Scheme 2.33 | Nucleophilic attack of the released peptide 
 
Generally with this class of elimination spacer, the highly reactive quinone methide 
intermediate is rapidly trapped by water to obtain a benzylic alcohol. In our case, it seems like 
the quinone methides are stabilised by the extra galactose units and thus react first with the 
amine nucleophile. This kind of behaviour has already been observed with other quinone 




Unfortunately rotaxane prodrug 2.62 is totally insoluble in the phosphate buffer and therefore 
no enzymatic activation can occur. Considering the complex release observed with this model 
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IV. Conclusion  
 
The model study investigated here revealed that various fundamental features have to 
be considered before achieving efficient rotaxane-based peptide delivery devices. First of all, 
while one of the main drawbacks associated with peptide drugs is their high hydrophilicity, 
the considerably decreased hydrophilic character encountered with peptide rotaxanes 
represents a serious issue. Consequently the poor or even non-existent water-solubility of 
enzyme-activable rotaxane prodrugs prevent such machines from working.  
 
Accordingly, after dealing with the unstable glucuronylated arylmalonaldehyde model 
rotaxane, we based our efforts on derivatising one of the most successful anticancer prodrugs, 
HMR 1826, comprising a benzyloxycarbonyl based 1,6-elimination spacer. Thus the first 
attempt was based on an “allyl-modified” HMR 1826 spacer. Nevertheless such chemical 
modification proved to totally inhibit the recognition of the glucuronide motif (PMT) and 
encouraged us to investigate a galactose trigger, which can be used in an ADEPT protocol. 
The resulting glycoside appeared to be recognised by E. coli β−galactosidase while the 
rotaxane derivative displayed limited water-solubility. As a consequence, variation of the 
macrocycle unit seems, to date, the ultimate measure to finely tune the physical properties of 
our rotaxane-based peptide prodrugs. Such an advance was achieved by constructing a 
rotaxane bearing a “clickable” macrocycle. Nevertheless the “allyl spacer” system has one 
limitation: the supplementary allyl group (along with the large macrocycles) significantly 
hinders the glycosidic bond and therefore the enzymatic activation of our delivery device, 
resulting in slow kinetics of peptide release.  
 
Consequently we developed the bis-galactosylated spacer. Introduction of a supplementary 
trigger unit to the self-immolative spacer results in the appropriate blockade of the amide-
based macrocycle. However such modification resulted in a complex enzymatic release with 
the prodrug thread and even two carbohydrates units are not enough to solubilise the rotaxane 
in water. Moreover, the possibility of using glucuronic acid triggers has to be considered since 
the o-nitro glycosidic bond does not seem to be so hindered in this case. The bis-
glucuronylated rotaxane should also present largely increased water-solubility. 
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V. Supporting information 
V.1. The acid-catalysed dimerisation of arylmalonaldehydes 
 
In a typical procedure, the arylmalonaldehyde (100 mg) was placed in CH3CN (0.2 
mmol/mL) and the slurry cooled to 0°C. TMSOTf (0.5 equiv.) was then added dropwise and 
the stirred mixture was slowly allowed to reach room temperature. Stirring was continued at 
room temperature for 17 hours. The reaction was quenched with a saturated aqueous solution 
of NaHCO3 and the aqueous layer was extracted 3 times with ethyl acetate. The combined 
organic extracts were dried (MgSO4), evaporated and concentrated in vacuo. Purification by 
























H NMR (300 MHz, CDCl3): δ 8.14 (d, 4H, 
J = 9.3 Hz, Hc), 7.45 (d, 4H, J = 9.3 Hz, Hb), 7.35 (s, 2H, 
H3+7), 6.08 (s, 2H, H1+5) 
13
C NMR (75 MHz, CDCl3):  
146.6, 143.1, 140.5, 124.6, 124.4, 111.8, 88.3 HRMS (EI): 
calcd. for C18H12N2O7 (M
+






















H NMR (300 MHz, CDCl3):  7.24 to 7.18 (m, 
8H, Hb+c), 7.00 (s, 2H, H3+7), 5.93 (s, 2H, H1+5) 
13
C NMR 
(75 MHz, CDCl3):  140.6, 133.8, 133.0, 129.4, 126.0, 
112.5, 88.6 HRMS (EI): calcd. for C18H12O3Cl2 (M
+
) 
























H NMR (300 MHz, CDCl3):  7.06 to 7.00 (m, 
10H, H3+7+b+c), 5.99 (s, 2H, H1+5) 
13
C NMR (75 MHz, 
CDCl3):  160.1, 139.7, 130.1, 126.4, 114.4, 112.3, 88.4 
HRMS (EI): calcd. for C18H12O3F2 (M
+
) 314.0755, found 
314.0755 





















H NMR (300 MHz, CDCl3):  7.17 (d, 2H, 
J = 8.3 Hz, Hb), 7.07 (d, 2H, J = 8.3 Hz, Hc), 6.97 (s, 2H, 
H3+7), 5.97 (s, 2H, H1+5), 2.26 (s, 6H, CH3) 
13
C NMR (75 
























H NMR (300 MHz, CDCl3):  7.21 (d, 2H, 
J = 8.4 Hz, Hb), 6.91 (s, 2H, H3+7), 6.81 (d, 4H, J = 8.4 Hz, 
Hc), 5.94 (s, 2H, H1+5), 3.73 (s, 6H, OMe) 
13
C NMR (75 
MHz, CDCl3):  158.9, 139.1, 127.1, 126.2, 114.4, 113.1, 
88.9, 55.5 HRMS (EI): calcd. for C20H18O5 (M
+
) 




















H NMR (300 MHz, CDCl3):  7.29 (bs, 8H, 
Hb+c), 7.18 (bs, 2H, Hd), 7.03 (s, 2H, H3+7), 6.01 (s, 2H, 
H1+5) 
13
C NMR (75 MHz, CDCl3):  140.3, 134.5, 129.3, 




















H NMR (300 MHz, CDCl3):  9.61 (s, 2H, 
CHO), 7.44 (s, 2H, H3), 7.33 (d, 4H, J = 8.2 Hz, Hb), 7.17 
(d, 4H, J = 8.2 Hz, Hc), 2.40 (s, 6H, CH3) 
13
C NMR (75 




















H NMR (300 MHz, CDCl3):  9.49 (s, 2H, 
CHO), 7.32 to 7.30 (m, 6H, H3+b), 6.80 (d, 4H, J = 7.9 Hz, 
Hc), 3.75 (s, 6H, OMe) 
13
C NMR (75 MHz, CDCl3):  
190.1, 160.4, 159.6, 130.0, 126.1, 120.6, 113.5, 55.2 
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To a solution of Boc-glycylglycine (2.63 g, 9.10 mmol), EDC.HCl (2.09 g, 1.2 equiv.) and 
DMAP (1.32 g, 1.2 equiv.) in CH2Cl2 (100 mL) at room temperature, was added 2,2-
diphenylethanamine (1.70 g, 0.95 equiv.) and the reaction mixture was stirred overnight. An 
aqueous solution of HCl (1M) (150 mL) was added. The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined organic fractions were 
washed with H2O (50 mL), dried (MgSO4) and concentrated under reduced pressure. The 
crude solid was dissolved in CH2Cl2 (10 mL) and Et2O (150 mL) was added. The resulting 
white precipitate was sonicated for 5 minutes and filtered by gravity to give 2.2 as a white 
solid (3.59 g, 8.70 mmol, 96%). The product (133 mg, 0.43 mmol) was dissolved in a 15% 
(v/v) solution of TFA in CH2Cl2 (15 mL) and the mixture was stirred overnight at room 
temperature. Solvents were evaporated under reduced pressure. To the crude oil was added 
Et2O (30 mL) and the resulting white precipitate was sonicated for 10 minutes and filtered by 
gravity. The solid was re-dissolved in CH2Cl2 (50 mL), an aqueous saturated solution of 
NaHCO3 (20 mL) was added, the layers were separated and the aqueous layer was extracted 
with CH2Cl2 (5 × 50 mL). The combined organic fractions were dried (MgSO4) and 
concentrated under reduced pressure to afford pure 2.2 as a light yellow oil (48%).  
 
1
H NMR (400 MHz, CDCl3/CD3OD: 3/1):  7.31-7.12 (m, 10H, H5+6+7), 4.26-4.12 (m, 3H, 
H3 and H1 or H2), 3.83 (d, 2H, J = 8.0 Hz, H4), 3.72 (s, 2H, H1 or H2) 
13
C NMR (100 MHz, 
CDCl3/CD3OD: 3/1):  173.4, 169.8, 142.1, 128.8, 128.2, 127.0, 50.6, 44.1 (×2), 42.6 
LRESI-MS: m/z 312 [M+H]
+



















To a solution of 4-hydroxy-3-nitrobenzaldehyde (5.00 g, 29.94 mmol) in CH3CN (200 mL) 
were added allyl bromide (10.40 mL, 4.0 equiv.) and K2CO3 (12.40 g, 3.0 equiv.). After being 
stirred at 60°C for 72 hours, the mixture was diluted with EtOAc and washed with water and 
brine. The combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 7/3 
then 6/4) afforded 2.22 (5.70 g, 27.54 mmol, 92%) as a white yellow powder. The compound 
showed identical spectroscopic data to that reported in Ando, H.; Manabe, S.; Nakahara, Y.; 
Ito, Y. J. Am. Chem. Soc., 2001, 123, 3848-9. 
 
1
H NMR (400 MHz, CDCl3): δ 9.91 (s, 1H, CHO), 8.32 (d, 1H, J = 2.0 Hz, H1), 8.04 (dd, 
1H, J = 8.8 Hz, J = 2.0 Hz, H2), 7.21 (d, 1H, J = 8.8 Hz, H3), 6.07 to 5.98 (m, 1H, H5), 5.50 
(dd, 1H, J = 17.6 Hz, J = 1.2 Hz, H6), 5.37 (dd, 1H, J = 7.8 Hz, J = 1.2 Hz, H6), 4.78 (dt, 2H, 











3-Nitro-4-(2-propenyloxy)benzaldehyde 2.22 (5.60 g, 27.05 mmol) was added in a 10 mL 
round-bottom flask equipped with a condenser and then heated at 160-165°C over a period of 
17 hours. After allowing the dark brown mixture to reach room temperature, it was poured 
into 1M HCl and extracted with dichloromethane. The combined organic layers were dried 
with MgSO4, filtered and concentrated in vacuo. Purification by column chromatography over 
silica gel (petroleum ether/ethyl acetate: 8/2 to 6/4) afforded 2.23 (3.20 g, 15.46 mmol, 57%) 
as a yellow powder and the remaining starting material 2.22. The latter was put in a second 
run in the same conditions described before to afford 680 mg of 2.23 (3.29 mmol, 12%) 
resulting in a total yield of 69%. 
 




H NMR (400 MHz, CDCl3): δ 11.41 (bs, 1H, OH), 9.91 (s, 1H, CHO), 8.51 (d, 1H, J = 2.0 
Hz, H1), 8.01 (d, 1H, J = 2.0 Hz, H2), 6.03 to 5.93 (m, 1H, H4), 5.20 to 5.18 (m, 1H, H5), 5.16 
(dq, 1H, J = 11.2 Hz, J = 1.6 Hz, H5), 3.53 (d, 2H, J = 6.8 Hz, H3) 
13
C NMR (100 MHz, 
CDCl3): δ 189.0, 157.7, 135.8, 134.1, 133.5, 133.3, 128.4, 126.9, 118.0, 33.7 LRFAB-MS 
(3-NOBA matrix): m/z 208 [M+H]
+












To a solution of 2.23 (100 mg, 0.48 mmol) in CHCl3/iPrOH (2.40 mL/1.60 mL) was added 
silica (90 mg). The mixture was cooled in an ice-water bath and NaBH4 (320 mg, 12.0 equiv.) 
was added portion wise. After 1 hour at 0°C, the solution was allowed to reach room 
temperature and filtered on Celite
®
, the pad being washed with CH2Cl2. Evaporation and 
purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 9/1 to 
8/2) afforded 2.24 as a yellow solid (40 mg, 0.19 mmol, 40%). 
 
1
H NMR (400 MHz, CDCl3): δ 10.92 (bs, 1H, OH), 7.98 (d, 1H, J = 2.0 Hz, H1), 7.48 (d, 
1H, J = 2.0 Hz, H2), 6.03 to 5.93 (m, 1H, H4), 5.15 (t, 1H, J = 1.2 Hz, H5), 5.12 (dq, 1H, J = 
6.4 Hz, J = 1.2 Hz, H5), 4.65 (s, 2H, H6), 3.48 (d, 2H, J = 6.4 Hz, H3), 1.91 (bs, 1H, CH2-OH) 
13
C NMR (100 MHz, CDCl3): δ 152.8, 136.4, 135.1, 133.3, 132.5, 131.9, 121.2, 117.2, 64.0, 
33.9 LRESI-MS (negative): m/z 208 [M-H]
-


















To a solution of 2.23 (370 mg, 1.79 mmol, 1.1 equiv.) in CH3CN (20 mL) cooled in an ice-
water bath was added glucuronide (645 mg, 1.62 mmol) and Ag2O (565 mg, 1.5 equiv.). After 
overnight stirring at room temperature, the solution was filtered through silica, eluted with 
ethyl acetate and concentrated under reduced pressure. Purification by column 
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chromatography over silica gel (petroleum ether/ethyl acetate: 85/15 then 6/4) afforded 2.25 
as a white yellow powder (776 mg, 1.48 mmol, 83%). 
 
1
H NMR (400 MHz, CDCl3): δ 9.95 (s, 1H, CHO), 8.12 (d, 1H, J = 2.0 Hz, H6), 7.95 (d, 1H, 
J = 2.0 Hz, H7), 5.94 to 5.85 (m, 1H, H9), 5.33 to 5.28 (m, 2H, H2+3), 5.24 to 5.14 (m, 3H, 
H4+10), 5.03 to 5.01 (m, 1H, H1), 3.91 (d, 1H, J = 10.0 Hz, H5), 3.68 (s, 3H, COOMe), 3.64 (d, 
2H, J = 6.8 Hz, H8), 2.13 (s, 3H, H-Ac), 2.02 (s, 3H, H-Ac), 1.99 (s, 3H, H-Ac) 
13
C NMR 
(100 MHz, CDCl3): δ 189.1, 170.0, 169.5 (x2), 166.3, 149.6, 145.2, 139.9, 134.8, 134.7, 
133.3, 124.1, 118.5, 102.1, 72.5, 71.6, 70.9, 69.1, 53.0, 34.2, 20.7, 20.6, 20.5 LRESI-MS: 
m/z 546 [M+Na]
+





















To a solution of 2.25 (330 mg, 0.63 mmol) in CHCl3/iPrOH (8.4 mL/5.6 mL) was added silica 
(312 mg). The mixture was cooled in an ice-water bath and NaBH4 (288 mg, 12.0 equiv.) was 
added portion-wise. After 2 hours at 0°C, the solution was allowed to reach room temperature 
and filtered on Celite
®
, the pad being washed with CH2Cl2. Evaporation and purification by 
column chromatography over silica gel (petroleum ether/ethyl acetate: 6/4 to 3/7) afforded 
2.26 as a white yellow powder (263 mg, 0.50 mmol, 79%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.62 (d, 1H, J = 2.0 Hz, H6), 7.40 (d, 1H, J = 2.0 Hz, H7), 
5.92 to 5.82 (m, 1H, H9), 5.32 to 5.19 (m, 3H, H2+3+4), 5.13 (bs, 1H, H10), 5.11 to 5.09 (m, 1H, 
H10), 4.93 to 4.91 (m, 1H, H1), 4.67 (s, 2H, H11), 3.87 (d, 1H, J = 10.0 Hz, H5), 3.69 (s, 3H, 
COOMe), 3.57 to 3.54 (m, 2H, H8), 2.42 (bs, 1H, OH), 2.13 (s, 3H, H-Ac), 2.01 (s, 3H, H-
Ac), 1.98 (s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 170.1, 169.7, 169.6, 166.5, 144.8, 
144.4, 139.2, 138.1, 135.6, 132.5, 121.2, 117.5, 102.3, 72.5, 71.8, 71.0, 69.3, 63.5, 52.9, 34.2, 
20.7 (x2), 20.5 LRFAB-MS (3-NOBA matrix): m/z 549 [M+Na]
+
 HRFAB-MS (3-NOBA 
matrix): m/z 549.1446 (calcd. for C23H28NO13Na 549.1453 [M+Na]
+
) m.p. 68-70°C 
 



















To a solution of 2.26 (328 mg, 0.62 mmol) in MeOH (20 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (68 mg, 2.0 equiv.) in MeOH (5 mL). Stirring was 
continued for 2 hours at 0°C and the solution was neutralised with Amberlite IR-120 and 
filtered. MeOH was then evaporated and the resulting mixture was purified by column 
chromatography over silica gel (CH2Cl2/MeOH: 1 to 10% MeOH) to afford 2.27 (242 mg, 
0.61 mmol, 98%) as a white yellow powder. 
 
1
H NMR (400 MHz, CD3OD): δ 7.56 (d, 1H, J = 2.0 Hz, H6), 7.46 (d, 1H, J = 2.0 Hz, H7), 
6.02 to 5.92 (m, 1H, H9), 5.14 to 5.09 (m, 2H, H10), 4.61 to 4.58 (m, 3H, H1+11), 3.73 (s, 3H, 
COOMe), 3.67 to 3.29 (m, 6H, H2+3+4+5+8) 
13
C NMR (100 MHz, CD3OD): δ 170.1, 147.7, 
145.9, 140.8, 138.0, 137.6, 133.5, 121.8, 117.4, 106.2, 76.9 (x2), 74.9, 72.6, 63.6, 52.8, 34.5 
LRESI-MS: m/z 423 [M+Na]
+
 HRESI-MS: m/z 417.1504 (calcd. for C17H25N2O10 417.1504 
[M+NH4]
+


















To a solution of 2.27 (133 mg, 0.34 mmol) in H2O (10 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of 1M NaOH (2 mL). Stirring was continued for 30 minutes 
at 0°C and the solution was neutralised with Amberlite IR-120, filtered and washed with 




H NMR (400 MHz, CD3OD): δ 7.55 (d, 1H, J = 2.0 Hz, H6), 7.42 (d, 1H, J = 2.0 Hz, H7), 
6.01 to 5.91 (m, 1H, H9), 5.10 to 5.05 (m, 2H, H10), 4.61 (d, 1H, J = 7.6 Hz, H1), 4.55 (s, 2H, 
H11), 3.60 (d, 1H, J = 6.8 Hz, H5), 3.54 to 3.25 (m, 5H, H2+3+4+8) 
13
C NMR (100 MHz, 
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CD3OD): δ 171.5, 147.3, 146.0, 140.6, 138.2, 137.6, 133.5, 121.8, 117.3, 106.2, 77.1, 77.0, 
74.9, 72.8, 63.6, 34.6 LRESI-MS (negative mode): m/z 384 [M-H]
-
 HRESI-MS (negative 
mode): m/z 384.0930 (calcd. for C16H18NO10 384.0925 [M-H]
-



















To a solution of 2.23 (570 mg, 2.75 mmol, 1.1 equiv.) in CH3CN (30 mL) cooled in an ice-
water bath was added α-D-galactopyranosyl bromide-2,3,4,6-tetraacetate (1.03 g, 2.51 mmol) 
and Ag2O (872 mg, 1.5 equiv.). After overnight stirring at room temperature, the solution was 
filtered through silica, eluted with ethyl acetate and concentrated under reduced pressure. 
Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 85/15 
then 6/4) afforded 2.29 as a white yellow powder (1.16 g, 2.16 mmol, 79%). 
 
1
H NMR (400 MHz, CDCl3): δ 9.97 (s, 1H, CHO), 8.11 (d, 1H, J = 2.0 Hz, H7), 7.96 (d, 1H, 
J = 2.0 Hz, H8), 5.96 to 5.86 (m, 1H, H10), 5.48 (dd, 1H, J = 10.4 Hz, J = 7.6 Hz, H2), 5.37 (d, 
1H, J = 2.8 Hz, H4), 5.22 to 5.14 (m, 2H, H11), 5.05 (dd, 1H, J = 10.4 Hz, J = 3.2, H3), 4.95 
(d, 1H, J = 8.0 Hz, H1), 4.02 (d, 2H, J = 6.8 Hz, H6), 3.81 (dt, 1H, J = 6.8 Hz, J = 0.8 Hz, H5), 
3.58 (dd, 2H, J = 6.4 Hz, J = 1.2 Hz, H9), 2.18 (s, 3H, H-Ac), 2.16 (s, 3H, H-Ac), 1.99 (s, 3H, 
H-Ac), 1.96 (s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 189.1, 170.3, 170.2, 170.1, 169.6, 
149.6, 145.5, 139.2, 134.7, 134.6, 133.1, 124.1, 118.3, 102.3, 71.5, 70.6, 68.7, 66.6, 60.8, 


































To a solution of 2.29 (700 mg, 1.30 mmol) in CHCl3/iPrOH (20 mL/14 mL) was added silica 
(1.0 g). The mixture was cooled in an ice-water bath and NaBH4 (594 mg, 12.0 equiv.) was 
added portion-wise. After 2 hours at 0°C, the solution was allowed to reach room temperature 
and filtered on Celite
®
, the pad being washed with CH2Cl2. Evaporation and purification by 
column chromatography over silica gel (petroleum ether/ethyl acetate: 6/4 to 3/7) afforded 
2.30 as a white yellow powder (608 mg, 1.13 mmol, 87%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.60 (d, 1H, J = 2.0 Hz, H9), 7.40 (d, 1H, J = 1.6 Hz, H11), 
5.93 to 5.83 (m, 1H, H14), 5.45 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.35 (d, 1H, J = 2.8 Hz, 
H4), 5.14 (bs, 1H, H15), 5.11 (dd, 1H, J = 7.2 Hz, J = 1.2 Hz, H15), 5.02 (dd, 1H, J = 10.4 Hz, 
J = 3.6 Hz, H3), 4.82 (d, 1H, J = 8.0 Hz, H1), 4.69 (bs, 2H, H16), 4.03 (dd, 2H, J = 6.8 Hz, J = 
3.6 Hz, H6), 3.77 (t, 1H, J = 6.4 Hz, H5), 3.50 (t, 2H, J = 4.8 Hz, H13), 2.37 (bs, 1H, CH2-OH), 
2.18 (s, 3H, H-Ac), 2.15 (s, 3H, H-Ac), 1.98 (s, 3H, H-Ac), 1.96 (s, 3H, H-Ac) 
13
C NMR 
(100 MHz, CDCl3): δ 170.5, 170.4, 170.2, 169.7, 145.3, 144.4, 139.0, 137.5, 135.6, 132.2, 
121.0, 117.4, 102.7, 71.2, 70.7, 68.7, 66.7, 63.5, 60.8, 34.1, 21.1, 20.9, 20.7, 20.6 LRFAB-




 HRFAB-MS (3-NOBA matrix): 
m/z 562.1528 (calcd. for C24H29NO13Na 562.1537 [M+Na]
+




















To a solution of 2.30 (90 mg, 0.17 mmol) in MeOH (10 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (90 mg, 10.0 equiv.) in MeOH (5 mL). Stirring 
was continued for one hour at 0°C and the solution was neutralised with Amberlite IRC-50 
and filtered. MeOH was then evaporated and the resulting mixture was purified by column 
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chromatography over silica gel (CH2Cl2/MeOH: 10 to 15% MeOH) to afford 2.31 (55 mg, 
0.15 mmol, 88%) as a white brown powder. 
 
1
H NMR (400 MHz, CD3OD): δ 7.57 (d, 1H, J =2.0 Hz, H7), 7.48 (d, 1H, J = 2.0 Hz, H8), 
6.06 to 5.96 (m, 1H, H10), 5.17 to 5.10 (m, 2H, H11), 4.60 (bs, 2H, H12), 4.50 (d, 1H, J = 7.6 
Hz, H1), 3.84 (d, 1H, J = 2.8 Hz, H4), 3.78 (dd, 1H, J = 10.0 Hz, J = 8.0 Hz, H2), 3.72 to 3.55 
(m, 4H, H6+9), 3.48 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 3.35 (t, 1H, J = 6.4 Hz, H5) 
13
C 
NMR (100 MHz, CD3OD): δ 147.9, 146.3, 140.5, 138.1, 137.7, 133.4, 121.5, 117.3, 107.1, 
77.0, 74.7, 72.5, 69.7, 63.7, 61.6, 34.5 LRFAB-MS (3-NOBA matrix): m/z 394 [M+Na]
+
 



























To a solution of 5 (433 mg, 0.80 mmol) in CH2Cl2 (15 mL) was added para-nitrophenyl 
chloroformate (356 mg, 2.2 equiv.) and pyridine (160 µL, 2.5 equiv.). After one day at room 
temperature, the solution was diluted with water and extracted with CH2Cl2. The combined 
organic layers were washed with water, dried over MgSO4 and concentrated in vacuo. 
Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 6/4) 
afforded 7 (540 mg, 0.77 mmol, 96%) as a white powder. 
 
1
H NMR (400 MHz, CDCl3): δ 8.29 (d, 2H, J = 9.2 Hz, H14), 7.71 (d, 1H, J = 2.0 Hz, H7), 
7.50 (d, 1H, J = 2.0 Hz, H8), 7.39 (d, 2H, J = 9.2 Hz, H13), 5.96 to 5.85 (m, 1H, H10), 5.48 (dd, 
1H, J = 10.8 Hz, J = 8.0 Hz, H2), 5.38 (d, 1H, J = 2.4 Hz, H4), 5.27 (bs, 2H, H12), 5.20 to 5.14 
(m, 2H, H11), 5.05 (dd, 1H, J = 10.8 Hz, J = 3.6 Hz, H3), 4.88 (d, 1H, J = 8.0 Hz, H1), 4.06 (t, 
2H, J = 6.8 Hz, H6), 3.80 (t, 1H, J = 7.6 Hz, H5), 3.56 (t, 2H, J = 6.0 Hz, H9), 2.20 (s, 3H, H-
Ac), 2.17 (s, 3H, H-Ac), 2.01 (s, 3H, H-Ac), 1.97 (s, 3H, H-Ac) 
13
C NMR (100 MHz, 
CDCl3): δ 170.4, 170.3, 170.2, 169.7, 155.4, 152.4, 145.7, 145.4, 138.5, 135.3, 134.1, 132.1, 
125.5, 122.9, 121.8, 118.0, 102.7, 71.3, 70.7, 69.1, 68.7, 66.7, 60.8, 34.1, 20.9, 20.8, 20.7, 




 m.p. 66-68°C 


























A solution of the Cbz-protected peptide (2.65 g, 5.27 mmol) in a 3:4:13 mixture 
H2O/MeOH/THF (500 mL) was heated up to 50°C until it had fully dissolved (5 min). The 
solution was then allowed to cool to room temperature and palladium (10%) on carbon (561 
mg) was added in one portion. The reaction vessel was purged with H2 by means of three 
vacuum/H2 cycles and the mixture stirred at room temperature for 15 hours. The solid was 
filtered off with Celite
®
, MeOH and THF were evaporated under reduced pressure and the 
remaining aqueous layer was extracted with CH3Cl/iPrOH (3/1) (3×50 mL). The combined 
organic fractions were dried (MgSO4) and concentrated under reduced pressure. The resulting 
yellow oil was re-dissolved in CH2Cl2 (10 mL) and Et2O (50 mL) was added. The resulting 
white precipitate was sonicated for 5 minutes and filtered by gravity to afford 2.33 as a white 
solid (1.30 g, 3.52 mmol, 67%).  
 
1
H NMR (400 MHz, CDCl3):  8.07-7.81 (m, 1H, H6), 7.42-7.25, 6.75-6.58 (2m, 2H, H2+4), 
7.25-6.95 (m, 10H, H9+10+11), 4.10 (t, 1H, J = 7.8 Hz, H8),  3.75-3.67 (m, 4H, H6+11),  3.75, 
3.64, 3.28 (3s, 4H, H3+5+7) 
13
C NMR (100 MHz, CDCl3):  169.7 (×2), 169.0, 141.7, 128.6, 
128.0, 126.7, 50.2, 43.8 (×2), 42.8, 42.6 LRESI-MS: m/z 391 [M+Na]
+
 HRESI-MS: m/z 
369.1924 (calcd. for C20H25O3N4  369.1921 [M+H]
+













































To a solution of 2.30 (529 mg, 0.75 mmol) in CH3CN (35 mL) was added the peptide 2.33 
(332 mg, 1.2 equiv.) and Et3N (260 µL, 2.5 equiv.). Stirring was continued at room 
temperature during one day and the solution was diluted with water and extracted with ethyl 
acetate. The combined extracts were washed with water, dried over MgSO4 and concentrated. 
Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 4/6 to 
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H NMR (400 MHz, CDCl3): δ 7.57 (d, 1H, J = 2.0 Hz, H7), 7.39 (m, 2H, NH15+17), 7.37 (d, 
1H, J = 2.0 Hz, H8), 7.27 to 7.16 (m, 10H, H22+23+24), 6.65 (t, 1H, J = 5.2 Hz, NH19), 6.08 (t, 
1H, J = 4.8 Hz, NH13), 5.93 to 5.82 (m, 1H, H10), 5.46 (dd, 1H, J = 10.8 Hz, J = 8.0 Hz, H2), 
5.37 (d, 1H, J = 2.8 Hz, H4), 5.15 (d, 1H, J = 1.2 Hz, H11), 5.12 (dd, 1H, J = 9.2 Hz, J = 1.2 
Hz, H11), 5.06 (dd, 1H, J = 10.4 Hz, J = 3.6 Hz, H3), 5.00 (s, 2H, H12), 4.85 (d, 1H, J = 8.0 
Hz, H1), 4.17 (t, 1H, J = 8.0 Hz, H21), 4.03 (d, 2H, J = 6.4 Hz, H6), 3.91 to 3.76 (m, 9H, 
H5+14+16+18+20), 3.50 (m, 2H, H9), 2.19 (s, 3H, H-Ac), 2.15 (s, 3H, H-Ac), 2.00 (s, 3H, H-Ac), 
1.95 (s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 170.5, 170.4, 170.2, 169.8, 169.7, 169.3, 
168.9, 156.4, 145.4, 145.0, 141.9, 137.9, 135.4, 134.4, 133.5, 128.8, 128.1, 126.9, 122.2, 
117.7, 102.7, 71.1, 70.7, 68.8, 66.7, 65.3, 60.7, 50.5, 44.4, 44.0, 43.1, 42.9, 34.0, 29.8, 20.9, 
20.8, 20.7, 20.6 LRESI-MS: m/z 957 [M+Na]
+
 LRFAB-MS (3-NOBA matrix): m/z 935 
[M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 934.3384 (calcd. for C45H52N5O17 934.3359 
[M+H]
+












































To a solution of 2.34 (100 mg, 0.11 mmol) in MeOH (10 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (58 mg, 10.0 equiv.) in MeOH (5 mL). Stirring 
was continued for one hour at 0°C and the solution was neutralised with Amberlite IRC-50 
and filtered. MeOH was then evaporated and the resulting mixture was purified by column 
chromatography over silica gel (CH2Cl2/MeOH: 5 to 20% MeOH) to afford 2.35 (57 mg, 0.07 
mmol, 64%) as a white brown powder. 
 
1
H NMR (400 MHz, CD3OD): δ 7.57 (d, 1H, J = 2.0 Hz, H7), 7.45 (d, 1H, J = 2.0 Hz, H8), 
7.24 to 7.19 (m, 8H, H22+23), 7.14 to 7.10 (m, 2H, H24), 5.99 to 5.89 (m, 1H, H10), 5.11 to 5.04 
(m, 4H, H11+12), 4.47 (d, 1H, J = 8.0 Hz, H1), 4.24 (t, 1H, J = 8.0 Hz, H21), 3.80 to 3.73 (m, 
8H, H14+16+18+20), 3.70 (m, 2H, H4+5), 3.66 to 3.54 (m, 4H, H6+9), 3.44 (dd, 1H, J = 10.0 Hz, J 
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= 3.6 Hz, H3) 
13
C NMR (100 MHz, CD3OD): δ 173.1, 172.1, 171.5, 159.0, 147.9, 147.0, 
143.8, 138.5, 137.5, 135.5, 134.7, 129.6, 129.2, 127.7, 122.8, 117.4, 107.1, 77.1, 74.7, 72.5, 
69.7, 66.5, 61.6, 51.6, 49.9, 45.1, 43.8, 43.3, 34.5 LRES
+





 LRFAB-MS (3-NOBA matrix): m/z 766 [M+H]
+
 HRFAB-MS (3-NOBA 
matrix): m/z 766.2928 (calcd. for C37H44N5O13 766.2936 [M+H]
+





























































Thread 2.34 (200 mg, 0.21 mmol) and Et3N (1.0 mL, 35.0 equiv.) were dissolved in 
anhydrous chloroform (40 mL) and stirred vigorously whilst solutions of p-xylylene diamine 
(466 mg, 16.0 equiv.) in anhydrous chloroform (40 mL) and isophthaloyl dichloride (696 mg, 
16.0 equiv.) in anhydrous chloroform (40 mL) were simultaneously added over a period of 3 
hours using motor-driven syringe pumps. After overnight stirring, 1 mL of MeOH was added 
and the resulting suspension filtered through Celite
®
. The pad was washed with CHCl3/MeOH 
2% (3 x 100 mL) and the combined filtrates were concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel using CH2Cl2/MeOH (1 to 15% 
MeOH) as eluent to give a mixture of thread 2.34 and rotaxane 2.36. This mixture was 
resolved by running a size exclusion chromatography using CHCl3/MeOH (50/50) as eluent to 
give rotaxane 2.36 as a white brown powder (161 mg, 0.11 mmol, 51%). 
 
1
H NMR (400 MHz, CDCl3): δ 8.19 (s, 2H, HC), 8.00 (d, 4H, J = 7.2 Hz, HB), 7.81 (bs, 4H, 
HD), 7.47 (t, 2H, J = 7.6 Hz, HA), 7.35 (s, 1H, H7), 7.23 (s, 1H, H8), 7.21 to 7.09 (m, 18H, 
H22+23+24+F), 6.98 (bs, 3H, NH15+17+19), 5.89 to 5.79 (m, 1H, H10), 5.73 (bs, 1H, NH13), 5.46 (t, 
1H, J = 8.8 Hz, H2), 5.37 (bs, 1H, H4), 5.14 to 5.05 (m, 3H, H3+11), 4.84 (d, 1H, J = 7.6 Hz, 
H1), 4.74 (bs, 2H, H12), 4.48 to 4.39 (m, 8H, HE), 4.05 (t, 1H, J = 8.0 Hz, H21), 4.02 (d, 2H, J 
= 6.8 Hz, H6), 3.80 (t, 1H, J = 6.0 Hz, H5), 3.70 (bs, 2H, H20), 3.46 to 3.42 (m, 4H, H9+14), 
3.30 (bs, 2H, H18), 2.93 (bs, 2H, H16), 2.17 (s, 3H, H-Ac), 2.16 (s, 3H, H-Ac), 2.01 (s, 3H, H-
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Ac), 1.94 (s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 170.5, 170.3, 170.2, 170.1, 169.7, 
169.2, 168.2, 167.2, 156.3, 145.3, 145.0, 141.7, 137.7, 137.4, 135.3, 134.3, 133.9, 133.7, 
131.0, 129.1, 129.0, 128.8, 128.0, 127.0, 125.4, 122.2, 117.7, 102.6, 71.1, 70.7, 68.8, 66.7, 
65.3, 60.7, 50.5, 44.5, 44.2, 42.7, 42.1, 33.9, 20.9, 20.8, 20.7, 20.6 LRFAB-MS (3-NOBA 
matrix): m/z 1467 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 1466.5485 (calcd. for 
C77H80N9O21 1466.5469 [M+H]
+





























































To a solution of 2.36 (98 mg, 0.067 mmol) in MeOH (10 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (36 mg, 10.0 equiv.) in MeOH (5 mL). Stirring 
was continued for one hour at 0°C and the solution was neutralised with Amberlite IRC-50 
resin and filtered. MeOH was then evaporated and the resulting mixture was purified by 
column chromatography over silica gel (CH2Cl2/MeOH: 2 to 10% MeOH) to afford 2.37 (75 
mg, 0.058 mmol, 87%) as a white brown powder. 
 
1
H NMR (400 MHz, CD3OD): δ 8.34 (bs, 2H, HC), 8.05 to 8.03 (m, 4H, HB), 7.59 (t, 2H, J = 
7.6 Hz, HA), 7.23 to 7.01 (m, 18H, H22+23+24+F), 5.97 to 5.87 (m, 1H, H10), 5.09 (dd, 1H, J = 
8.8 Hz, J = 1.6 Hz, H11), 5.05 (bs, 1H, H11), 4.57 (bs, 2H, H12), 4.48 to 4.39 (m, 9H), 3.93 (t, 
1H, J = 8.0 Hz, H21), 3.82 (t, 1H, J = 3.2 Hz), 3.76 (dd, 1H, J = 9.6 Hz, J = 7.6 Hz), 3.65 (dd, 
1H, J = 11.2 Hz, J = 6.8 Hz), 3.57 to 3.44 (m, 10H, H14+16+18+20) 
13
C NMR (100 MHz, 
CD3OD): δ 172.4, 171.2, 170.5, 169.0, 158.1, 147.7, 147.0, 143.6, 138.8, 138.3, 137.5, 135.7, 
134.9, 134.7, 131.7, 130.1, 130.0, 129.9, 129.8, 129.6, 129.4, 129.0, 127.8, 127.7, 122.8, 
117.4, 107.1, 77.1, 74.7, 72.5, 69.7, 66.2, 61.7, 51.7, 49.9, 45.2, 45.0, 44.9, 43.2, 42.6, 34.4 
LRFAB-MS (3-NOBA matrix): m/z 1299 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 
1299.5104 (calcd. for C69H73N9O17 calcd. 1299.5124 [M+H]
+
) m.p. 178-180°C 
 
































































Thread 2.34 (400 mg, 0.43 mmol) and Et3N (2.1 mL, 35.0 equiv.) were dissolved in 
anhydrous chloroform (80 mL) and stirred vigorously whilst solutions of p-xylylene diamine 
(933 mg, 16.0 equiv.) in anhydrous chloroform (60 mL) and 5-azidoisophthaloyl dichloride 
(1.67 g, 16.0 equiv.) in anhydrous chloroform (60 mL) were simultaneously added over a 
period of 5 hours using motor-driven syringe pumps. After overnight stirring, 2 mL of MeOH 
were added and the resulting suspension filtered through Celite
®
. The pad was washed with 
CHCl3/MeOH 2% (2 x 200 mL) and the combined filtrates were concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel using 
CHCl3/acetone (10 to 60% acetone) as eluent to give rotaxane 2.38 as a white yellow powder 
(421 mg, 0.27 mmol, 63%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.88 (bs, 2H, HB), 7.62 (bs, 4H, HC), 7.54 (bs, 4H, HA), 7.34 
(s, 1H, H7), 7.18 to 7.17 (m, 1H, NH), 7.14 (d, 4H, J = 7.6 Hz, HE), 7.10 (s, 1H, H8), 7.07 (bs, 
10H, H22+23+24), 7.01 (d, 4H, J = 7.2 Hz, HE), 6.86 (bs, 2H, NH), 5.83 to 5.73 (m, 1H, H10), 
5.63 (bs, 1H, NH13), 5.39 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.30 (d, 1H, J = 3.6 Hz, H4), 
5.08 to 4.97 (m, 3H, H3+11), 4.77 to 4.76 (m, 3H, H1+12), 4.50 to 4.46 (m, 4H, HD), 4.31 to 4.27 
(m, 4H, HD), 4.00 to 3.91 (m, 3H, H6+21), 3.74 (t, 1H, J = 7.2 Hz, H5), 3.66 (bs, 2H, H20), 3.45 
(bs, 2H, H14), 3.41 (d, 2H, J = 6.4 Hz, H9), 3.25 (bs, 2H, H16/18), 2.97 (bs, 2H, H16/18), 2.10 (s, 
3H, H-Ac), 2.08 (s, 3H, H-Ac), 1.93 (s, 3H, H-Ac), 1.88 (s, 3H, H-Ac) 
13
C NMR (100 MHz, 
CDCl3): δ 170.6, 170.4, 170.2, 169.7, 169.4, 168.1, 166.0, 156.5, 145.3, 145.1, 141.6, 141.5, 
137.8, 137.2, 135.7, 135.3, 133.8, 133.5, 129.3, 128.9, 127.9, 127.2, 122.1, 121.6, 121.0, 
117.8, 102.7, 71.1, 70.7, 68.7, 66.7, 65.4, 60.7, 53.9, 50.6, 44.5, 44.4, 42.9, 42.4, 34.0, 31.9, 
29.4, 21.0, 20.8, 20.7 (x2) LRESI-MS: m/z 1550 [M+H]
+
 LRFAB-MS (3-NOBA matrix): 
m/z 1551 [M+H]
+
 m.p. degradation 
 

















To a solution of peracetylated -D-glucose (1.21 g, 3.10 mmol) and propargyl alcohol (0.27 
mL, 1.5 equiv.) in anhydrous CH2Cl2 (8 mL) under N2 at 0ºC, was added BF3.Et2O (2 mL, 5.0 
equiv.) dropwise. The reaction mixture was allowed to warm up to room temperature and 
stirred overnight. An aqueous saturated solution of NaHCO3 (30 mL) was added, the layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3×25 mL). The combined 
organic fractions were dried (Na2SO4) and concentrated under reduced pressure. The resulting 
brown residue was purified by flash column chromatography on silica gel with CH2Cl2-
acetone (98/2) as eluent to give pure 2.39 as a white solid (940 mg, 2.43 mmol, 79%). The 
compound showed identical spectroscopic data to that reported in Hoheisel, T. N.; Frauenrath, 
H. Org. Lett. 2008, 10, 4525-4528. 
 
1
H NMR (400 MHz, CDCl3):  5.22 (t, 1H, J = 9.5 Hz, H3), 5.08 (t, 1H, J = 9.5 Hz, H4), 4.99 
(t, 1H, J = 9.5 Hz, H2), 4.76 (d, 1H, J = 7.9 Hz, H1),  4.35 (d, 2H, J = 2.4 Hz, H7), 4.26 (dd, 
1H, J = 4.6 Hz, J = 12.3 Hz, H6), 4.13 (dd, 1H, J = 2.2 Hz, J = 12.3 Hz, H6’), 3.71 (ddd, 1H, J 
= 2.4 Hz, J = 4.5 Hz, J = 10.0 Hz, H5), 2.46 (t, 1H, J = 2.4 Hz, H8), 2.07, 2.04, 2.10, 1.99 (4s, 
12H, H-Ac) 
13
C NMR (100 MHz, CDCl3):  170.6, 170.2, 169.3, 169.2, 98.0, 78.0, 75.4, 
72.6, 71.8, 70.8, 68.2, 61.6, 55.8, 20.7, 20.6, 20.5, 20.4 LRESI-MS: m/z 409 [M+Na]
+
  
HRESI-MS: m/z 404.1552 (calcd. for C17H26O10N  404.1551 [M+H]
+




























To a solution of peracetylated -D-glucose (317 mg, 0.81 mmol) and alcohol (283 mg, 1.5 
equiv.) in anhydrous CH2Cl2 (2 mL) under N2 at 0ºC, was added BF3.Et2O (0.52 mL, 5.0 
equiv.) dropwise. The reaction mixture was allowed to warm up to room temperature and 
stirred overnight. An aqueous saturated solution of NaHCO3 (10 mL) was added, the layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3×15 mL). The combined 
organic fractions were dried (Na2SO4) and concentrated under reduced pressure. The resulting 
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brown residue was purified by flash column chromatography on silica gel with 




H NMR (400 MHz, CDCl3):  5.13 (t, 1H, J = 9.5 Hz, H3), 5.01 (t, 1H, J = 9.6 Hz, H4), 4.91 
(dd, 1H, J = 8.0 Hz, J = 9.5 Hz, H2), 4.55 (d, 1H, J = 8.0 Hz, H1),  4.19 (dd, 1H, J = 4.7 Hz, J 
= 12.3 Hz, H6), 4.14 (d, 2H, J = 2.4 Hz, H15), 4.06 (dd, 1H, J = 2.3 Hz, J = 12.3 Hz, H6’), 3.87 
(dt, 1H, J = 4.0 Hz, J = 11.0 Hz, H7), 3.71 to 3.52 (m, 16H, H5+7’+8+9+10+11+12+13+14), 2.40 (t, 
1H, J = 2.3 Hz, H16), 2.01, 1.97, 1.95, 1.93 (4s, 12H, H-Ac) 
13
C NMR (100 MHz, CDCl3):  
170.4, 170.0, 169.2, 169.1, 100.6, 79.5, 74.4, 72.6, 71.5, 71.0, 70.5, 70.4 (×2), 70.3, 70.1, 
70.0, 68.8 (×2), 68.2, 61.7, 58.1, 20.6, 20.5, 20.4, 20.3 LRESI-MS: m/z 585 [M+Na]
+
 






















































































To a solution of rotaxane 2.38 (61 mg, 39.40 µmol) and alkyne 2.39 (30 mg, 2.0 equiv.) in 
CH2Cl2 (7 mL) was added Cu(CH3CN)4PF6 (7 mg, 0.5 equiv.) and Et3N (12 µL, 2.2 equiv.) 
and the solution stirred overnight at room temperature. A saturated NH4Cl solution was then 
added to the reaction mixture and air was bubbled for 30 min. The organic layer was 
separated and washed with 1M EDTA, dried over MgSO4, filtrated and concentrated under 
reduced pressure. The resulting solid was purified by column chromatography on silica gel 
using CHCl3/acetone (30 to 55% acetone) to give rotaxane 2.43 as a white yellow powder (31 
mg, 13.40 µmol, 34%). 
 




H NMR (400 MHz, CDCl3): δ 8.25 (bs, 4H, HA), 8.20 (bs, 2H, HF), 8.09 (bs, 2H, HB), 8.01 
(bs, 4H, HC), 7.35 (s, 1H, H7), 7.17 (s, 1H, H8), 7.10 to 6.99 (m, 19H, HE+19+22+23+24), 6.93 to 
6.87 (m, 3H, H15+17), 5.79 to 5.69 (m, 2H, H10+13), 5.36 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 
5.31 (d, 1H, J = 3.2 Hz, H4), 5.20 to 5.16 (m, 2H, HJ), 5.08 to 4.88 (m, 16H, 
H1+3+11+12+G+H+I+K), 4.47 to 4.44 (m, 4H, HD), 4.34 to 4.31 (m, 4H, HD), 4.22 to 4.11 (m, 4H, 
HM), 4.00 to 3.90 (m, 3H, H6+21), 3.79 to 3.71 (m, 3H, H5+L), 3.62 (bs, 2H, H20), 3.51 (bs, 2H, 
H14), 3.36 (d, 2H, J = 6.8 Hz, H9), 3.24 (bs, 2H, H18), 2.82 (bs, 2H, H16), 2.11 (s, 3H, H-Ac), 
2.07 (s, 3H, H-Ac), 2.01 (s, 6H, H-Ac), 1.97 (s, 6H, H-Ac), 1.95 (s, 6H, H-Ac), 1.94 (s, 6H, 
H-Ac), 1.93 (s, 3H, H-Ac), 1.88 (s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 171.1, 170.7, 
170.4, 170.2, 170.0, 169.7, 169.6, 169.2, 165.7, 145.5, 145.3, 145.0, 141.7, 137.8, 137.3, 
137.2, 136.3, 136.2, 135.3, 133.4, 129.2 (x2), 128.8, 127.9, 127.0, 122.1, 121.9, 121.6, 117.8, 
102.6, 100.4 (x2), 72.8, 72.1, 71.3, 71.1, 70.7, 68.8, 68.4, 66.7, 65.3, 63.0, 62.0, 60.7, 44.7, 
44.2, 33.9, 29.8, 21.0 (x3), 20.9 (x2), 20.8 (x 6), 20.7 LRFAB-MS (3-NOBA matrix): m/z 
2322 [M+H]
+





























































































To a solution of rotaxane 2.38 (100 mg, 64.60 µmol) and alkyne 2.40 (30 mg, 2.0 equiv.) in 
CH2Cl2 (10 mL) was added Cu(CH3CN)4PF6 (12 mg, 0.5 equiv.) and Et3N (20 µL, 2.2 equiv.) 
and the solution stirred overnight at room temperature. A saturated NH4Cl solution was then 
added to the reaction mixture and air was bubbled for 30 min. The organic layer was 
separated and washed with 1M EDTA, dried over MgSO4, filtrated and concentrated under 
reduced pressure. The resulting solid was purified by column chromatography on silica gel 
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using CHCl3/acetone (30 to 55% acetone) to give rotaxane 2.44 as a white yellow powder (31 
mg, 13.40 µmol, 24%). 
 
1
H NMR (400 MHz, CDCl3): δ 8.31 (bs, 6H, HA+F), 8.22 (bs, 2H, HB), 8.18 (bs, 4H, HC), 
7.35 (s, 1H, H7), 7.18 (s, 1H, H8), 7.09 to 6.99 (m, 21H, HE+22+23+24+15+17+19), 5.96 (bs, 1H, 
H13), 5.79 to 5.69 (m, 1H, H10), 5.36 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.30 (d, 1H, J = 
3.2 Hz, H4), 5.03 to 4.98 (m, 3H, H3+11), 4.77 to 4.74 (m, 3H, H1+12), 4.68 (bs, 4H, HG), 4.39 
to 4.35 (m, 8H, HD), 3.97 to 3.94 (m, 3H, H6+21), 3.77 (t, 1H, J = 6.8 Hz, H5), 3.69 to 3.47 (m, 
34H, H20+H+I+J+K+L+M+N+O), 3.37 to 3.35 (m, 2H, H9), 2.96 to 2.79 (m, 7H, H14+16+18), 2.11 (s, 
3H, H-Ac), 2.06 (s, 3H, H-Ac), 1.93 (s, 3H, H-Ac), 1.87 (s, 3H, H-Ac) 
13
C NMR (100 MHz, 
CDCl3): δ 170.6, 170.4, 170.2, 170.1, 170.0, 169.7, 169.2, 168.6, 166.0 (x2), 156.3, 146.2, 
145.3, 145.0, 141.9, 137.7, 137.3, 137.2, 136.3, 136.2, 135.4, 134.2, 133.4, 129.1, 128.7, 
128.0, 126.9, 126.2, 122.0, 121.4, 117.7, 102.6, 72.7, 71.1, 70.7, 70.5 (x2), 70.2, 70.1, 68.8, 
66.7, 65.2, 64.6, 61.5, 60.7, 50.5, 44.7, 44.2, 42.4, 41.8, 34.0, 29.8, 20.9, 20.8, 20.7 (x2) 




 HRFAB-MS (3-NOBA 







































































































To a solution of rotaxane 2.38 (70 mg, 45.20 µmol) and alkyne 2.41 (51 mg, 2.0 equiv.) in 
CH2Cl2 (7 mL) was added Cu(CH3CN)4PF6 (8 mg, 0.5 equiv.) and Et3N (14 µL, 2.2 equiv.) 
and the solution was stirred overnight at room temperature. A saturated NH4Cl solution was 
then added to the reaction mixture and air was bubbled for 30 min. The organic layer was 
separated and washed with 1M EDTA, dried over MgSO4, filtrated and concentrated under 
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reduced pressure. The resulting solid was purified by column chromatography on silica gel 
using CHCl3/acetone (50 to 80% acetone) to give rotaxane 2.45 as a white yellow powder (26 
mg, 9.70 µmol, 21%). 
 
1
H NMR (400 MHz, CDCl3): δ 8.38 (bs, 2H, HB), 8.34 (bs, 2H, HF), 8.25 to 8.19 (m, 8H, 
HA+C), 7.40 (s, 1H, H7), 7.22 (s, 1H, H8), 7.18 to 6.95 (m, 21H, H15+17+19+22+23+24+E), 5.85 to 
5.75 (m, 2H, H10+13), 5.43 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.37 (d, 1H, J = 3.6 Hz, H4), 
5.20 (t, 2H, J = 9.6 Hz, HR), 5.10 to 5.04 (m, 5H, H3+11+S), 5.97 (dd, 2H, J = 9.6 Hz, J = 8.0 
Hz, HQ), 4.82 (m, 3H, H1+12), 4.76 (bs, 4H, HG), 4.58 (d, 2H, J = 8.0 Hz, HP), 4.55 to 4.43 (m, 
8H, HD), 4.24 (dd, 2H, J = 12.0 Hz, J = 4.4 Hz, HU), 4.11 (dd, 2H, J = 12.0 Hz, J = 2.0 Hz, 
HU), 4.07 to 3.98 (m, 3H, H6+21), 3.77 to 3.76 (m, 3H, H5+T), 3.72 to 3.56 (m, 36H, 
H14+20+H+I+J+K+L+M+N+O), 3.42 (d, 2H, J = 6.4 Hz, H9), 3.34 to 3.25 (m, 2H, H18), 2.84 (bs, 2H, 
H16), 2.17 (s, 3H, H-Ac), 2.13 (s, 3H, H-Ac), 2.06 (s, 6H, H-Ac), 2.03 (s, 6H, H-Ac), 2.01 (s, 
6H, H-Ac), 2.00 (s, 3H, H-Ac), 1.99 (s, 6H, H-Ac), 1.95 (s, 3H) 
13
C NMR (100 MHz, 
CDCl3): δ 170.9, 170.4 (x2), 170.2, 169.7, 169.6, 165.8, 146.5, 145.0, 141.8, 137.7, 137.4, 
137.3, 136.4, 136.3, 135.3, 134.1, 133.3, 129.9, 129.1, 128.8, 128.0, 126.9, 126.1, 121.9 (x2), 
121.2, 117.7, 102.6, 101.0 (x2), 72.9, 71.9, 71.4, 71.0, 70.7, 70.6, 70.3, 70.1, 69.3, 68.8, 68.5, 
66.8, 65.2, 64.6, 62.1, 60.7, 50.5, 44.7, 44.3, 44.1, 42.4, 42.3, 41.8, 33.9, 29.8, 29.4, 21.0, 20.9 





MS (3-NOBA matrix): m/z 2695.9802 (calcd. for C126
13
CH153N15O49Na calcd. 2695.9873 
[M+Na]
+

















































































To a solution of rotaxane 2.38 (107 mg, 69.20 µmol) and alkyne 2.42 (14 mg, 2.0 equiv.) in 
CH2Cl2 (10 mL) was added Cu(CH3CN)4PF6 (52 mg, 2.0 equiv.) and the solution stirred 
overnight at room temperature. The solution was then acidified with 1N HCl and then 
extracted with CHCl3/iPrOH (3/1). The organic layer was dried over MgSO4, filtrated and 
concentrated under reduced pressure. The resulting solid was purified by column 
chromatography on silica gel using CH2Cl2/MeOH (2 to 9% MeOH) followed by 
CH2Cl2/MeOH/AcOH (9% MeOH, 0.25% AcOH) to give rotaxane 2.46 as a white yellow 
powder (41 mg, 13.40 µmol, 34%). 
 
1
H NMR (400 MHz, CDCl3:CD3OD 7:3): δ 8.40 (bs, 4H, HA), 8.27 (bs, 2H, HF), 8.14 (bs, 
2H, HB), 7.20 to 6.84 (m, 20H, H7+8+22+23+24+E), 5.84 to 5.74 (m, 1H, H10), 5.37 (dd, 1H, J = 
10.4 Hz, J = 8.0 Hz, H2), 5.32 (d, 1H, J = 3.2 Hz, H4), 5.07 to 5.02 (m, 3H, H3+11), 4.79 (d, 
1H, J = 7.6 Hz, H1), 4.75 (bs, 2H, H12), 4.49 to 4.26 (m, 12H, HD+G), 3.99 to 3.95 (m, 4H, 
H6+21), 3.82 (t, 1H, J = 6.8 Hz, H5), 3.56 (d, 2H, J = 7.6 Hz, HH), 3.45 (bs, 2H), 3.39 (d, 2H, J 
= 6.4 Hz, HH), 3.27 (m, 2H, H9), 3.12 to 3.09 (m, 4H, H14+18), 2.76 (bs, 2H, H16), 2.16 (s, 3H, 
H-Ac), 2.11 (s, 3H, H-Ac), 1.97 (s, 3H, H-Ac), 1.92 (s, 3H, H-Ac) 
13
C NMR (100 MHz, 
CDCl3:CD3OD 7:3): δ 170.7, 170.6, 170.3, 170.1, 169.9, 169.1, 167.3, 166.1, 156.3, 145.1, 
144.6, 141.7, 137.3, 137.2, 136.9, 136.0, 135.9, 135.0, 134.0, 133.2, 128.8, 128.4, 127.6, 
126.6, 126.0, 121.8, 121.7, 120.9, 120.1, 117.2, 102.3, 70.8, 70.6, 68.6, 66.6, 64.9, 60.5, 50.2, 
44.3, 43.7, 43.6, 43.3, 41.8, 41.2, 33.6, 29.5, 20.7, 20.5, 20.3, 20.2 LRESI-MS (negative): 
m/z 1743 [M-H]
-





























































































To a solution of 2.44 (27 mg, 13.40 µmol) in MeOH (4 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (7 mg, 10.0 equiv.) in MeOH (2 mL). Stirring was 
continued for one hour at 0°C and the solution was neutralised with Amberlite IR-120 resin 
and filtered. MeOH was then evaporated and the resulting mixture was purified by preparative 
RP-HPLC using a linear gradient (37 to 55% in 20 min) of MeCN (containing 6.6 mM of 
HCOOH) in H2O (containing 6.6 mM of HCOOH) at a flow rate of 10 ml/min to give 
rotaxane 2.47 as a light yellow solid (17 mg, 9.40 µmol, 70%). Purity (HPLC): >94%. 
 
1
H NMR (400 MHz, CD3OD): δ 8.57 (s, 2H, HB), 8.36 (s, 4H, HA), 8.29 (s, 2H, HF), 7.16 to 
6.89 (m, 20H, H7+8+22+23+24+E), 5.78 to 5.68 (m, 1H, H10), 4.95 to 4.90 (m, 2H, H11), 4.45 to 
4.34 (m, 12H, HD+G), 4.21 (d, 1H, J = 8.0 Hz, H1), 3.88 (t, 1H, J = 8.0 Hz, H21), 3.69 to 3.28 
(m, 52H, H2+3+4+5+6+9+12+14+16+18+20+H+I+J+K+L+M+N+O) 
13
C NMR (100 MHz, CD3OD): δ 171.2, 
167.5, 167.4, 158.1, 147.4, 143.6, 138.7 (x2), 137.4, 134.4, 130.0, 129.6, 129.0, 127.8, 127.7, 
127.3, 123.5, 123.1, 123.0, 122.6, 117.4, 106.9, 77.1, 74.6, 73.6, 72.4, 71.6, 71.5, 71.4, 71.0, 








































































































To a solution of 2.45 (24 mg, 9.00 µmol) in MeOH (4 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (16 mg, 30.0 equiv.) in MeOH (3 mL). Stirring 
was continued for one hour at 0°C and the solution was neutralised with Amberlite IRC-50 
resin and filtered. MeOH was then evaporated and the resulting mixture was purified by 
preparative RP-HPLC using a linear gradient (33 to 45 % in 15 min) of MeCN (containing 6.6 
mM of HCOOH) in H2O (containing 6.6 mM of HCOOH) at a flow rate of 10 ml/min to give 
rotaxane 2.48 as a pink solid (12 mg, 5.50 µmol, 61%). Purity (HPLC): >94%. 
 
1
H NMR (400 MHz, CD3OD): δ 8.72 (s, 2H, HB), 8.54 to 8.51 (m, 4H, HA), 8.43 (s, 2H, HF), 
7.35 to 6.99 (m, 20H, H7+8+22+23+24+E), 5.89 to 5.79 (m, 1H, H10), 5.05 to 4.79 (m, 6H, H11+G), 
4.57 to 4.38 (m, 8H, HD), 4.32 (d, 1H, J = 7.7 Hz, H1), 4.29 (d, 2H, J = 7.8 Hz, HP), 4.03 to 
3.99 (m, 3H, H21+O), 3.87 to 3.39 (m, 52 H, H2+3+4+5+6+9+12+14+16+18+20+H+I+J+K+L+M+N+O) 
13
C 
NMR (100 MHz, CD3OD): δ 168.7, 154.4, 142.0, 137.1, 136.6, 135.9, 128.4, 128.0, 127.4, 
126.2, 126.1, 122.1, 121.7, 121.1, 101.9, 76.5, 76.4, 73.3, 70.0, 69.4 (x2), 69.3, 69.0, 68.9, 
67.6, 63.2, 60.9, 60.1, 43.6, 43.4, 29.2 LRFAB-MS (3-NOBA matrix): m/z 1085 [M+2H]
2+
, 




































To a solution of 3,3,3-tris-(4-chloro-phenyl)-propionic acid (1.53 g, 2.0 equiv.), EDC.HCl 
(984 mg, 3.0 equiv.) and DMAP (625 mg, 3.0 equiv.) in CH2Cl2 (30 mL) at room 
temperature, was added fumaramide (490 mg, 1.71 mmol). The reaction mixture was stirred 
overnight. CH2Cl2 (250 mL) and an aqueous solution (1M) of HCl (50 mL) were added. The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (2×25 mL). The 
combined organic fractions were washed with an aqueous saturated solution of NaHCO3, 
dried (MgSO4) and concentrated under reduced pressure. Purification by flash column 
chromatography on silica using CH2Cl2/MeOH (98/2) as eluent gave 2.49 as a white solid 
(1.50 g, 1.41 mmol, 84%).  
 
1
H NMR (400 MHz, CDCl3/CD3OD: 9/1): δ 8.01 (t, 2H, J = 5.6 Hz, H9), 7.23 to 7.16 (m, 
12H, H1), 7.12 to 7.04 (m, 12H, H2), 6.71 (s, 2H, H10), 3.75 (t, 4H, J = 6.5 Hz, H4), 3.59 (s, 
4H, H3), 3.23 to 3.17 (m, 4H, H8), 1.51-1.26 (m, 8H, H5+7), 1.19 to 1.05 (m, 4H, H6) 
13
C 
NMR (400 MHz, CDCl3/CD3OD: 9/1): δ 170.4, 164.2, 144.2, 133.0, 132.6, 130.3, 128.2, 
64.3, 54.6, 46.0, 39.6, 29.0, 28.0, 23.2 LRFAB-MS: m/z 1061 [M+H]
+
 HRFAB-MS 































































To a vigorously stirred solution of thread 2.49 (525 mg, 4.94 mmol) and Et3N (2 ml, 30.0 
equiv.) in 1 L of dry CHCl3 under nitrogen, was simultaneously added a solution of para-
xylylene diamine (1.00 g, 15.0 equiv.) in CHCl3 (50 mL) and a solution of isophthaloyl 
dichloride (1.81 g, 15.0 equiv.) in CHCl3 (50 mL) over a period of 3 hours using motor-driven 
syringe pumps. The reaction mixture was stirred for another 2 hours, filtered over a Celite

 
pad and the filtrate was concentrated under reduced pressure. The resulting orange solid was 
purified by flash column chromatography on silica with acetone/CH2Cl2 (10/90) as eluent to 
give rotaxane 2.50 (690 mg, 4.12 mmol, 83%).  
 
1
H NMR (400 MHz, CDCl3):  8.03 (m, 2H, HC), 7.81-7.67 (m, 6H, H10+D), 7.66 (s, 4H, HB), 
7.21-7.12 (m, 20H, H1+F), 7.09-7.01 (m, 12H, H2), 5.74 (s, 2H, H10), 4.45 (bs, 8H, HE), 3.72 (t, 
4H, J = 6.5 Hz, H4), 3.14 (m, 2H, H8), 1.45 (bquint, 4H, J = 7.2 Hz, H5),   1.37 to 1.21 (m, 4H, 
H7), 1.17 to 1.05 (m, 4H, H6) 
13
C NMR (100 MHz, CDCl3):  170.3, 165.9, 165.4, 143.8, 
141.6, 136.6, 135.3, 132.3, 130.0, 129.5, 128.7, 127.9, 121.4, 120.8, 64.0, 54.4, 45.7, 43.8, 
39.5, 28.4, 27.7, 23.0 LRESI-MS: m/z 1697 [M+Na]
+
 HRESI-MS: m/z 1694.4408 (calcd. for 
C88H82Cl6N13O10 1694,4439 [M+NH4]
+
), isotopic pattern matches that calculated for 
C88H82Cl6N13O10 m.p. 174-176°C (decomposition) 
 
General method to access functionalised macrocycle 2.53 and 2.54 (click) 
 
To a solution of rotaxane, alkyne (2.0 equiv.), and Cu(CH3CN)4PF6 (0.5 equiv.) in dry CH2Cl2 
(5 mL) and under N2 at room temperature was added Et3N (2.2 equiv.) and the mixture was 
stirred overnight. Air was bubbled through the mixture for 15 minutes then a saturated 
solution of NH4Cl was added (15 ml). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (1 × 10 mL). The combined organic fractions were washed with a 1M 
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solution of EDTA/K2CO3 (2 x 10 mL) and brine (10 mL), then dried (MgSO4) and 










































































Using the general method, rotaxane 2.50 (97 mg, 0.060 mmol), alkyne 2.40 (27 mg, 2.0 
equiv.), Cu(CH3CN)4(PF6) (11 mg, 0.5 equiv.) and Et3N (16 µL, 2.2 equiv.) in CH2Cl2 (15 




H NMR (400 MHz, CDCl3): δ 8.50 to 8.23 (m, 8H, HA, HB+F), 8.23 to 8.07 (m, 2H, H9), 
7.95 to 7.74 (m, 4H, HC), 7.21 to 6.92 (m, 32H, H1, H2+E), 5.86 (s, 2H, H10), 4.80 (s, 4H, HG), 
4.46 to 4.09 (m, 8H, HD), 3.84 to 3.43 (m, 40H, H3+4+H+I+J+K+L+M+N+O), 3.21 to 3.03 (m, 4H, 
H8), 1.53 to 1.19 (m, 8H, H5+7), 1.18 to 1.00 (m, 4H, H6)  
13
C NMR (100 MHz, CDCl3): δ  
170.2, 165.6, 165.0, 146.1, 144.0, 137.4, 136.6, 135.5, 132.4, 130.2, 129.1 (x 2), 129.0, 128.1, 
124.5, 122.2, 121.8, 72.5, 70.5, 70.4, 70.3, 70.0, 69.9, 64.5, 64.1, 61.4, 54.5, 45.8, 44.1, 39.7, 
29.6, 27.9, 23.2 LRMALDI-MS: m/z 2164 [M+Na]
+
, isotopic pattern matches that calculated 



























































































Using the general method, rotaxane 2.50 (250 mg, 0.150 mmol), alkyne 2.41 (168 mg, 2.0 
equiv.), Cu(CH3CN)4(PF6) (28 mg, 0.5 equiv.) and Et3N (455 µL, 2.2 equiv.) in CH2Cl2 (15 




H NMR (400 MHz, CDCl3): δ 8.41 (s, 2H, HB), 8.36 (s, 4H, HA), 8.26 (s, 2H, HF), 7.98-7.77 
(m, 4H, HC), 7.74-7.56 (m, 2H, H9), 7.22-7.12 (m, 12H, H1), 7.12-6.97 (m, 20H, H2 and HE), 
5.75 (s, 2H, H10) 5.21 (t, 2H, J = 9.5 Hz, HR), 5.08 (t, 2H, J = 9.6 Hz, HS), 4.98 (t, 2H, J = 8.8 
Hz, HQ), 4.80 (s, 4H, HG), 4.60 (d, 2H, J = 7.9 Hz, HP), 4.47-4.30 (m, 8H, HD), 4.25 (dd, 2H, J 
= 4.4 Hz and J = 12.2 Hz, HU), 4.13 (d, 2H, J = 11.5Hz, HU’), 3.93 (dt, 2H, J = 4.3Hz and J = 
11.1 Hz, HH), 3.81-3.45 (m, 40H, H3, H4, HH’, HI, HJ, HK, HL HM, HN and HO), 3.20-297 (m, 
4H, H8), 2.07, 2.04, 2.01, 1.99 (4s, 24H, H-Ac), 1.51-1.17 (m, 8H, H5 and H7), 1.17-1.00 (m, 
4H, H6) 
13
C NMR (100 MHz, CDCl3): δ 170.7, 170.2, 169.4, 165.6, 165.5, 165.1, 144.0, 
132.5, 130.2, 128.9, 128.1, 122.3, 100.8, 72.8, 71.7, 71.2, 70.6, 70.5, 70.5, 70.2, 70.0, 69.0, 
68.3, 64.5, 64.1, 61.9, 55.4, 54.5, 45.9, 44.2, 44.2, 39.6, 29.6, 28.7, 27.8, 20.7, 20.6, 20.6, 20.5 
LRMALDI-MS: m/z 2824 [M+Na]
+























































Rotaxane 2.51 (40 mg, 0.018 mmol) was stirred for 4 days at room temperature in a 1M 
solution of NaOH in THF/H2O/EtOH (3/2/5) (10 mL). A 1M aqueous solution of HCl was 
added drop wise until pH equalled 7. The whole solution was loaded on a preparative silica 
TLC plate that was eluted with CH2Cl2/MeOH (15:85) to give macrocycle 2.53 as white waxy 
solid (18 mg, 0.016 mmol, 90%).  
 
1
H-NMR (400 MHz, CD3OD/CDCl3 : 1/1): δ 8.41 (2s, 4H, HA), 8.35 (bs, 2H, HB), 8.11 (t, 
2H, J = 1.4 Hz, HF), 7.28 (s, 8H, HE), 4.53 (s, 8H, HD), 4.70 (s, 2H, HG), 3.72-3.49 (m, 32H, 
HH+I+J+K+L+M+N+O) 
13
C-NMR (100 MHz, CD3OD/CDCl3: 1/1): δ 166.4, 137.8, 137.7, 136.9, 
128.9, 125.3, 122.7, 122.1, 72.8, 70.8, 70.7, 70.6, 70.5, 70.3, 70.1, 64.4, 61.4, 44.3 (x2) 
LRESI-MS: m/z 1101 [M+Na]
+






































































Rotaxane 2.52 (122 mg, 0.050 mmol) was stirred for 48 hours at room temperature in a 10M 
solution of NaOH in THF/H2O/EtOH (1/1/1) (10 mL). A 1M aqueous solution of HCl was 
added drop wise until pH equalled 7. Solvents were removed under vacuum. The resulting 
solid was re-dissolved in a 1/1 mixture of MeCN/H2O (10 mL), filtered by gravity and the 
filtrate used for purification by preparative RP-HPLC using a linear gradient of MeCN (25 to 
40% in 20 min) in H2O to give macrocycle 2.54 as a white solid (18 mg, 0.012 mmol, 25%).  
 
1
H-NMR (400 MHz, CD3OD/CDCl3: 1/1): δ 8.41, 8.40 (2s, 6H, HA+B), 8.09 (s, 2H, HF), 
7.23 (s, 8H, HE), 4.70 (s, 4H, HG), 4.55-4.42 (m, 8H, HD), 4.16 (d, J = 7.8 Hz, 2H, HP), 3.95 to 
3.83 (m, 2H, HO), 3.74 (dd, 2H, J = 2.7 Hz, J = 12.1 Hz, HU) 3.73-3.49 (m, 32H, 
HH+I+J+K+L+M+N+O’+U’) 3.26 to 3.00 (m, 8H, HQ+R+S+T) 
13
C-NMR (100 MHz, CD3OD/CDCl3: 
1/1): δ 166.5, 146.3, 137.8, 137.7, 136.8, 128.9, 125.4, 122.7, 122.2, 103.1, 76.6, 76.5, 73.8, 
70.8 (x 2), 70.7, 70.6, 70.5, 70.4, 70.3, 70.0, 68.7, 64.4, 61.9, 44.3 LRESI-MS: m/z 1425 
[M+H]
+
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2,4-Dihydroxybenzaldehyde (2.00 g, 14.49 mmol) was slowly added to a mixture of 
HNO3/AcOH (20 mL/8 mL). The solution was stirred overnight at room temperature and 
poured into water. Extraction with CH2Cl2, MgSO4 drying and evaporation afforded a yellow 
powder which was co-evaporated with toluene several times to remove AcOH. Purification by 
column chromatography over silica gel (petroleum ether/ethyl acetate: 8/2 then 7/3) afforded 
2.55 (1.3 g, 7.10 mmol, 48%) as a yellow powder. 
 
1
H NMR (300 MHz, CDCl3): δ 11.64 (s, 1H, OH), 11.21 (s, 1H, OH), 9.83 (s, 1H, CHO), 
8.49 (s, 1H, H2), 6.63 (s, 1H, H1) 
13
C NMR (75 MHz, CDCl3): δ 194.0, 168.0, 161.4, 133.6, 
125.9, 115.2, 106.1 LRESI-MS (negative mode): m/z 182 [M-H]
-

























To a solution of α-D-galactopyranosyl bromide-2,3,4,6-tetraacetate (3.30 g, 2.1 equiv.) in 
CH3CN (30 mL) cooled in an ice-water bath was added 2.55 (730 mg, 3.99 mmol) and Ag2O 
(2.30 g, 2.5 equiv.). After overnight stirring at room temperature, the solution was filtered 
through silica, washed with ethyl acetate and concentrated under reduced pressure. 
Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 1/1 to 
10/11) afforded 2.56 as a white powder (2.20 g, 2.61 mmol, 65%). 
 
1
H NMR (300 MHz, CDCl3): δ 10.22 (s, 1H, CHO), 8.43 (s, 1H, H8), 6.91 (s, 1H, H7), 5.44 
(d, 1H, J = 7.9 Hz, H1), 5.65 to 5.28 (m, 6H, H2+3+4), 5.35 (d, 1H, J = 8.2 Hz, H1), 4.41 to 4.26 
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(m, 4H, H5+6b), 4.05 to 3.95 (m, 2H, H6a), 2.23 to 1.99 (m, 24H, H-Ac) 
13
C NMR (75 MHz, 
CDCl3): δ 186.1, 171.3, 171.1, 170.3 (x2), 170.2, 170.1, 169.4, 169.3, 161.2, 154.8, 135.7, 
126.9, 120.2, 103.4, 99.1, 97.8, 71.2, 71.0, 70.5, 70.3, 68.0, 67.5, 67.0, 66.9, 61.3, 61.2, 20.8, 
20.6 (x2), 20.5 LRFAB-MS (3-NOBA matrix): m/z 867 [M+Na]
+
 HRFAB-MS (3-NOBA 
matrix): m/z 866.1958 (calcd. for C35H41NO23Na 866.1962 [M+Na]
+

























To a solution of 2.56 (2.00 g, 2.37 mmol) in CHCl3/iPrOH (16 mL/11 mL) was added silica 
(1.80 g). The mixture was cooled in an ice-water bath and NaBH4 (1.10 g, 12.0 equiv.) was 
added portion wise. After 3 h at 0°C, the solution was allowed to reach room temperature and 
filtered on Celite
®
, the pad being washed with CH2Cl2. Evaporation and purification by 
column chromatography over silica gel (petroleum ether/ethyl acetate: 4/6 to 3/7) afforded 
2.57 as a white powder (1.70 g, 1.97 mmol, 83%). 
 
1
H NMR (300 MHz, CDCl3): δ 7.95 (s, 1H, H8), 6.91 (s, 1H, H7), 5.61 to 5.48 (m, 4H, H2+4), 
5.35 to 5.31 (m, 2H, H1+3), 5.25 to 5.19 (m, 2H, H1+3), 4.64 and 4.57 (d, AB system, 2H, J = 
13.9 Hz, H9), 4.38 to 4.27 (m, 3H, H5+6b), 4.20 to 4.13 (m, 1H, H5), 4.05 to 3.98 (m, 2H, H6a), 
2.62 (bs, 1H, OH), 2.23 to 2.02 (m, 24H, H-Ac) 
13
C NMR (75 MHz, CDCl3): δ 171.0, 170.8, 
170.4, 170.3, 170.2 (x2), 170.0, 169.5, 157.5, 150.4, 135.3, 126.4, 126.1, 104.9, 100.0, 98.1, 
71.1, 71.0, 70.6, 70.3, 68.5, 67.8, 67.0, 66.8, 61.2, 61.1, 59.8, 20.9 (x2), 20.8, 20.7, 20.6 
LRFAB-MS (3-NOBA matrix): m/z 868 [M+Na]
+
 HRFAB-MS (3-NOBA matrix): m/z 
852.2361 (calcd. for C35H43NO23Li 852.2386 [M+Li]
+


































To a solution of 2.57 (700 mg, 0.83 mmol) in CH2Cl2 (15 mL) was added para-nitrophenyl 
chloroformiate (370 mg, 2.2 equiv.) and pyridine (170 µL, 2.5 equiv.). After one day at room 
temperature, the solution was diluted with water and extracted with CH2Cl2. The combined 
organic layers were washed with water, dried over MgSO4 and concentrated in vacuo. 
Purification by column chromatography over silica gel (petroleum ether/ethyl acetate: 7/3-
65/35 and 1/1) afforded 2.58 (803 mg, 0.80 mmol, 96%) as a white powder. 
 
1
H NMR (300 MHz, CDCl3): δ 8.29 (d, 2H, J = 9.2 Hz, H11), 8.07 (s, 1H, H8), 7.43 (d, 2H, J 
= 9.2 Hz, H10), 6.94 (s, 1H, H7), 5.63 to 5.50 (m, 4H, H2+4), 5.36 to 5.14 (m, 6H, H1+3+9), 4.38 
to 4.22 (m, 4H, H5+6b), 4.07 to 3.98 (m, 2H, H6a), 2.23 to 2.02 (m, 24H, H-Ac) 
13
C NMR (75 
MHz, CDCl3): δ 171.1, 170.4, 170.3, 170.2, 170.1, 169.7, 169.5, 158.3, 155.5, 152.4, 151.8, 
145.7, 135.0, 128.5, 125.5, 122.0, 118.8, 104.3, 99.5, 98.1, 71.1, 71.0, 70.5, 70.4, 68.0, 67.7, 
67.0, 66.9, 64.6, 61.2, 61.1, 21.0 (x2), 20.8 (x3), 20.7 LRESI-MS: m/z 1033, 1034, 1035 
[M+Na]
+












































To a solution of 2.58 (780 mg, 0.77 mmol) in CH3CN (40 mL) was added peptide 2.2 (286 
mg, 1.2 equiv.) and Et3N (0.3 mL, 2.5 equiv.). Stirring was continued at room temperature 
during a period of 19 hours then the solution was diluted with water and extracted with ethyl 
acetate. The combined extracts were washed with water, dried over MgSO4 and concentrated 
under reduced pressure. Purification by column chromatography over silica gel (petroleum 
ether/ethyl acetate: 4/6 to 2/8 then CH2Cl2/MeOH: 9/1) yielded 2.59 as a white powder (699 
mg, 0.59 mmol, 77%). 




H NMR (400 MHz, CDCl3): δ 7.89 (s, 1H, H8), 7.31 to 7.18 (m, 10H, H17+18+19), 7.07 (bt, 
1H, J = 4.8 Hz, NH14), 6.94 (s, 1H, H7), 6.32 (bt, 1H, J = 5.6 Hz, NH12), 5.75 (bt, 1H, J = 5.2 
Hz, NH10), 5.57 (dd, 1H, J = 8.0 Hz, J = 10.4 Hz, H2), 5.51 to 5.49 (m, 3H, H2+4), 5.32 to 5.30 
(m, 3H, H1+3), 5.23 (dd, 1H, J = 3.2 Hz, J = 10.4 Hz, H3), 5.19 (d, 1H, J = 8.0 Hz, H1), 5.06 
and 4.98 (d, AB system, 2H, J = 13.9 Hz, H9), 4.37 to 4.26 (m, 3H, H5+6b), 4.20 to 4.16 (m, 
2H, H5+16), 4.09 to 4.00 (m, 2H, H6a), 3.88 (t, 2H, J = 6.4 Hz, H15), 3.81 to 3.78 (m, 4H, 
H11+13), 2.22 to 2.02 (m, 24H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 170.9, 170.7, 170.2, 
170.1, 170.0, 169.9, 169.7, 169.3 (x2), 168.6, 157.2, 156.1, 150.6 , 141.7, 141.6, 135.0, 128.7, 
127.9, 126.8, 126.3, 121.2, 104.9, 99.6, 98.0, 70.9, 70.4, 70.2, 68.1, 67.5, 66.8, 66.7, 61.0 





HRFAB-MS (3-NOBA matrix): m/z 1183.3765 (calcd. for 
C54H63N4O26 1183.3731 [M+H]
+






























































Thread 2.59 (200 mg, 0.17 mmol) and triethylamine (0.9 mL, 35.0 equiv.) were dissolved in 
anhydrous chloroform (40 mL) and stirred vigorously whilst solutions of p-xylylene diamine 
(377 mg, 16.0 equiv.) in anhydrous chloroform (40 mL) and isophthaloyl dichloride (563 mg, 
16.0 equiv.) in anhydrous chloroform (40 mL) were simultaneously added over a period of 3 
hours using motor-driven syringe pumps. After overnight stirring, 1 mL of MeOH was added 
and the resulting suspension filtered through Celite
®
. The solid was washed with 
CHCl3/MeOH 2% (3 x 100 mL) and the combined filtrates were concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel using 
CHCl3/MeOH (1 to 7% MeOH) as eluent to give a mixture of thread and rotaxane. This 
mixture was resolved by size exclusion chromatography using CHCl3/MeOH (50/50: v/v) as 
eluent to give rotaxane 2.60 as a white powder (93 mg, 0.05 mmol, 31%). 
 
1
H NMR (400 MHz, CDCl3): δ 8.15 (s, 2H, HC), 7.98 (t, 4H, J = 7.6 Hz, HB), 7.64 (t, 2H, J = 
4.4 Hz, HD), 7.55 (bs, 3H, H8+D), 7.46 (t, 2H, J = 8.0 Hz, HA), 7.32 (ls, 1H, NH14), 7.23 to 
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7.06 (m, 18H, H17+18+19+F), 6.91 (s, 1H, H7), 6.49 (bs, 1H, NH12), 5.64 (bs, 1H, NH10), 5.56 
(dd, 1H, J = 8.0 Hz, J = 10.4 Hz, H2), 5.49 (d, 2H, J = 3.2 Hz, H4), 5.46 (dd, 1H, J = 8.0 Hz, J 
= 10.4 Hz, H2), 5.31 (dd, 1H, J = 3.6 Hz, J = 10.4 Hz, H3), 5.23 (dd, 1H, J = 10.4 Hz, J = 3.2 
Hz, H3), 5.21 (t, 2H, J = 8.0 Hz, H1), 4.64 (bs, 2H, H9), 4.54 to 4.49 (m, 8H, HE), 4.45 to 4.27 
(m, 3H, H5+6b), 4.19 (t, 1H, J = 6.4 Hz, H5), 4.10 to 4.00 (m, 3H, H6a+16), 3.71 (t, 2H, J = 6.0 
Hz, H15), 3.34 (d, 2H, J = 5.2 Hz, H11), 2.80 (bdd, 2H, J = 22.4 Hz, J = 17.2 Hz, H13), 2.14 to 
2.02 (m, 24H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 170.9, 170.8, 170.1 (x2), 170.0, 169.9, 
169.5, 169.5, 169.4, 168.4, 166.9, 166.8, 157.2, 156.2, 156.1, 150.6, 141.4, 137.3, 137.2, 
134.8, 134.0, 133.9, 131.0, 130.8, 128.9, 128.7, 127.8, 126.9, 126.3, 124.8, 120.8, 105.6, 99.5, 
98.2, 77.2, 70.9, 70.3, 70.1, 68.1, 67.6, 66.8, 61.0, 60.4, 44.3, 44.1, 41.8, 29.6, 20.8 (x2), 20.7, 
20.6, 20.5 LRESI-MS: m/z 1716 [M+H]
+
 LRFAB-MS (3-NOBA matrix): m/z 1717 
[M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 1715.5789 (calcd. for C86H91N8O30 1715.5841 
[M+H]
+












































To a solution of 2.59 (250 mg, 0.21 mmol) in MeOH (40 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (228 mg, 20.0 equiv.) in MeOH (12 mL). Stirring 
was continued for one hour at 0°C and the solution was neutralised with IRC-50 resin and 
filtered. MeOH was then evaporated and the resulting mixture was purified by column 
chromatography over silica gel (CH2Cl2/MeOH: 20 to 50% MeOH) to afford 2.61 (144 mg, 
0.17 mmol, 81%) as a yellow powder. 
 
1
H NMR (400 MHz, CDCl3): δ 7.98 (s, 1H, H8), 7.30 to 7.15 (m, 11H, H7+17+18+19), 5.18 (m, 
2H, H9), 5.14 (d, 1H, J = 8.0 Hz, H1), 5.09 (d, 1H, J = 8.0 Hz, H1), 4.27 (t, 1H, J = 8.0 Hz, 
H16), 4.03 (dd, 2H, J = 4.0 Hz, J = 8.0 Hz, H5), 3.91 to 3.72 (m, 16H, H2+4+6+11+13+15) 
13
C 
NMR (100 MHz, CD3OD): δ 172.8, 171.6, 170.4, 160.7, 153.7, 143.8, 134.7, 129.6, 129.2, 
127.7, 127.6 , 120.4, 104.7, 102.3, 102.1, 77.7, 74.9, 74.8, 71.9 (x2), 70.6, 63.1 (x2), 62.2, 
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HRFAB-MS (3-NOBA matrix): m/z 869.2698 (calcd. for C38H46N4O18Na 869.2699 
[M+Na]
+






























































To a solution of 2.60 (43 mg, 0.025 mmol) in MeOH (5 mL) cooled in an ice-water bath was 
added dropwise at 0°C solution of MeONa (27 mg, 20.0 equiv.) in MeOH (1.5 mL). Stirring 
was continued for one hour at 0°C and the solution was neutralised with IRC-50 resin and 
filtered. MeOH was then evaporated and the resulting mixture was purified by column 
chromatography over silica gel (CH2Cl2/MeOH: 10 to 50% MeOH) to afford 2.62 (30 mg, 
0.022 mmol, 88%) as a yellow powder. 
 
1
H NMR (400 MHz, CD3OD): δ 8.27 (bs, 2H, HC), 8.01 (dd, 4H, J = 7.6 Hz, J = 1.6 Hz, HB), 
7.62 to 7.58 (m, 3H, H8+A), 7.21 to 7.12 (m, 15H, H7+17+18+19+F), 6.99 to 6.97 (m, 4H, HF), 5.10 
(d, 1H, J = 7.6 Hz, H1), 4.98 (d, 1H, J = 8.0 Hz, H1), 4.78 and 4.68 (d, AB system, 2H, J = 
13.2 Hz, H9), 4.33 (bs, 8H, HE), 4.06 to 3.80 (m, 11H, H2+4+5+6+15+16), 3.63 (dd, 1H, J = 9.6 
Hz, J = 3.2 Hz, H3), 3.57 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 3.49 to 3.38 (m, 4H, H6+13), 
2.78 and 2.65 (d, AB system, 2H, J = 16.4 Hz, H11) 
13
C NMR (100 MHz, CD3OD): δ 171.9, 
170.3, 169.3, 160.4, 158.3, 153.6, 143.6, 138.6, 135.6, 135.5, 134.0, 131.8, 131.7, 130.1, 
129.9, 129.8, 129.6, 129.0, 127.8, 127.7, 119.6, 104.3, 102.2, 102.1, 77.7, 77.6, 74.9, 74.8, 
71.8, 71.7, 70.6, 70.5, 63.2, 63.1, 61.8, 49.9, 45.3, 45.2, 44.9, 44.8, 42.3 LRESI-MS: m/z 
1401.8, 1402.8, 1403.8 [M+Na]
+
 LRFAB-MS (3-NOBA matrix): m/z 1403 [M+Na]
+
 









CHAPT. 3 | ROTAXANE-BASED DELIVERY 
SYSTEMS: PROTECTION AND ENZYMATIC 
RELEASE OF A BIOACTIVE PENTAPEPTIDE 
 
 
Prepared as a paper for Angewandte Chemie 
 
 
The work presented in this chapter was done in collaboration with Aurélien Viterisi who 
carried out the HPLC purifications of the final prodrugs 1 and 7 and monitored their 
enzymatic hydrolysis and plasma stability. 




In the light of the encouraging results obtained in the model studies presented in 
Chapter 2, we decided to apply our concept to a biologically active peptide, Met-enkephalin 
(H-Tyr-Gly-Gly-Phe-Met-OH). The anticancer potential of Met-enkephalin and the presence 
of the Gly-Gly motif in its primary structure prompted us to choose this opioid peptide. 
Moreover, the CPK models demonstrated on the one hand that the PheMet motif acts as a 
natural C-terminal stopper, on the other hand the consecutive HMR 1826 spacer and the first 











































Scheme 3.1 | The Met-enkephalin rotaxane prodrug 
 
Accordingly, it is not necessary in this system to add a supplementary group to the self-
immolative spacer (as we have tried to do in Chapter 2) to transform it into a stopper. As a 
result this system seems quite interesting since the spacer moiety is not modified and the 
macrocycle is held away from the trigger and the glycosidic bond. Additionally, the free C-
terminus group also bodes well for good water solubility and persuaded us to use the easily 
synthesisable galactosyl derivative along with the classical non-functionalised amide-based 
macrocycle.  
 
We designed the galactosylated Met-enkephalin rotaxane 1 associating the conventional 
enzyme-activated constructions with the hydrogen bond-directed assembly of peptide 
rotaxanes. Met-enkephalin 2 (H-Tyr-Gly-Gly-Phe-Met-OH), also termed the opioid growth 
factor (OGF), has unambiguously been identified as a potential antitumour peptide controlling 
cell growth activity.
114
 The receptor-mediated antiproliferative effect of the opioid peptide 
was recently reported on human head and neck squamous cell carcinoma (HNSCC) and 
                                                 
114
 a) Fichna, J.; Janecka, A. Cancer and Metastasis Rev. 2004, 23, 351-366; b) Zagon, I. S.; Rahn, K. A.; 
McLaughlin, P. J. Neuropeptides 2007, 41, 441-452; c) Zagon, I. S.; McLaughlin, P. J. Neuropeptides 2005, 39, 
495-5005; d) Zagon, I. S.; McLaughlin, P. J. Neuropeptides 2003, 37, 79-88. 




pancreatic tumour xenografts in nude mice.
115
 Consequently the attractive inhibitory system 
formed by OGF and its receptor (OGFr) has obviously gained attention in anticancer 
chemotherapy. Nevertheless the poor bioavailability of Met-enkephalin remains a serious 
restriction for further development.
116
 Thus the three-part prodrug thread (comprising trigger, 
self-immolative linker and peptide) is trapped within a benzylic amide-based macrocycle 
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Zagon, I. S.; Smith, J. P.; McLaughlin, P. J. Int. J. Oncol. 1999, 14, 577-584; c) Zagon, I. S.; Hytrek, S. D.; 
Smith, J. P.; McLaughlin, P. J. Cancer Lett. 1997, 112, 167-175. 
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 Boarder, M. R. ; McArdle, W. Biochem. Pharmacol. 1986, 35, 1043-1047. 




The carbohydrate trigger designed to target cancer cells and hence to activate the prodrug 
molecule, is attached to the peptide drug through a benzyloxycarbonyl linker unit. Therefore 
following enzymatic activation, self-immolation of the sugar-free spacer results in the release 
of the parent Met-enkephalin 2 along with the mechanical disassembly of the rotaxane 
architecture.  
 
Rotaxane 1 was prepared using the elongation strategy recently developed in our group which 


































































































































































































































Scheme 3.3. Synthesis of rotaxane 1. Reagents: a) isophthaloyl chloride, p-xylylenediamine, 
CHCl3, Et3N; b) H-Phe-Met-OH, CHCl3, reflux; c) MeONa, MeOH, 0°C. 
 
Thus glycorotaxane 4 was synthesised from galactosylated thread 3 bearing the temporary 
2,6-diphenyl-4-nitrophenyl ester stopper. Treatment of 4 with H-Phe-Met-OH in CHCl3 
afforded the elongated rotaxane 5 which was further deprotected to furnish final Met-
enkephalin rotaxane prodrug 1. The corresponding galactosylated prodrug of Met-enkephalin 
7 was also prepared (See Supporting Information). 
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H NMR spectra of 7 and 1 in CD3OD are shown in Figure 3.1. Apart from the signals 
corresponding to the carbohydrate protons, most of the resonances in the thread are shifted in 
the rotaxane. Peptidic protons (shown in orange) along with spacer protons (shown in green) 
experience the shielding effect of the aromatic rings of the macrocycle. This effect is 
particularly observed for protons H14 and H16 thus indicating that the glycyl residues are 







H NMR spectra of galactosylated prodrug 7 and rotaxane 1 (400 MHz, 298 K, 
CD3OD). 
 
Accordingly we investigated the enzymatic activation of rotaxane 1 by HPLC since, contrary 
to the previous model rotaxane prodrugs, this rotaxane is soluble in water. Incubation of 1 
with excess E. coli β−galactosidase in phosphate buffer (0.02 M, pH 7.2) at 37°C resulted in 
the simultaneous release of Met-enkephalin 2 together with a quinone methide intermediate 
which spontaneously reacts with water to form benzylic alcohol 6 (Scheme 3.4). A 
comparison with the non-interlocked galactosylated prodrug 7 was also conducted.  
 






Scheme 3.4. Enzymatic hydrolysis of A) prodrug thread 7 and B) rotaxane 1 with E. coli β-
galactosidase in phosphate buffer (0.02 M, pH 7.2) at 37°C using 10 U/µmol of substrate. 
 
Therefore HPLC results obtained with non-interlocked prodrug 7 confirmed the release of 
Met-enkephalin 2 along with nitrophenol 6. Concerning rotaxane 1, HPLC also established 
the efficiency of our machine. Indeed, after treatment of the aliquots, chromatograms 
demonstrated the rapid delivery of the free peptide drug following the addition of E. coli β-
galactosidase. After 10 minutes no starting rotaxane could be observed but the macrocycle 
along with free peptide and spacer 6. It should also be noticed that for both prodrugs 1 and 7 
the phenolic intermediates could be observed on LCMS.  
 
In comparison with the models constructed in chapter 2, the fast kinetics of hydrolysis and 
release observed for these prodrug systems are explained by the absence of additional groups 
on the spacer moiety which hinder the recognition of the carbohydrate and the self-
immolation step as discussed previously. 
 




In the light of these results we first tried to ascertain the stability of Met-enkephalin rotaxane 
1 in phosphate buffer at 37°C. After 48 hours no decomposition was observed by HPLC. 
Moreover, to assess the protease stability of our rotaxane prodrug we investigated and 
compared the behaviour of both Met-enkephalin 2, rotaxane 1 and is non-interlocked 
derivative 7 under the action of peptidases. Initially, enzymatic digestion with 
Aminopeptidase M (which hydrolyses the N-terminal amide bond of Met-enkephalin) was 




Figure 3.2. Enzymatic digestion of rotaxane 1, prodrug 7 and Met-enkephalin 2 with 
Aminopeptidase M. Reactions were carried out at 25°C in pH 7.2 phosphate buffer 0.05 M 
using 0.5 U/µmol of substrate. 0.25 U/µmol of enzyme was added every 12 hours.  
 
While Met-enkephalin is rapidly degraded (< 30 min.) prodrug 7 and rotaxane 1 displayed 
extremely enhanced stability. Accordingly such prolonged stability is easily explained by the 
fact that the N-terminus is masked in both interlocked and non-interlocked prodrugs. 
 
Consequently we explored the enzymatic hydrolysis of 1, 2 and 7 with Angiotensin 
Converting Enzyme (ACE) (Figure 3.3). ACE is a dipeptidyl exopeptidase which hydrolyses 
Met-enkephalin between Gly and Phe residues. HPLC monitoring allowed confirmation of the 
protective effect of encapsulating peptides within rotaxane architectures. Indeed, although 2 
and 7 are readily hydrolysed within hours, rotaxane 1 exhibits almost total unreactivity 
towards the action of ACE. 






Figure 3.3. Enzymatic digestion of rotaxane 1, prodrug 7 and Met-enkephalin 2 with 
Angiotensin Converting Enzyme (ACE). Reactions were carried out at 25°C in pH 8.3 
HEPES buffer 0.05 M, NaCl 0.3 M using 0.8 U/µmol of substrate. 0.4 U/µmol of enzyme was 
added every 12 hours.  
 
Finally the stability of both compounds 1, 2 and 7 was evaluated in human plasma (Figure 
3.4). The results confirmed the poor bioavailability of Met-enkephalin 2 which is totally 
degraded in less than 5 min in human plasma. Under identical conditions prodrug thread 7 
was degraded with a half-life of approximately 5 hours while only 10% degradation of the 
rotaxane 1 could be observed on HPLC after 120 hours incubation. 
 
 
Figure 3.4. Stability of 1, 2 and 7 in human plasma.  




In conclusion, we have developed the first rotaxane-based delivery device designed to 
simultaneously protect and target bioactive peptides to tumour cells. In this study we have 
demonstrated that a rotaxane prodrug of the anticancerous peptide Met-enkephalin is 
efficiently and selectively activated by the action of β−galactosidase, an enzyme that can be 
targeted to cancer cells via an ADEPT protocol. Moreover the protective effect of the 
macrocycle was evidenced with two proteases which are largely responsible for the poor 
bioavailability of the OGF.
118
 Thus until the trigger is selectively recognised at the tumour 
site, the peptide drug stays entirely protected within the cavity of the macrocycle. Therefore 
associating the hydrogen bond-directed assembly of peptide rotaxanes with the enzyme-
responsive prodrugs has allowed the construction of versatile nanosystems to overcome the 
limited stability of peptides while selectively targeting their active release to malignant 
tissues. The concept presented here might find interesting development since the modularity 
of our construction allows the fine tuning of both trigger, spacer and macrocycle units.  
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1. General Experimental Section 
 
Unless otherwise stated, all reactions were run under an atmosphere of N2. Prior to use, 
isophthaloyl dichloride was purified by recrystallization from hexane; p-xylylenediamine was 
purified by distillation under reduced pressure. Met-enkephalin was purchased from Sigma-
Aldrich. Dry acetonitrile, chloroform, dichloromethane, N,N-dimethylformamide, methanol, 
tetrahydrofuran and toluene were obtained by passing these solvents through activated 
alumina columns on a PureSolv
TM
 solvent purification system (Innovative Technologies, Inc., 
MA). Unless otherwise stated, all other reagents were purchased from commercial sources 
and used without further purification. Flash column chromatography was carried out using 
Kiesegel C60 (Fisher Scientific) as the stationary phase. Analytical TLC was performed on 
aluminium-backed sheets pre-coated with silica 60 F254 adsorbent (0.25 mm thick, Merck, 
Germany) and visualized under UV light. Size exclusion chromatography was performed 





C NMR spectra were recorded at 400 MHz on a Bruker AV 400 instrument. 
Chemical shifts () are reported in parts per million from low to high field and referenced to 
residual solvent. Coupling constants (J) are reported in hertz (Hz). Standard abbreviations 
indicating multiplicity are used as follows: b = broad, s = singlet, d = doublet, t = triplet, q = 
quartet, quint. = quintet, m = multiplet. All melting points were determined using a Sanyo 
Gallenkamp apparatus and are uncorrected. FAB and ESI mass spectrometry was carried out 
by the mass spectrometry services at the University of Edinburgh and at the EPSRC National 
Centre, Swansea. Analytical RP-HPLC was carried out on a Gilson instrument composed of 
306 pumps, 811C dynamic mixer (100 µL), 806 manometric module and an Applied 
Biosciences 759A UV detector with a Phenomenex C18 (2) Luna column (2 x 250 mm, 5 µm, 
100A). Preparative RP-HPLC was carried out on a Gilson instrument composed of 306 
pumps, 811C dynamic mixer (1.5 mL), 806 manometric module and a 118 UV detector with a 
Spherisorb ODS2 column (21.2 x 250 mm, 5 µm, 100A). LCMS was carried out on a 
Finnigan Mat system composed of an LCQ mass spectrometer, P4000 pumps, and a UV2000 
UV detector with a Phenomenex C18 (2) Luna column (2 x 250 mm, 5µm, 100A). 








E. coli β-galactosidase enzymatic cleavage  
Enzymatic hydrolysis was carried out with commercial β-galactosidase from Escherichia coli 
E.C. 3.2.1.23 (1000 units/mg protein (biuret), aqueous glycerol suspension (1:1), 10 mM Tris 
buffer salts and 10 mM magnesium chloride, pH 7.3). Prodrugs were incubated at 37°C with 
the enzyme (1-100 Units/0.1 µmol of substrate) in 20 mM Phosphate buffer at pH 7.0 
containing 2.5-10% DMSO (0.2-0.33 µmol of substrate/mL). Aliquots (20 µL) were 
periodically withdrawn from the medium and diluted into a solution of TFA (0.1%) in H2O 
(40 µL). Rate of hydrolysis was monitored by analytical HPLC and LCMS. 
 
Enzymatic stability toward Aminopeptidase M 
Peptidase degradation was carried out with commercial microsomal Leucine Aminopeptidase 
(Aminopeptidase M), from porcine kidney, type IV-S, E.C. 3.4.11.2 (24 units/mg protein 
(Bradford), suspension in 3.5 M (NH4)2SO4 solution, pH 7.7, containing 10 mM MgCl2). 
Peptide and prodrugs were incubated at 25°C (to minimize loss of activity) with the enzyme 
(5.10
-4
 Units/0.1 µmol of substrate) in 50 mM Phosphate buffer at pH 7.2 containing 5% 
DMSO (C 0.25 µmol of substrate/mL). Enzyme was added to the medium every 12 hours to 
compensate for loss of activity (2.5.10
-4
 Units). Aliquots (5 µL) were periodically withdrawn 
from the medium and directly used for analytical HPLC monitoring. Rate of decomposition 
was measured by plotting the absolute area of the peak of interest against time. 
 
Enzymatic stability toward Angiotensin Converting Enzyme 
Peptidase degradation was carried out with commercial Angiotensin Converting Enzyme from 
rabbit lung (3.92 units/mg protein (modified Warburg-Christian), lyophilized powder). The 
enzyme was kept in a solution of in 10 mM potassium phosphate buffer, pH 7.0, containing 
0.5 M NaCl (1 mg of enzyme/mL) and stored at -20°C. Peptide and prodrugs were incubated 
at 25°C (to minimize loss of activity) with the enzyme (0.02 Units/0.025 µmol of substrate) in 
50 mM HEPES buffer at pH 8.3 containing 0.3 M NaCl and 5% DMSO (C 0.125 µmol of 
substrate/mL). Enzyme was added to the medium every 12 hours to compensate for loss of 
activity (0.01 Units). Aliquots (5 µL) were periodically withdrawn from the medium and 
directly used for analytical HPLC monitoring. The rate of decomposition was measured by 
plotting the absolute area of the peak of interest against time. 
 
 




Stability in human plasma 
Stability in human plasma was carried out with commercial lyophilized human plasma 
reconstituted by dissolving the solid in the appropriate volume of 0.01M Tris buffer at pH 7.4. 
Peptide and prodrugs were incubated at 37°C in the freshly prepared solution (0.150 µmol of 
substrate/mL). Aliquots (50 µL) were periodically withdrawn from the medium, poured into 
cold MeOH (50 µL) to precipitate the proteins and cooled on ice. After 30 min., the sample 
was centrifuged (17 000 g, 2 min) and the supernatant analyzed by analytical HPLC. The rate 
of decomposition was measured by plotting the absolute area of the peak of interest against 
time. 
 
2. Synthetic Routes to Met-enkephalin Rotaxane Prodrug 1 and Prodrug 7 
 














(a) Ac2O, NaOH, H2O, 91% (b) All-OH, PTSA, toluene, reflux, quant. (c) EDC.HCl, HOBt, DIPEA, CH2Cl2, 45% (d) TFA, CH2Cl2, 92%. 
 
 
Scheme 2 - Synthesis of H-Phe-Met-OAll and H-Phe-Met-OH 
 
H-Met-OH PTSA.H-Met-OAll Boc-Phe-Met-OAll H-Phe-Met-OAll




S8 S9 S10  
 
(a) All-OH, PTSA, toluene, reflux, 82% (b) Boc-Phe-OH, EDC.HCl, HOBt, DIPEA, CH2Cl2, 43% (c) TFA, CH2Cl2, 92% (d) Boc-Phe-OH, 
EDC.HCl, HOBt, DIPEA, CH2Cl2, 42% (e) TFA, CH2Cl2, 97% (f) NaOH, H2O, THF, 0°C, 93%. 
 
















































































































































































(a) H-Tyr(Ac)-Gly-Gly-OAll, pyridine, DMF, 97% (b) Pd(PPh3)4, PhSiH3, CH2Cl2, 85% (c) 2,6-diphenyl-4-nitrophenol, BOP, Et3N, CHCl3, 
67% (d) p-xylylenediamine, isophthaloyl dichloride, Et3N, CHCl3, 26% (e) H-Phe-Met-OH, CHCl3, reflux, 40% (f) MeONa, MeOH, 0°C, 
quant. 
 


















































(a) H-Phe-Met-OAll, EDC.HCl, DIPEA, CH2Cl2, 37% (b) Pd(PPh3)4, PhSiH3, CH2Cl2, 67% (c) MeONa, MeOH, 0°C, 87%. 
 


















Compound S1 was prepared according to the procedure described in Braun, N. A.; Ousmer, 
M.; Bray, J. D.; Bouchu, D.; Peters, K.; Peters, E-M; Ciufolini, M. A. J. Org. Chem. 2000, 65, 
4397-4408. Boc-L-Tyrosine (7.00 g, 24.91 mmol) was dissolved in a 15% aqueous NaOH 
solution (25 mL) and a few chips of ice were added. Acetic anhydride (8.8 mL, 3.75 equiv.) 
was added and the solution stirred for 25 minutes. The mixture was then cooled to 0°C, 
acidified with 3N HCl and extracted with ethyl acetate. The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The resulting oil was co-evaporated 
several times with toluene to obtain S1 as clear yellow oil (7.35 g, 22.75 mmol, 91%). (S1 
Registry Number: 80971-82-0) 
 
1
H NMR (400 MHz, DMSO-d6): δ 7.28 (d, 2H, J = 8.0 Hz, H4), 7.10 (d, 1H, J = 8.4 Hz, 
NH), 7.02 (d, 2H, J = 8.0 Hz, H5),  4.17 to 4.11 (m, 1H, H2), 3.05 (dd, 1H, J = 14.0 Hz, J = 
4.0 Hz, H3), 2.86 (dd, 1H, J = 13.2 Hz, J = 11.2 Hz, H3), 2.23 (s, 3H, H-Ac), 1.33 (s, 9H, H-
tBu) 
13
C NMR (100 MHz, DMSO-d6): δ 173.7, 169.3, 155.6, 149.2, 135.6, 130.2, 121.5, 
78.2, 59.9, 55.2, 35.9, 28.2, 20.9 LRFAB-MS (3-NOBA matrix): m/z 346 [M+Na]
+
 





















To a solution of glycylglycine (7.00 g, 53.03 mmol) in toluene (20 mL) was added allyl 
alcohol (21.7 mL, 6.0 equiv.) and PTSA (11.00 g, 1.2 equiv.). The mixture was refluxed in a 
Dean-Stark apparatus until no water was recovered and the solvent was removed under 
reduced pressure. The residue was crystallized from diethylether to give S2 as a yellowish 
solid (18.10 g, 52.62 mmol, quant.). 
 





H NMR (400 MHz, CDCl3): δ 8.15 (t, 1H, J = 5.6 Hz, NH3), 7.63 (m, 3H, 
+
NH3), 7.61 (d, 
2H, J = 8.0 Hz, Ha), 6.95 (d, 2H, J = 8.0 Hz, Hb), 5.80 to 5.71 (m, 1H, H6), 5.20 (dd, 1H, J = 
17.2 Hz, J = 1.6 Hz, H7), 5.14 (dd, 1H, J = 10.4 Hz, J = 1.2 Hz, H7), 4.43 (d, 2H, J = 5.6 Hz, 
H5), 3.94 (bd, 2H, J = 4.8 Hz, H2), 3.74 (d, 2H, J = 5.2 Hz, H4), 2.25 (s, 3H, CH3) 
13
C NMR 
(100 MHz, CDCl3): δ 169.7, 167.3, 141.2, 140.4, 131.8, 129.1, 126.1, 118.7, 66.0, 41.4, 41.2, 
21.4 LRFAB-MS (3-NOBA matrix): m/z 345 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 
173.0920 (calcd. for C7H13N2O3 173.0921 [M-PTSA+H]
+


























To a solution of Boc-Tyr(Ac)-OH S1 (1.00 g, 3.10 mmol) and glycylglycine salt S2 (1.28 g, 
1.2 equiv.) in CH2Cl2 (10 mL) was added EDC.HCl (713 mg, 1.2 equiv.), HOBt (167 mg, 0.4 
equiv.) and DIPEA (1.35 mL, 2.5 equiv.). The mixture was stirred for 64 hours at room 
temperature, hydrolyzed and extracted with CH2Cl2. The combined organic layers were 
washed with water, brine, dried and concentrated in vacuo. Purification by column 
chromatography over silica gel (petroleum ether/ethyl acetate: 6/4 then CH2Cl2/MeOH: 2.5 to 
5% MeOH) afforded S3 (665 mg, 1.39 mmol, 45%) as a white solid. 
 
1
H NMR (400 MHz, CDCl3): δ 7.46 (bs, 1H, NH), 7.32 (bs, 1H, NH), 7.17 (d, 2H, J = 8.0 
Hz, H11), 6.95 (d, 2H, J = 8.0 Hz, H12), 5.89 to 5.79 (m, 1H, H8), 5.57 (d, 1H, J = 6.8 Hz, 
NH1), 5.27 (d, 1H, J = 18.4 Hz, H9), 5.19 (d, 1H, J = 10.4 Hz, H9), 4.52 (d, 2H, J = 6.0 Hz, 
H7), 4.37 (bd, 1H, J = 6.4 Hz, H2), 3.84 to 4.03 (m, 4H, H4+6), 3.09 (dd, 1H, J = 13.6 Hz, J = 
5.6 Hz, H10), 2.91 (dd, 1H, J = 13.6 Hz, J = 8.0 Hz, H10), 2.23 (s, 3H, H-Ac), 1.32 (s, 9H, H-
tBu) 
13
C NMR (100 MHz, CDCl3): δ 172.4, 169.6, 169.5, 155.9, 149.5, 134.3, 131.5, 130.3, 
121.6, 118.8, 80.2, 65.9, 55.9, 42.8, 41.1, 37.4, 28.2, 21.1 LRFAB-MS (3-NOBA matrix): 
m/z 479 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 478.2180 (calcd. for C23H32N3O8 
478.2184 [M+H]
+
































Trifluoroacetic acid (27 mL, 45.0 equiv.) was added dropwise to a solution of Boc-Tyr(Ac)-
Gly-Gly-OAll S3 (3.80 g, 7.97 mmol) in CH2Cl2 (200 mL) at 0°C. After 30 minutes at 0°C, 
the solution was stirred a further 2 hours at room temperature and then cooled to 0°C. After 
neutralisation with a saturated solution of NaHCO3, the mixture was extracted with a 
CHCl3/iPrOH (3/1, v/v) mixture, dried and evaporated to give S4 (2.77 g, 7.35 mmol, 92%) 
as a white solid. 
 
1
H NMR (400 MHz, CDCl3): δ 7.99 (t, 1H, J = 5.2 Hz, NH), 7.20 (d, 2H, J = 8.4 Hz, H11), 
7.07 (t, 1H, J = 5.6 Hz, NH), 7.00 (d, 2H, J = 8.4 Hz, H12), 5.92 to 5.82 (m, 1H, H8), 5.30 (dd, 
1H, J = 17.2 Hz, J = 1.6 Hz, H9), 5.23 (dd, 1H, J = 10.4 Hz, J = 1.2 Hz, H9), 4.60 (d, 2H, J = 
5.6 Hz, H7), 3.99 (dd, 4H, J = 16.8 Hz, J = 5.6 Hz, H4+6), 3.61 (dd, 1H, J = 9.2 Hz, J = 4.0 Hz, 
H2), 3.20 (dd, 1H, J = 14.0 Hz, J = 4.0 Hz, H10), 2.69 (dd, 1H, J = 13.6 Hz, J = 9.2 Hz, H10), 
2.26 (s, 3H, H-Ac), 1.64 (bs, 2H, NH2) 
13
C NMR (100 MHz, CDCl3): δ 175.3, 169.7, 169.5, 
149.6, 135.4, 131.5, 130.3, 121.9, 119.0, 66.1, 56.4, 42.9, 41.3, 40.4, 21.2 LRFAB-MS (3-
NOBA matrix): m/z 378 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 378.1664 (calcd. for 
C18H24N3O6 378.1660 [M+H]
+
















To a solution of L-methionine (7.00 g, 46.98 mmol) in toluene (20 mL) was added allyl 
alcohol (19.3 mL, 6.0 equiv.) and PTSA (10.70 g, 1.2 equiv.). The mixture was refluxed in a 
Dean-Stark apparatus until no water was recovered and the solvent was removed under 
pressure. The residue was co-evaporated several times with toluene and precipitated with 
diethylether to give a white solid. Purification by column chromatography over silica gel 
(CH2Cl2/MeOH: 5 to 10% MeOH) afforded S5 as a white solid (11.00 g, 53.49 mmol, 82%). 
(S5 Registry Number: 142601-87-4) 





H NMR (400 MHz, CDCl3): δ 8.22 (s, 3H, 
+
NH3), 7.74 (d, 2H, J = 8.0 Hz, Ha), 7.15 (d, 2H, 
J = 8.0 Hz, Hb), 5.83 to 5.73 (m, 1H, H4), 5.25 (dd, 1H, J = 17.2 Hz, J = 1.6 Hz, H5), 5.17 (dd, 
1H, J = 10.4 Hz, J = 1.2 Hz, H5), 4.55 and 4.47 (dd, AB system, 2H, J = 12.8 Hz, J = 6.0 Hz, 
H3), 4.14 (bs, 1H, H2), 2.59 to 2.43 (m, 2H, H7), 2.35 (s, 3H, CH3-PTSA), 2.02 to 2.19 (m, 
2H, H6), 1.90 (s, 3H, S-CH3) 
13
C NMR (100 MHz, CDCl3): δ 168.8, 141.2, 140.8, 131.2, 
129.1, 126.2, 119.4, 67.0, 52.3, 29.5, 29.2, 21.5, 15.0 LRFAB-MS (3-NOBA matrix): m/z 
191 [M-PTSA+H]
+ 
HRFAB-MS (3-NOBA matrix): m/z 190.0899 (calcd. for C8H16NO2S 
190.0896 [M-PTSA+H]
+

























To a solution of Boc-Phe-OH (3.40 g, 12.83 mmol) and L-methionine salt S5 (7.00 g, 1.5 
equiv.) in CH2Cl2 (50 mL) was added EDC.HCl (3.70 g, 1.5 equiv.), HOBt (693 mg, 0.4 
equiv.) and DIPEA (6.7 mL, 3.0 equiv.). The mixture was stirred for 24 hours at room 
temperature, hydrolyzed and extracted with CH2Cl2. The combined organic layers were 
washed with water, brine, dried and concentrated in vacuo. Purification by column 
chromatography over silica gel (petroleum ether/ethyl acetate: 6/4 then CH2Cl2/MeOH: 2.5 to 
5% MeOH) afforded S6 (2.38 g, 1.39 mmol, 43%) as a white solid. 
 
1
H NMR (400 MHz, CDCl3): δ 7.32 to 7.19 (m, 5H, H9+10+11), 6.55 (d, 1H, J = 7.6 Hz, NH3), 
5.93 to 5.84 (m, 1H, H6), 5.32 (dd, 1H, J = 17.2 Hz, J = 1.2 Hz, H7), 5.27 (dd, 1H, J = 10.4 
Hz, J = 1.2 Hz, H7), 4.97 (bs, 1H, NH1), 4.65 (dd, 1H, J = 12.4 Hz, J = 7.2 Hz, H4), 4.61 (dd, 
2H, J = 5.6 Hz, J = 1.2 Hz, H5), 4.36 (bd, 1H, J = 7.2 Hz, H2), 3.10 and 3.05 (dd, AB system, 
2H, J = 14.0 Hz, J = 6.8 Hz, H8), 2.46 to 2.35 (m, 2H, H13), 2.17 to 2.09 (m, 1H, H12), 2.05 (s, 
3H, S-CH3), 1.99 to 1.88 (m, 1H, H12), 1.41 (s, 9H, H-tBu) 
13
C NMR (100 MHz, CDCl3): δ 
171.1, 131.5, 129.5, 128.9, 127.2, 119.3, 66.3, 55.9, 51.8, 38.1, 31.8, 29.8, 28.4, 15.5 
LRFAB-MS (3-NOBA matrix): m/z 438 [M+H]
+ 
HRFAB-MS (3-NOBA matrix): m/z 
437.2104 (calcd. for C22H33N2O5S 437.2105 [M+H]
+
) m.p. 106-108°C  
 























Trifluoroacetic acid (16 mL, 45.0 equiv.) was added dropwise to a solution of Boc-Phe-Met-
OAll S6 (2.13 g, 4.89 mmol) in CH2Cl2 (100 mL) at 0°C. After 30 minutes at 0°C, the 
solution was stirred a further 1.5 hours at room temperature and then cooled to 0°C. After 
neutralisation with a saturated solution of NaHCO3, the mixture was extracted with a 
CHCl3/iPrOH (3/1, v/v) mixture, dried and evaporated to give S7 (1.51 g, 4.49 mmol, 92%) 
as a white solid. 
 
1
H NMR (400 MHz, CDCl3): δ 7.92 (d, 1H, J = 6.4 Hz, H3), 7.31 to 7.18 (m, 5H, H9+10+11), 
5.93 to 5.83 (m, 1H, H6), 5.31 (dd, 1H, J = 17.2 Hz, J = 1.2 Hz, H7), 5.23 (dd, 1H, J = 10.4 
Hz, J = 1.2 Hz, H7), 4.71 to 4.66 (m, 1H, H4), 4.60 (d, 2H, J = 6.0 Hz, H5), 3.67 (bs, 1H, H2), 
3.18 (dd, 1H, J = 13.6 Hz, J = 3.6 Hz, H8), 2.79 (dd, 1H, J = 13.6 Hz, J = 8.4 Hz, H8), 2.46 to 
2.35 (m, 2H, H13), 2.18 to 2.09 (m, 1H, H12), 2.05 (s, 3H, S-CH3), 2.00 to 1.91 (m, 3H, 
H12+NH2) 
13
C NMR (100 MHz, CDCl3): δ 174.0, 171.6, 137.3, 131.5, 129.4, 128.7, 127.0, 
119.0, 66.1, 56.1, 51.2, 40.6, 31.7, 29.9, 15.4 LRFAB-MS (3-NOBA matrix): m/z 338 
[M+H]
+ 
HRFAB-MS (3-NOBA matrix): m/z 337.1575 (calcd. for C17H25N2O3S 337.1580 
[M+H]
+






















To a solution of Boc-Phe-OH (9.00 g, 33.96 mmol) and L-methionine methyl ester 
hydrochloride salt (8.13 g, 1.2 equiv.) in CH2Cl2 (150 mL) was added EDC.HCl (7.82 g, 1.2 
equiv.), HOBt (1.83 g, 0.4 equiv.) and DIPEA (14.8 mL, 2.5 equiv.). The mixture was stirred 
overnight at room temperature, hydrolyzed and extracted with CH2Cl2. The combined organic 
layers were washed with water, brine, dried and concentrated in vacuo. Purification by 




column chromatography over silica gel (petroleum ether/ethyl acetate: 9/1 to 3/7) afforded S8 
(6.68 g, 16.30 mmol, 42%) as a white solid. (S8 Registry Number: 40290-63-9) 
 
1
H NMR (400 MHz, CDCl3): δ 7.34 to 7.21 (m, 5H, H6+7+8), 6.57 (d, 1H, J = 7.2 Hz, NH3), 
5.01 (bs, 1H, NH1), 4.66 (dd, 1H, J = 12.0 Hz, J = 6.8 Hz, H4), 4.37 (bd, 1H, J = 6.4 Hz, H2), 
3.73 (s, 3H, COOCH3), 3.15 to 3.04 (m, 2H, H5), 2.45 to 2.36 (m, 2H, H10), 2.18 to 2.09 (m, 
1H, H9), 2.07 (s, 3H, S-CH3), 1.99 to 1.90 (m, 1H, H9), 1.43 (s, 9H, H-tBu) 
13
C NMR (100 
MHz, CDCl3): δ 171.9, 171.2, 155.5, 136.5, 129.5, 128.8, 127.1, 80.5, 55.9, 52.6, 51.6, 38.1, 
31.7, 29.8, 28.4, 15.5 LRFAB-MS (3-NOBA matrix): m/z 411 [M+H]
+
 HRFAB-MS (3-
NOBA matrix): m/z 411.1947 (calcd. for C20H31N2O5S 411.1948 [M+H]
+



















Trifluoroacetic acid (12.2 mL, 45.0 equiv.) was added dropwise to a solution of Boc-Phe-Met-
OMe S8 (1.60 g, 3.90 mmol) in CH2Cl2 (70 mL) at 0°C. After 30 minutes at 0°C, the solution 
was stirred a further 1.5 hours at room temperature and then cooled to 0°C. After 
neutralisation with a saturated solution of NaHCO3, the mixture was extracted with a 
CHCl3/iPrOH (3/1, v/v) mixture, dried and evaporated to give S9 (1.17 g, 3.77 mmol, 97%) 
as a yellow oil.  
 
1
H NMR (400 MHz, CDCl3): δ 7.90 (bd, 1H, J = 6.0 Hz, H3), 7.29 to 7.16 (m, 5H, H6+7+8), 
4.65 (bd, 1H, J = 4.8 Hz, H4), 3.68 (m, 4H, H2 + COOCH3), 3.14 (d, 1H, J = 12.4 Hz, H5), 
2.80 to 2.75 (m, 1H, H5), 2.39 to 2.35 (m, 2H, H10), 2.14 to 2.05 (m, 1H, H9), 2.02 (s, 3H, S-
CH3), 1.96 to 1.87 (m, 1H, H9), 1.77 (bs, 2H, NH2) 
13
C NMR (100 MHz, CDCl3): δ 174.0, 
172.1, 137.2, 129.2, 128.5, 126.7, 55.9, 52.3, 50.9, 40.5, 31.4, 29.7, 15.2 LRFAB-MS (3-
NOBA matrix): m/z 311 [M+H]
+ 


























To a solution of H-Phe-Met-OMe S9 (155 mg, 0.5 mmol) in H2O/THF (4.8 mL / 2.4 mL) 
cooled in an ice-water bath was added dropwise a 0°C solution of NaOH (100 mg, 5.0 equiv.) 
in H2O (5 mL). Stirring was continued for 2.5 h at 0°C and the solution was neutralized with 
Amberlite IR-120, filtered and washed with MeOH. MeOH was then evaporated to afford S10 
(137 mg, mmol, 93%) as a white oily solid. (S10 Registry Number: 15080-84-9) 
 
1
H NMR (400 MHz, CD3OD): δ 7.33 to 7.20 (m, 5H, H6+7+8), 4.30 (dd, 1H, J = 7.6 Hz, J = 
4.8 Hz, H4), 3.88 (dd, 1H, J = 7.6 Hz, J = 5.6 Hz, H2), 3.18 (dd, 1H, J = 14.0 Hz, J = 5.2 Hz, 
H5), 2.94 (dd, 1H, J = 14.0 Hz, J = 8.0 Hz, H5), 2.46 to 2.42 (m, 2H, H10), 2.17 to 2.09 (m, 
1H, H9), 2.06 (s, 3H, S-CH3), 2.01 to 1.95 (m, 1H, H9) 
13
C NMR (100 MHz, CD3OD): δ 
178.1, 173.0, 137.5, 130.6, 129.8, 128.2, 56.7, 55.8, 40.3, 33.7, 31.3, 15.3 LRFAB-MS (3-
NOBA matrix): m/z 297 [M+H]
+
















































To a solution of activated galactoside (1.32 g, 1.99 mmol) in DMF (50 mL) was added H-
Tyr(Ac)-Gly-Gly-OAll S4 (1.50 g, 2.0 equiv.) and pyridine (400 µL, 2.5 equiv.). Stirring was 
continued at room temperature during one day then the solution was diluted with 1N HCl and 
extracted with ethyl acetate. The combined extracts were washed with 1N HCl, dried with 
MgSO4, filtered and concentrated under reduced pressure. Purification by column 
chromatography over silica gel (petroleum ether/ethyl acetate: 4/6 to 2/8 then CH2Cl2/MeOH: 
2.5 to 7% MeOH) yielded S11 as a white yellow powder (1.74 g, 1.93 mmol, 97%). 
 





H NMR (400 MHz, CDCl3): δ 7.72 (s, 1H, H9), 7.43 (d, 1H, J = 8.0 Hz, NH), 7.30 (d, 1H, J 
= 8.4 Hz, NH), 7.19 to 7.14 (m, 3H, H8+21), 6.96 (d, 3H, J = 8.0 Hz, H7+22), 5.91 to 5.81 (m, 
2H, NH+H18), 5.51 (dd, 1H, J = 10.8 Hz, J = 8.0 Hz, H2), 5.45 (d, 1H, J = 3.2 Hz, H4), 5.30 
(dd, 1H, J = 13.2 Hz, J = 1.2 Hz, H19), 5.22 (d, 1H, J = 10.4 Hz, H19), 5.10 (dd, 1H, J = 10.4 
Hz, J = 3.2 Hz, H3), 5.07 (d, 1H, J = 8.0 Hz, H1), 4.99 (bs, 2H, H10), 4.59 (d, 2H, J = 6.0 Hz, 
H17), 4.44 (dd, 1H, J = 13.6 Hz, J = 6.8 Hz, H12), 4.25 to 4.08 (m, 3H, H5+6), 4.01 to 3.83 (m, 
4H, H14+16), 3.09 (dd, 1H, J = 14.0 Hz, J = 6.0 Hz, H20), 2.97 (dd, 1H, J = 13.2 Hz, J = 7.2 Hz, 
H20), 2.26 (s, 3H, H-Ac-Tyr), 2.17 (s, 3H, H-Ac), 2.10 (s, 3H, H-Ac), 2.05 (s, 3H, H-Ac), 2.00 
(s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3): δ 171.7, 170.5, 170.3, 170.2, 169.8, 169.7, 
169.5, 169.1, 155.9, 149.8, 149.1, 141.1, 134.0, 133.4, 132.3, 131.5, 130.4, 124.8, 121.9, 
119.6, 119.1, 100.6, 71.4, 70.6, 67.9, 66.8, 66.2, 65.3, 61.4, 56.3, 42.9, 41.3, 37.7, 21.2, 20.8, 
20.7 (x2) LRFAB-MS (3-NOBA matrix): m/z 904 [M+H]
+
 HRFAB-MS (3-NOBA 
matrix): m/z 903.2779 (calcd. for C40H47N4O20 903.2778 [M+H]
+










































To a solution of S11 (1.74 g, 1.93 mmol) in degassed CH2Cl2 (150 mL) were added 
phenylsilane (480 µL, 2.0 equiv.) and Pd(PPh3)4 (223 mg, 0.1 equiv.). The mixture was stirred 
during 2.5 hours at room temperature and the solvent evaporated under reduced pressure. The 
crude mixture was purified by column chromatography over silica gel (CH2Cl2/MeOH/AcOH: 
0.5 to 7% MeOH, 1% AcOH) to afford S12 (1.42 g, 1.65 mmol, 85%) as a white brown solid. 
 
1
H NMR (400 MHz, CDCl3/CD3OD: 9/1): δ 7.65 (s, 1H, H9), 7.36 (d, 1H, J = 8.4 Hz, NH), 
7.22 (d, 1H, J = 8.8 Hz, NH), 7.14 to 7.02 (m, 4H, H7+8+18), 6.87 (d, 2H, J = 8.4 Hz, H19), 5.39 
(dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.35 (d, 1H, J = 3.2 Hz, H4), 5.04 to 4.99 (m, 2H, H1+3), 
4.93 and 4.89 (d, AB system, 2H, J = 13.2 Hz, H10), 4.23 (t, 1H, J = 6.0 Hz, H12), 4.13 to 4.02 
(m, 3H, H5+6), 3.88 to 3.67 (m, 4H, H14+16), 3.01 (dd, 1H, J = 13.6 Hz, J = 6.0 Hz, H17), 2.84 
(dd, 1H, J = 13.2 Hz, J = 7.6 Hz, H17), 2.17 (s, 3H, H-Ac-Tyr), 2.08 (s, 3H, H-Ac), 2.01 (s, 
3H, H-Ac), 1.95 (s, 3H, H-Ac), 1.90 (s, 3H, H-Ac) 
13
C NMR (100 MHz, CDCl3/CD3OD: 
9/1): δ 172.2, 171.7, 170.7, 170.5, 170.4, 170.1, 169.8, 169.7, 156.2, 149.5, 148.9, 134.1, 




133.1, 132.3, 130.2, 128.9, 128.1, 125.2, 124.4, 121.6, 119.1, 100.2, 71.2, 70.5, 67.9, 66.8, 
65.0, 61.3, 56.4, 42.4, 40.7, 37.0, 20.9, 20.5 (x2), 20.4, 20.3 LRFAB-MS (3-NOBA matrix): 
m/z 864 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 863.2464 (calcd. for C37H43N4O20 
863.2465 [M+H]
+














































To a solution of S12 (985 mg, 1.14 mmol) in CHCl3 (50 mL) were added 2,6-diphenyl-4-
nitrophenol (1.33 g, 4.0 equiv.), Et3N (2.4 mL, 15.0 equiv.) and BOP (758 mg, 1.5 equiv.). 
The reaction mixture was stirred 3 hours at room temperature and then evaporated under 
reduced pressure. The crude mixture was purified by column chromatography over silica gel 
(CH2Cl2/acetone: 5 to 30% acetone) to afford 3 (867 mg, 0.35 mmol, 67%) as a white solid. 
 
1
H NMR (400 MHz, CDCl3): δ 8.28 (s, 2H, H17), 7.70 (d, 1H, J = 1.2 Hz, H9), 7.48 to 7.39 
(m, 7H, H8+18+19+20), 7.31 (d, 1H, J = 8.8 Hz, H7), 7.12 (d, 2H, J = 8.4 Hz, H22), 6.96 (d, 2H, J 
= 8.4 Hz, H23), 6.54 (t, 1H, J = 4.8 Hz, NH13), 6.34 (bs, 1H, NH15), 5.54 (dd, 1H, J = 10.8 Hz, 
J = 8.0 Hz, H2), 5.47 (d, 1H, J = 3.6 Hz, H4), 5.42 (d, 1H, J = 7.2 Hz, NH11), 5.11 (dd, 1H, J = 
10.4 Hz, J = 3.2 Hz, H3), 5.07 (d, 1H, J = 8.0 Hz, H1), 4.94 (bs, 2H, H10), 4.31 (dd, 1H, J = 
13.6 Hz, J = 6.8 Hz, H12), 4.24 (dd, 1H, J = 11.2 Hz, J = 6.8 Hz, H6), 4.16 (dd, 1H, J = 11.2 
Hz, J = 6.4 Hz, H6), 4.08 (t, 1H, J = 6.8 Hz, H5), 3.83 to 3.69 (m, 4H, H14+16), 3.05 (dd, 1H, J 
= 14.0 Hz, J = 6.4 Hz, H21), 2.96 (dd, 1H, J = 13.6 Hz, J = 7.2 Hz, H21), 2.28 (s, 3H, H-Ac-
Tyr), 2.19 (s, 3H, H-Ac), 2.13 (s, 3H, H-Ac), 2.06 (s, 3H, H-Ac), 2.02 (s, 3H, H-Ac) 
13
C 
NMR (100 MHz, CDCl3): δ 171.2, 170.5, 170.3, 170.2, 169.7, 169.5, 168.4, 167.3, 155.8, 
149.9, 149.3, 149.2, 146.2, 141.3, 137.5, 135.4, 133.6, 133.4, 132.1, 130.3, 129.1, 129.0, 
128.9, 125.1, 124.9, 122.1, 119.8, 100.8, 77.4, 71.5, 70.6, 67.9, 66.8, 65.4, 61.4, 56.5, 42.8, 
41.1, 37.6, 29.4, 21.2, 20.9, 20.8 (x2), 20.7 LRFAB-MS (3-NOBA matrix): m/z 1137 
[M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 1136.3286 (calcd. for C55H54N5O22 1136.3260 
[M+H]
+
) m.p. 122-126°C 
 

































































Thread 3 (390 mg, 0.34 mmol) was dissolved in anhydrous chloroform (80 mL) and stirred 
vigorously whilst solutions of p-xylylene diamine (766 mg, 16.0 equiv.) and Et3N (1.71 mL, 
35.0 equiv.) in anhydrous chloroform (60 mL) and isophthaloyl dichloride (1.14 g, 16.0 
equiv.) in anhydrous chloroform (60 mL) were simultaneously added over a period of 3 hours 
using motor-driven syringe pumps. After overnight stirring, 2 mL of MeOH were added and 
the resulting suspension filtered through Celite®. The pad was washed with CHCl3/MeOH 
2% (3 x 200 mL) and the combined filtrates were concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel using CHCl3/acetone (5 to 35% 
acetone) as eluent to give a mixture of thread 3 and rotaxane 4. This mixture was resolved by 
size exclusion chromatography using CHCl3/MeOH (50/50: v/v) as eluent to give rotaxane 4 
as a white powder (143 mg, 0.09 mmol, 26%). 
 
1
H NMR (400 MHz, CDCl3): δ 8.18 (s, 2H, H17), 8.00 to 7.94 (m, 6H, HB+C), 7.68 to 7.63 
(m, 4H, HD), 7.50 to 7.47 (m, 3H, H9+A), 7.38 (bs, 1H, NH15), 7.36 to 7.34 (m, 3H, H7+8+NH15), 
7.27 to 7.18 (m, 10H, H18+19+20), 6.94 (d, 4H, J = 8.0 Hz, HF), 6.79 (d, 4H, J = 8.0 Hz, HF), 
6.70 and 6.66 (d, AB system, 4H, J = 8.8 Hz, H22+23), 6.34 (bs, 1H, NH13), 5.49 (dd, 1H, J = 
10.4 Hz, J = 8.0 Hz, H2), 5.43 (d, 1H, J = 3.2 Hz, H4), 5.20 (d, 1H, J = 8.4 Hz, NH11), 5.08 
(dd, 1H, J = 10.4 Hz, J = 3.2 Hz, H3), 5.04 (d, 1H, J = 8.0 Hz, H1), 4.70 and 4.55 (d, AB 
system, 2H, J = 12.4 Hz, H10), 4.46 to 4.37 (m, 4H, HE), 4.30 to 4.20 (m, 4H, HE), 4.17 to 
4.07 (m, 3H, H5+6), 4.00 (dd, 1H, J = 14.8 Hz, J = 7.6 Hz, H12), 3.58 and 3.50 (dd, AB system, 
2H, J = 18.8 Hz, J = 5.6 Hz, H16), 2.70 (dd, 1H, J = 13.2 Hz, J = 8.0 Hz, H21), 2.55 (dd, 1H, J 
= 13.6 Hz, J = 6.0 Hz, H21), 2.25 (s, 3H, H-Ac-Tyr), 2.19 to 2.25 (m, 2H, H14), 2.13 (s, 3H, H-
Ac), 2.06 (s, 3H, H-Ac), 2.02 (s, 3H, H-Ac), 1.97 (s, 3H, H-Ac) 
13
C NMR (100 MHz, 
CDCl3): δ 170.5, 170.3 (x3), 169.6, 169.5, 169.0, 167.4 (x2), 166.3, 155.6, 149.3, 149.1, 
146.2, 141.0, 137.8, 137.5, 137.2, 135.4, 134.9, 134.4, 133.8, 133.7, 131.8, 130.9, 130.5, 
130.4, 129.2, 128.9 (x2), 128.8, 128.4, 126.2, 125.1, 124.9, 121.3, 119.5, 100.6, 71.5, 70.6, 
67.9, 66.8, 65.4, 61.3, 55.3, 44.6, 44.2, 41.4, 40.8, 36.5, 29.8, 29.2, 22.7, 21.4, 20.8 (x3), 20.7 




LRFAB-MS (3-NOBA matrix): m/z 1668 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 
1668.5323 (calcd. for C87H82N9O26 1668.5371 [M+H]
+












































































Rotaxane 4 (63 mg, 0.038 mmol) and H-Phe-Met-OH S10 (56 mg, 5.0 equiv.) were dissolved 
in CHCl3 (10 mL). The reaction mixture was then heated at reflux during 4 days. The solvent 
was removed under reduced pressure and the crude material purified by column 
chromatography on silica gel (CHCl3/MeOH: 2 to 30% MeOH) to give elongated rotaxane 5 
as a white powder (25 mg, 0.015 mmol, 40%) and starting rotaxane 4 (37 mg, 59%) 
 
1
H NMR (400 MHz, CDCl3/CD3OD: 5/3): δ 8.26 (bs, 2H, HC), 7.97 (d, 4H, J = 7.2 Hz, HB), 
7.52 to 7.48 (m, 3H, H9+A), 7.28 to 7.15 (m, 3H, H7+8+D), 7.10 to 6.99 (m, 13H, H25+26+27+F), 
6.92 (d, 2H, J = 8.4 Hz, H22), 6.80 (d, 2H, J = 8.4 Hz, H23), 5.43 to 5.39 (m, 2H, H2+4), 5.13 
(d, 1H, J = 8.0 Hz, H1), 5.10 (dd, 1H, J = 10.4 Hz, J = 3.6 Hz, H3), 4.79 and 4.64 (d, AB 
system, 2H, J = 12.8 Hz, H10), 4.46 to 4.26 (m, 10H, H18+20+E), 4.20 to 4.11 (m, 4H, H5+6+12), 
2.99 to 2.95 (m, 1H, H24), 2.90 to 2.80 (m, 5H, H14+16+21), 2.76 to 2.71 (m, 1H, H24), 2.58 (dd, 
1H, J = 14.0 Hz, J = 8.8 Hz, H21), 2.27 (m, 2H, H29), 2.22 (s, 3H, H-Ac-Tyr), 2.12 (s, 3H, H-
Ac), 2.05 (s, 3H, H-Ac), 2.00 (s, 3H, H-Ac), 1.94 (s, 3H, H-Ac), 1.93 (s, 3H, S-CH3), 1.99 to 
1.93 (m, 2H, H28), 
13
C NMR (100 MHz, CDCl3/CD3OD: 5/3): δ 174.1, 173.0, 171.7, 171.0, 
170.8, 170.7, 170.6, 170.4, 170.2, 169.9, 156.7, 149.7, 149.2, 141.1, 136.9, 134.5, 133.6, 
132.6, 130.4, 129.4, 128.7, 127.1, 124.8, 121.8, 119.3, 100.4, 71.4, 70.9, 68.2, 67.1, 65.3, 
61.6, 56.7, 54.9, 52.1, 43.1, 42.8, 37.8, 37.3, 31.4, 30.1, 29.8, 21.1, 20.7 (x2), 20.6 (x2) 











 LRESI-MS (negative mode): m/z 1672 [M-H]
-
 
HRFAB-MS (3-NOBA matrix): m/z 1673.5680 (calcd. for C83H89N10O26S 1673.5670 
[M+H]
+
) m.p. decomposition 
 














































































To a solution of 5 (31 mg, 0.019 mmol) in MeOH (5 mL) cooled in an ice-water bath was 
added dropwise a 0°C solution of MeONa (10 mg, 10.0 equiv.) in MeOH (3 mL). Stirring was 
continued for 1 hour at 0°C and the solution was neutralized with Amberlite IR-120 and 
filtered. MeOH was then evaporated to afford 1 (29 mg, 0.019 mmol, quant.) as a white 
brown solid which was then purified by preparative RP-HPLC using a linear gradient (58 to 
80% in 20 min) of MeCN (containing 6.6 mM of HCOOH) in H2O (containing 6.6 mM of 




H NMR (400 MHz, CD3OD): δ 8.46 (s, 2H, HC), 8.06 (d, 4H, J = 8.0 Hz, HB), 7.63 to 7.59 
(m, 3H, H9+A), 7.35 (d, 1H, J = 8.8 Hz, H7), 7.23 to 7.08 (m, 16H, H8+25+26+27+F), 6.82 (d, 2H, 
J = 8.4 Hz, H22), 6.61 (d, 2H, J = 8.4 Hz, H23), 5.01 (d, 1H, J = 8.0 Hz, H1), 4.95 to 4.73 (m, 
2H, H10), 4.56 to 4.29(m, 10H, H18+20+E), 4.21 (dd, 1H, J = 9.6 Hz, J = 4.8 Hz, H12), 3.91 (d, 
1H, J = 3.2 Hz, H4), 3.85 to 3.74 (m, 4H, H2+5+6), 3.59 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 
3.15 to 3.02 (m, 3H, H16+24), 2.86 (dd, 1H, J = 14.0 Hz, J = 5.2 Hz, H21), 2.78 to 2.64 (m, 3H, 
H14+24), 2.48 (dd, 1H, J = 14.0 Hz, J = 10 Hz, H21), 2.39 to 2.28 (m, 2H, H29), 2.06 to 1.97 (m, 
1H, H28), 2.00 (s, 3H, S-CH3), 1.83 to 1.72 (m, 1H, H28) 
13
C NMR (100 MHz, CD3OD): δ 
174.8, 174.2, 173.9, 170.7, 170.0, 169.2, 169.1, 157.8, 157.1, 156.7, 151.0, 141.5, 138.6, 
138.5, 138.4, 135.6 (x2), 134.1, 132.4, 132.0, 131.4, 130.4, 130.2 (x2), 130.0, 129.6, 129.2, 
128.0, 127.9, 125.3, 125.2, 118.7, 116.2, 102.9, 77.4, 74.9, 72.0, 70.2, 65.8, 62.5, 57.6, 56.2, 
52.8, 45.4, 45.3, 43.2, 42.4, 39.2, 37.9, 31.9, 31.2, 30.8, 15.2 LRFAB-MS (3-NOBA 




 LRESI-MS: m/z 1463 [M+H]
+
 HRESI-MS: m/z 
1463.5122 (calcd. for C73H79N10O21S 1463.5136 [M+H]
+
) m.p. 172-174°C 
 































































To a solution of S12 (500 mg, 0.58 mmol) in CH2Cl2 was added H-Phe-Met-OAll S7 (292 
mg, 1.5 equiv.) and DIPEA (0.2 mL, 2.0 equiv.). The mixture was then cooled to 0°C and 
EDC.HCl (167 mg, 1.5 equiv.) was added. After 30 minutes at 0°C, the reaction was allowed 
to reach room temperature and stirred overnight. The crude mixture was then extracted with 
1N NaOH, 1N HCl and brine. The organic phase was dried over MgSO4 and evaporated under 
reduced pressure. Purification by column chromatography over silica gel (CH2Cl2/MeOH: 2 
to 8% MeOH) afforded S13 (255 mg, 0.22 mmol, 37%) as a white yellow powder. 
 
1
H NMR (400 MHz, CDCl3/CD3OD: 7/3): δ 7.71 (d, 1H, J = 1.6 Hz, H9), 7.42 (dd, 1H, J = 
8.4 Hz, J = 1.6 Hz, H8), 7.28 (d, 1H, J = 8.4 Hz, H7), 7.26 to 7.12 (m, 7H, H25+28+29+30), 6.91 
(d, 2H, J = 8.4 Hz, H26), 5.86 to 5.76 (m, 1H, H22), 5.43 (dd, 1H, J = 10.4 Hz, J = 8 Hz, H2), 
5.40 (d, 1H, J = 3.6 Hz, H4), 5.24 (dd, 1H, J = 17.2 Hz, J = 1.6 Hz, H23), 5.17 (dd, 1H, J = 
10.4 Hz, J = 1.2 Hz, H23), 5.12 (d, 1H, J = 8.0 Hz, H1), 5.08 (dd, 1H, J = 10.4 Hz, J = 3.2 Hz, 
H3), 4.98 and 4.92 (d, AB system, 2H, J = 12.8 Hz, H10), 4.56 (dd, 1H, J = 8.4 Hz, J = 5.6 Hz, 
H18), 4.52 (d, 2H, J = 6.0 Hz, H21), 4.52 to 4.48 (m, 1H, H20), 4.27 (dd, 1H, J = 8.0 Hz, J = 6.4 
Hz, H12), 4.17 to 4.11 (m, 3H, H5+6), 3.84 to 3.77 (m, 2H, H14/16), 3.72 to 3.65 (m, 2H, H14/16), 
3.12 to 3.03 (m, 2H, H24+27), 2.95 to 2.84 (m, 2H, H24+27), 2.46 to 2.32 (m, 2H, H32), 2.22 (s, 
3H, H-Ac-Tyr), 2.12 (s, 3H, H-Ac), 2.07 to 2.03 (m, 4H, H31+ H-Ac), 2.00 (s, 3H, H-Ac), 
1.98 (s, 3H, S-CH3), 1.96 to 1.93 (m, 4H, H31+H-Ac) 
13
C NMR (100 MHz, CDCl3/CD3OD: 
7/3):): δ 173.3, 172.1, 171.8, 171.2, 171.1, 170.9, 170.8, 170.7, 170.4, 170.1, 168.5, 167.8, 
156.9, 150.0, 149.4, 141.3, 137.1, 135.4, 134.7, 133.7, 132.8, 131.9, 130.8, 130.6, 129.6, 
129.0, 128.8, 127.9, 127.2, 124.9, 122.0, 119.4, 119.1, 100.6, 71.7, 71.1, 68.5, 67.4, 66.4, 
65.5, 61.8, 56.9, 56.5, 54.9, 53.9, 52.0, 43.4, 42.9, 39.8, 37.9, 37.4, 33.3, 31.3, 30.2, 29.5, 
21.2, 20.9, 20.8 (x2), 20.7, 15.3, 15.0 LRFAB-MS (3-NOBA matrix): m/z 1181 [M+H]
+
 
HRFAB-MS (3-NOBA matrix): m/z 1181.3897 (calcd. for C54H65N6O22S 1181.3873 
[M+H]
+
) m.p. 196-198°C 
 




























































To a solution of S13 (210 mg, 0.18 mmol) in degassed CH2Cl2 (15 mL) were added 
phenylsilane (40 µL, 2.0 equiv.) and Pd(PPh3)4 (21 mg, 0.1 equiv.). The mixture was stirred 
overnight at room temperature and the solvent was evaporated in vacuo. The crude mixture 
was purified by column chromatography over silica gel (CHCl3/MeOH/AcOH: 1 to 8% 
MeOH, 1% AcOH) to afford S14 (139 mg, 0.12 mmol, 67%) as a white brown solid. 
 
1
H NMR (400 MHz, CDCl3/CD3OD: 8/2): δ 7.69 (s, 1H, H9), 7.40 (d, 1H, J = 8.4 Hz, H8), 
7.26 (d, 1H, J = 8.8 Hz, H7), 7.19 to 7.11 (m, 7H, H22+25+26+27), 6.90 (d, 2H, J = 8.0 Hz, H23), 
5.43 (dd, 1H, J = 10.4 Hz, J = 8.0 Hz, H2), 5.39 (d, 1H, J = 3.2 Hz, H4), 5.11 to 5.05 (m, 2H, 
H1+3), 4.97 and 4.89 (d, AB system, 2H, J = 12.8 Hz, H10), 4.57 (t, 1H, J = 6.8 Hz, H12/18), 
4.41 (bs, 1H, H20), 4.29 (t, 1H, J = 7.6 Hz, H12/18), 4.18 to 4.10 (m, 3H, H5+6), 3.83 to 3.65 (m, 
4H, H14+16), 3.11 to 3.04 (m, 2H, H21+24), 2.93 to 2.83 (m, 2H, H21+24), 2.38 to 2.37 (m, 2H, 
H29), 2.21 (s, 3H, H-Ac), 2.11 (s, 3H, H-Ac-Tyr), 2.05 (s, 3H, H-Ac), 1.99 to 1.94 (m, 11H, S-
CH3, H-Ac (x2), H28) 
13
C NMR (100 MHz, CDCl3/CD3OD: 8/2): δ 174.1, 173.0, 171.7, 
171.0, 170.8, 170.7, 170.6, 170.4, 170.2, 169.9, 156.7, 149.7, 149.2, 141.1, 136.9, 134.5, 
133.6, 132.6, 130.4, 129.4, 128.7, 127.1, 124.8, 121.8, 119.3, 100.4, 71.4, 70.9, 68.2, 67.1, 
65.3, 61.6, 56.7, 54.9, 52.1, 43.1, 42.8, 37.8, 37.3, 31.4, 30.1, 29.8, 21.1, 20.7 (x2), 20.6 (x2), 








































































To a solution of S14 (54 mg, 0.047 mmol) in MeOH (7 mL) cooled in an ice-water bath was 
added dropwise a 0°C solution of MeONa (26 mg, 10.0 equiv.) in MeOH (4 mL). Stirring was 
continued for one hour at 0°C and the solution was neutralized with Amberlite IR-120 and 
filtered. MeOH was then evaporated and the resulting mixture was purified by column 
chromatography over silica gel (CH2Cl2/MeOH: 10 to 50% MeOH) to afford 7 (38 mg, 0.041 
mmol, 87%) as a white brown solid which was then purified by preparative RP-HPLC using a 
linear gradient (27 to 45% in 15 min) of MeCN (containing 6.6 mM of HCOOH) in H2O 
(containing 6.6 mM of HCOOH) at a flow rate of 10 mL/min to give rotaxane 7 as a white 
solid. Purity (HPLC): >98%. 
 
1
H NMR (400 MHz, CD3OD): δ 7.76 (bs, 1H, H9), 7.41 (bs, 2H, H7+8), 7.26 to 7.24 (m, 4H, 
H25+26), 7.19 to 7.16 (m, 1H, H27), 7.04 (d, 2H, J = 8.0 Hz, H22), 6.69 (d, 2H, J = 8.0 Hz, H23), 
5.08 (d, 1H, J = 7.6 Hz, H1), 5.09 to 4.94 (m, 2H, H10), 4.63 (dd, 1H, J = 9.2 Hz, J = 4.4 Hz, 
H18), 4.30 (m, 2H, H12+20), 3.93 (d, 1H, J = 3.2 Hz, H4), 3.89 to 3.75 (m, 8H, H2+5+6+14+16), 
3.63 (dd, 1H, J = 9.6 Hz, J = 3.2 Hz, H3), 3.21 (dd, 1H, J = 14.4 Hz, J = 4.4 Hz, H24), 3.07 
(dd, 1H, J = 13.6 Hz, J = 5.6 Hz, H21), 2.98 (dd, 1H, J = 14.0 Hz, J = 9.6 Hz, H24), 2.81 (dd, 
1H, J = 13.6 Hz, J = 9.2 Hz, H21), 2.46 (t, 2H, J = 8.0 Hz, H29), 2.13 to 2.10 (m, 1H, H28), 
2.03 (s, 3H, S-CH3), 2.00 to 1.93 (m, 1H, H28) 
13
C NMR (100 MHz, CD3OD): δ 177.6, 
175.2, 172.8, 172.2, 171.6, 170.0, 158.4, 157.3, 151.0, 141.7, 138.7, 134.3, 132.6, 131.4, 
130.4, 129.5, 129.1, 127.8, 125.3, 118.8 , 116.3, 102.9, 77.2, 74.8, 72.0, 70.2, 66.1, 62.4, 58.6, 
56.5, 55.4, 43.9, 43.4, 38.4, 37.9, 33.6, 31.2, 15.3 LRESI-MS: m/z 953 [M+Na]
+
 LRESI-MS 
(negative mode): m/z 929 [M-H]
-
 HRESI-MS m/z 948.3287 (calcd. for C41H54N7O17S 
948.3297 [M+NH4]
+
) m.p. 158-160°C 
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H NMR spectra of thread 3 and rotaxane 4,  





H NMR spectra of Met-enkephalin prodrug 7 and rotaxane prodrug 1,  
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During the final months of my PhD, I was involved together with Dr. Dominik Heckmann, 
Dr. Daniel D’Souza and Dr. Stephen Goldup in the construction of a novel rotaxane-based 
molecular machine designed to sequentially synthesise an oligopeptide unit. In this project, I 
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Rotaxanes constitute interesting molecular architectures for the construction of 
nanoscale devices and have inspired numerous attempts to create artificial machines.
119
 In 
nature, the accurate synthesis of biopolymers such as nucleic acids or proteins relies primarily 
on complex macromolecular machines. The ribosome, for instance, is used in cells to catalyse 
the assembly of individual amino acids into polypeptides. The ribosome translates each codon 
expressed in the mRNA strand into a peptide chain using the appropriate amino acids 
provided by tRNA. The high level of processivity and accuracy displayed by the transcription 
machinery is the consequence of its unusual arrangement with the mRNA template.
120
 The 
ribosome forms a sort of dynamic clamp which holds the mRNA template, as in rotaxanes, 
and unidirectionaly shuttles along it to read and translate the genetic information. 
 
Therefore, encouraged by such a remarkable biological process we devised a rotaxane that 
might be capable of assembling a peptide from the amino acid information carried by the 
thread subunit. Thus our prototype rotaxane consists of a macrocycle, displaying catalyst and 
transporter properties, entrapped around a template thread possessing three distinctive amino 
acid stations (Scheme 4.1). 
 
Accordingly, following activation of the rotaxane machine, the macrocycle unit shuttles and 
catalyses the undocking of the first amino acid (AA1). Transport of AA1 along the thread and 
reaction with the second amino acid (AA2) simultaneously forms dipeptide AA1-AA2 and 
releases the active catalyst, which can in turn uncouple the dipeptide cargo from the thread. 






                                                 
119
 a) Balzani, V.; Credi, A.; Raymo, E. M.; Stoddart, J. F. Angew. Chem. Int. Ed. 2000, 39, 3348-3491; b) Kay, 
E. R. ; Leigh, D. A.; Zerbetto, F. Angew. Chem. Int. Ed. 2007, 46, 72-191. 
120
 Patrick, G. L. An Introduction to Medicinal Chemistry (Fourth Edition) 2009, Oxford University Press. 





Scheme 4.1 | Operation of the rotaxane-based peptide synthesiser 
 
 
The operation of our machine relies on acyl-transfer catalysis. Indeed the catalytic moiety 
carried by the macrocycle (a pyrrolidinopyridine, PPY) is designed to mediate the transfer of 
the amino acid building blocks to the adjacent station on the track. Each amino acid is 
anchored to the thread as a phenolic ester. Phenolic esters of the amino acids were chosen as 
acyl donors to maintain the balance between the stability needed for the synthesis of the target 




The macrocycle shuttles  
along the thread to transport 
AA1 to the next AA2 station 
PEPTIDE BOND FORMATION 
 
AA1-AA2 dipeptide is formed 
and the released catalyst-
bearing macrocycle can 
process again… 
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Consecutively the macrocycle transports the peptide as an activated pyridinium species to 































Scheme 4.2 | Acyl-transfer catalysis as a motor mechanism 
 
Such construction implies that the successive phenolic amino acid esters efficiently act as 
stoppers for the macrocycle, until the latter properly deactivates each station one after the 
other. Accordingly the high local concentration of the catalyst in the rotaxane architecture 
should drive the formation of the N-acyl pyridinium species which irreversibly reacts to form 
the new peptide bond. Moreover, high dilution conditions should preclude intermolecular 
reactions that would lead to unexpected peptide sequences. 
 
I.1. Preliminary study 
 
 A model system was designed in order to study the kinetics of transacylation of a 
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Scheme 4.3 | Transacylation on a tyrosine ester model 
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We observed by NMR spectroscopy the reaction of the tyrosine ester (33 µM in CDCl3 – the 
high dilution in which the molecular machine should work best) with benzylamine (1 equiv.) 
under the action of different amounts of the PPY catalyst. Results showed that PPY 
significantly catalyses the transacylation of phenolic esters under high dilution conditions, 
with a conversion approximatively 4-times higher than without catalyst (Figure 4.1). Despite 
the slow kinetics of the reaction (half-life of 200 hours), further acceleration is expected in the 
rotaxane structure since the interlocked macrocycle would provide a high local concentration 




Figure 4.1 | Transacylation on a tyrosine ester model observed  
by 
1




 Initially, we proposed the preparation of a rotaxane possessing the general structure 
depicted in Figure 4.2 using the CuCAAC active-template methodology recently reported in 
our group.
121
 Reaction of the alkyne thread with an azide stopper within the cavity of an 
endopyridine-bearing macrocycle should promote efficient access to the interlocked 
architecture. The alkyne thread was designed to consist of peptidic building blocks, each of 
them bearing two N-methyl(aminomethyl)benzoic acids and one tyrosine.  
                                                 
121
 Aucagne, V.; Hänni, K.; Leigh, D. A.; Lusby, P. J.; Walker, D. B. J. Am. Chem. Soc. 2006, 128, 2186-2187. 
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Therefore, each separated tyrosine station supports the different amino acids thus providing 
sequence information. Pyrrolidinopyridine (PPY) was chosen as the acyl-transfer catalyst and 










































Figure 4.2 | Proposed rotaxane-based peptide synthesiser 
 
Before reaching a final three-station peptide synthesiser we decided to prepare the shortened 
rotaxane version 4.1 possessing only one tyrosine ester (Scheme 4.4). This model would give 
essential information required to build an effective elongated rotaxane-based peptide 
synthesiser. 
 
Reaction of fragments 4.A and 4.B with aldehyde macrocycle 4.C would afford inactive 
aldehyde rotaxane 4.D, which should in turn be activated following oxime ligation with 
hydroxylamino substituted pyrrolidinopyridine 4.E.  
 
 







































































Scheme 4.4 | Convergent approach to model rotaxane 4.1 
 
II.1. Synthesis of aldehyde macrocycle 4.C 
 
 Synthesis of macrocycle 4.C started simply by preparation of building block 4.5. 
Reduction of commercially available 3-(4-hydroxyphenyl)propionic acid 4.2 afforded 
hydroxy phenol 4.3. Benzylation of the phenolic position followed by bromination of primary 
alcohol 4.4 afforded intermediate 4.5 in excellent yields (Scheme 4.5).  
 
 


























Scheme 4.5 | Synthesis of 4.5 
 
An organozinc derivative was prepared from bromide 4.5 using the procedure described by 
Huo.
122
 This was then subjected to a PEPPSI (Pyridine-Enhanced Precatalyst Preparation 
Stabilisation and Initiation)-catalysed Negishi coupling with dibromo pyridine 4.6 (prepared 




















































Scheme 4.6 | Synthesis of U-shape 4.7 
 
 
The U-shape 4.7 was debenzylated by hydrogenolysis using Pearlman’s catalyst (Pd(OH)2/C). 
Double Williamson macrocyclisation of bis-phenol 4.8 with 1,10-dibromodecane at high 
dilution afforded pyridine macrocycle 4.9 in 37% yield, which after TBDMS deprotection and 
Dess-Martin oxidation yielded aldehyde macrocycle 4.C (Scheme 4.7). 
 
                                                 
122
 Huo, S. Org. Lett. 2003, 5, 423-425. 
123
 Organ, M. G.; Avola, S.; Dubovyk, I.; Hadei, N.; Kantchev, E. A. B.; O’Brien, C. J.; Valente, C. Chem. Eur. 
J. 2006, 12, 4749-4755. 





































Scheme 4.7 | Synthesis of aldehyde macrocycle 4.C 
 
II.2. Synthesis of alkyne thread 4.B 
 
Thread building block 4.16 has been designed to serve as a monomer for the 
preparation of the multi-station rotaxane track. Boc- and Alloc-protected derivatives (4.11 and 












4.11 4.12  
 
Scheme 4.8 | Preparation of intermediates 4.11 and 4.12 
 
Boc-derivative 4.11 was coupled with tyrosine methyl ester hydrochloride to afford 4.13. 
Boc-deprotection afforded N-methyl benzylamine 4.14 which was further reacted with the 
Alloc-protected benzoic acid 4.12. Tyrosine methyl ester was hydrolysed to yield 4.16, which 
was as far as I progressed with this synthesis (Scheme 4.9). 




























































Scheme 4.9 | Synthesis of building block 4.16 
 
Coupling of the resulting carboxylic acid 4.16 with 3,3-diphenylpropylamine will give 
tyrosine derivative 4.17. Subsequent palladium-mediated Alloc deprotection will afford 
intermediate 4.18. Reaction of the resulting secondary amine 4.18 with 4-pentynoic acid will 
afford alkyne thread 4.19. Finally, formation of phenolic ester with N-Boc phenylalanine will 









































































Scheme 4.10 | Access to alkyne thread 4.B 
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II.3. Synthesis of pyrrolidinopyridine hydroxylamine 4.E 
 
 Hydroxylamine 4.E was prepared starting with pyrrolidinopyridine 4.20 (prepared by 
Dr. Dominik Heckmann) (Scheme 4.11). The hydroxylamine moiety was introduced by 
Mitsunobu reaction of alcohol 4.20 with N-hydroxyphtalimide 4.21. Hydrazinolysis of 4.21 




































Scheme 4.11 | Synthesis of fragment 4.E 
 
III. Discussion and outlook 
 
To date, aldehyde rotaxane 4.D has been successfully synthesised and isolated in a 
reasonable 35% yield. Assembly of the final machine was monitored by NMR. Acid-
catalysed oxime ligation of aldehyde rotaxane 4.D with hydroxylamine 4.E afforded the Boc-
deprotected one-station rotaxane TFA salt in short reaction times and nearly quantitative 
conversion by NMR. The mixture was then passed through a pad of potassium carbonate to 
give the one-station rotaxane 4.1 (Scheme 4.12).  



























































Scheme 4.12 | Recent results 
 
However, against all expectations, no evidence was found to demonstrate the function of our 
machine. The intramolecular catalyst did not react with the tyrosine ester and no reaction 
could be observed, even on addition of an external nucleophile. As initial model studies on the 
PPY-catalysed aminolysis of tyrosine esters displayed a reaction rate proportional to the 
catalyst concentration, this would mean that one premise – a high local concentration of 
catalyst – was not met by the system. Saponification (MeOH, K2CO3) resulted in cleavage of 
the ester and loss of the macrocycle for both rotaxanes 4.D and 4.1. 
 
Accordingly, several factors can be considered. First of all, phenolic esters are too stable 
against the attack of the trans-acylation catalyst, that means the equilibrium between the acyl-
pyridinium and the ester lies almost totally on the side of the ester. On the other hand, folding 
of the thread can prevent the shuttle of the macrocycle which then cannot reach the amino 
acid station. Our intention was that this would be prevented by the use of N-methylated 
peptide bonds in the thread as such bonds tend to decrease the energy barrier between cis- and 
trans-amide bonds thus favouring flexibility of the backbone. Indeed a general line 
broadening along with the presence of two sets of signals per N-methylated amide bond has 
been observed in NMR spectra, which means that the interconversion between cis- and trans 
peptide bonds occurs on the NMR-timescale.  
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Finally, it can be envisaged that the acyl-transfer catalyst grafted on the macrocycle is 
inappropriate. Different solutions are now being thought of to construct an improved 2
nd
 
generation design for the rotaxane-based peptide synthesiser (e.g. labile o-nitro-tyrosine esters 
on the thread, an additional thiol-based transporter on the macrocycle). 
 

















To a solution of Zn dust (2.31 g, 1.5 equiv.) in NMP (24 mL, 1M) was added I2 (299 mg, 0.05 
equiv.). After the coloration vanished 3-[4-(benzyloxy)phenyl]propyl bromide (7.18 g, 23.50 
mmol) was added and the mixture heated at 80°C for 7 hours. The mixture was then allowed 
to reach room temperature. In another flask, PEPPSI (Pyridine-Enhanced Precatalyst 
Preparation Stabilisation and Initiation) catalyst (160 mg, 0.01 equiv.) was dissolved in THF 
(24 mL) / NMP (24 mL) and LiBr (4.10 g, 2.0 equiv.) was added. When all solids had 
dissolved, the organozinc solution was added followed by the substituted 2,6-dibromopyridine 
(2.70 g, 0.3 equiv.). The resulting solution was then stirred overnight at room temperature 
and, after this time the mixture was diluted with diethyl ether and brine was added. The 
aqueous layer was extracted with diethyl ether and the combined organic layers washed 
several times with water. After drying (MgSO4), the solution was filtered and concentrated 
under reduced pressure. Purification by column chromatography over silica gel (petroleum 




H NMR (400 MHz, CDCl3): δ 7.50 to 7.35 (m, 10H, HI+J+K), 7.19 (d, 4H, J = 8.0 Hz, HF), 
6.96 to 7.00 (m, 6H, HB+G), 5.09 (s, 4H, HH), 4.76 (s, 2H, HA), 2.89 (t, 4H, J = 7.6 Hz, HC), 
2.71 (t, 4H, J = 7.6 Hz, HE), 2.07 to 2.15 (m, 4H, HD), 1.05 (s, 9H, H-Si-tBu), 0.20 (s, 6H, H-





C NMR (100 MHz, CDCl3): δ 161.4, 157.0, 151.0, 137.3, 134.7, 129.4, 128.6, 
127.9, 127.5, 117.0, 114.7, 70.0, 63.8, 38.0, 34.7, 32.0, 26.0 LRESI-MS: m/z 672 [M+H]
+
 















To a solution of 4.7 (1.09 g, 1.62 mmol) in MeOH (50 mL)/DMF (10 mL) was added 
Pd(OH)2 on carbon (109 mg, 10% by weight). The solution was degassed under low pressure 
and H2 was added. After two days stirring, the resulting mixture was filtered over celite and 
the pad washed with MeOH. The solution was then concentrated under reduced pressure and 
purified by column chromatography over silica gel (petroleum ether/ethyl acetate: 15 to 50% 




H NMR (400 MHz, CDCl3): δ 7.23 (s, 2H, HB), 7.12 (d, 4H, J = 8.4 Hz, HF), 6.94 (d, 4H, J 
= 8.4 Hz, HG), 4.96 (s, 2H, HA), 3.05 (t, 4H, J = 7.6 Hz, HC), 2.76 (t, 4H, J = 7.6 Hz, HE), 2.15 
to 2.23 (m, 4H, HD), 1.20 (s, 9H, H-Si-tBu), 0.37 (s, 6H, H-SiMe2) 
13
C NMR (100 MHz, 
CDCl3): δ 163.0, 161.4, 154.8, 152.5, 133.0, 129.4, 117.7, 115.4, 63.8, 37.1, 34.8, 32.2, 26.0 
LRESI-MS: m/z 492 [M+H]
+


























To a solution of 4.8 (670 mg, 1.36 mmol) in DMF (680 mL, 2 mM) was added K2CO3 (3.76 
g, 20.0 equiv.) and 1,10-dibromodecane (409 mg, 1.0 equiv.) and the resulting suspension 
stirred at 70°C for two days. The solvent was removed under reduced pressure and the residue 
dissolved in Ethyl acetate. This solution was washed with sat. aqueous NaHCO3 and the 
aqueous layer extracted with ethyl acetate. The resulting organic layers were washed with 
water, dried (MgSO4) and concentrated in vacuo. Purification by column chromatography 
over silica gel (petroleum ether then petroleum ether/ethyl acetate: 10% ethyl acetate) yielded 
4.9 as a colourless oil that crystallised upon standing (314 mg, 0.50 mmol, 37%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.06 (d, 4H, J = 8.4 Hz, HF), 6.93 (s, 2H, HB), 6.77 (d, 4H, J 
= 8.4 Hz, HG), 4.70 (s, 2H, HA), 3.94 (t, 4H, J = 6.4 Hz, HH), 2.79 (t, 4H, J = 7.6 Hz, HC), 2.59 
(t, 4H, J = 8.0 Hz, HE), 1.95 to 2.03 (m, 4H, HD), 1.75 (qt, 4H, J = 6.8 Hz, HI), 1.43 to 1.46 
(m, 4H, HJ), 1.31 (bs, 8H, HK+L), 0.97 (s, 9H, H-Si-tBu), 0.13 (s, 6H, H-SiMe2) 
13
C NMR 
(100 MHz, CDCl3): δ 161.5, 157.3, 134.5, 129.4, 117.2, 114.6, 67.6, 63.9, 38.2, 34.9, 32.6, 
29.0, 28.8, 28.4, 26.1, 25.7 LRESI-MS: m/z 630 [M+H]
+
 HRESI-MS: m/z 630.4328 (calcd. 
for C40H60NO3Si 630.4337 [M+H]
+























To a solution of 4.9 (100 mg, 0.16 mmol) in THF (5 mL) cooled to 0°C was added TBAF (0.2 
mL, 1M in THF) and the solution stirred for 30 minutes at 0°C. The resulting mixture was 
then concentrated under reduced pressure and purified by column chromatography over silica 
gel (petroleum ether then petroleum ether/ethyl acetate: 20 to 50% ethyl acetate) yielded 4.10 
as a white solid (83 mg, 0.16 mmol, quant.). 
 
1
H NMR (400 MHz, CDCl3): δ 7.05 (d, 4H, J = 8.4 Hz, HF), 6.95 (s, 2H, HB), 6.77 (d, 4H, J 
= 8.4 Hz, HG), 4.65 (s, 2H, HA), 3.94 (t, 4H, J = 6.4 Hz, HH), 2.79 (t, 4H, J = 7.6 Hz, HC), 2.58 
(t, 4H, J = 8.0 Hz, HE), 1.95 to 2.03 (m, 4H, HD), 1.72 to 1.79 (m, 4H, HI), 1.45 (t, 4H, J = 6.4 
Hz, HJ), 1.31 (bs, 8H, HK+L) 
13
C NMR (100 MHz, CDCl3): δ 161.7, 157.3, 150.6, 134.4, 
129.4, 117.7, 114.6, 67.7, 63.7, 38.0, 34.9, 32.4, 28.9, 28.8, 28.4, 25.7 LRESI-MS: m/z 517 
[M+H]
+






















To a solution of macrocycle 4.10 (228 mg, 0.44 mmol) in CH2Cl2 (20 mL) was added Dess-
Martin periodinane (234 mg, 1.25 equiv.) at 0°C. The reaction was then allowed to reach 
room temperature and stirred for 4 hours. The resulting mixture was then concentrated under 
reduced pressure and purified by column chromatography over silica gel (petroleum 
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ether/ethyl acetate: 20% ethyl acetate) to yield 4.C as a colourless oil that crystallised upon 
standing (210 mg, 0.41 mmol, 93%). 
 
1
H NMR (400 MHz, CDCl3): δ 10.03 (s, 1H, HA), 7.38 (s, 2H, HB), 7.08 (d, 4H, J = 8.4 Hz, 
HF), 6.80 (d, 4H, J = 8.4 Hz, HG), 3.96 (t, 4H, J = 6.4 Hz, HH), 2.91 (t, 4H, J = 7.6 Hz, HC), 
2.63 (t, 4H, J = 7.6 Hz, HE), 2.09 to 2.02 (m, 4H, HD), 1.80 to 1.74 (m, 4H, HI), 1.48 to 1.45 
(m, 4H, HJ), 1.33 (bs, 8H, HK+L) 
13
C NMR (100 MHz, CDCl3): δ 192.4, 163.4, 157.3, 142.4, 
134.0, 129.4, 118.8, 114.5, 67.5, 37.9, 34.8, 32.1, 28.9, 28.7, 28.3, 25.6 LRESI-MS: m/z 547 
[M+Na]
+
 HRESI-MS: m/z 514.3318 (calcd. for C34H44NO3 514.3316 [M+H]
+









To a solution of N-methylated 4-aminomethylbenzoic acid (12.00 g, 26.80 mmol) in THF-
H2O (200 mL-100 mL) cooled to 0°C was added Et3N (7.5 mL, 2.0 equiv.) and Boc2O (5.90 
g, 1.0 equiv.). The resulting mixture was allowed to reach room temperature and then stirred 
overnight. After concentration under reduced pressure, the aqueous layer was extracted with 
Et2O and acidified with 1N HCl. The resulting acidic aqueous layer was then extracted with 
ethyl acetate, dried (MgSO4) and concentrated to give 4.11 as a white powder (7.50 g, 28.30 
mmol). (4.11 Registry Number: 210963-04-05) 
 
1
H NMR (400 MHz, CDCl3): δ 8.08 (d, 2H, J = 8.0 Hz, H4), 7.32 (d, 2H, J = 8.0 Hz, H3), 
4.49 (bs, 2H, H2), 2.90 and 2.82 (m, 3H, H1), 1.50 and 1.45 (m, 9H, H-tBu) 
13
C NMR (100 
MHz, CDCl3): δ 171.8, 156.4, 155.9, 144.5, 130.6, 128.5, 127.6, 127.1, 80.3, 52.7, 52.0, 
34.5, 34.4, 28.5 LRESI-MS: m/z 266 [M+H]
+
 HRESI-MS: m/z 266.1382 (calcd. for 
C14H20NO4 166.1387 [M+H]
+














To a solution of N-methylated 4-aminomethylbenzoic acid (10.40 g, 23.30 mmol) in THF-
H2O (100 mL-100 mL) cooled to 0°C was added Et3N (6.5 mL, 2.0 equiv.) and allyl 
CHAPT. 4 | TOWARDS A SYNTHETIC MOLECULAR PEPTIDE SYNTHESISER 
155 
 
chloroformate (2.5 mL, 1.0 equiv.). The resulting mixture was then allowed to reach room 
temperature and stirred overnight. After concentration under reduced pressure, the aqueous 
layer was extracted with Et2O and acidified with 1N HCl. The resulting acid layer was then 
extracted with ethyl acetate, dried (MgSO4) and concentrated to give 4.12 as a white powder 
(3.90 g, 15.70 mmol). 
 
1
H NMR (400 MHz, CDCl3): δ 11.00 (bs, 1H, COOH), 8.08 (d, 2H, J = 8.0 Hz, H7), 7.31 to 
7.36 (m, 2H, H6), 5.88 to 6.01 (m, 1H, H2), 5.18 to 5.36 (m, 2H, H1), 4.66 (bs, 2H, H3), 4.57 
(bs, 2H, H5), 2.94 and 2.89 (m, 3H, H4) 
13
C NMR (100 MHz, CDCl3): δ 171.7, 156.9, 156.3, 
143.8, 133.0, 132.9, 130.7, 128.7, 127.8, 127.3, 117.8, 117.6, 66.5, 52.6, 52.3, 34.8, 34.0 
LRESI-MS: m/z 250 [M+H]
+
 HRESI-MS: m/z 250.1069 (calcd. for C13H16NO4 250.1074 
[M+H]
+



















To a solution of 4.11 (2.45 g, 9.20 mmol) and HCl.TyrOMe (2.14 g, 1.0 equiv.) in DMF (50 
mL) was added EDC (1.80 g, 1.0 equiv.), HOBt (1.40 g, 1.1 equiv.) and DIPEA (1.8 mL, 1.1 
equiv.). After stirring overnight the solution was concentrated under reduced pressure. The 
resulting oil was diluted with ethyl acetate, washed with water, brine, dried (MgSO4) and 
concentrated. Purification by column chromatography over silica gel (petroleum ether/ethyl 
acetate: 50 to 65% ethyl acetate) yielded 4.13 as a white solid (3.10 g, 7.00 mmol, 76%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.59 (d, 2H, J = 7.6 Hz, H4), 7.26 (d, 2H, J = 7.6 Hz, H3), 
6.97 (d, 2H, J = 8.4 Hz, H8), 6.75 (d, 2H, J = 8.4 Hz, H9), 6.58 (d, 2H, J = 7.6 Hz, H5), 5.04 
(dd, 1H, J = 13.2 Hz, J = 5.6 Hz, H6), 4.45 (bs, 2H, H2), 3.77 (bs, 3H, OMe), 3.21 and 3.13 
(dd, AB system, 2H, J = 14.0 Hz, J = 5.6 Hz, H7), 2.85 and 2.80 (m, 3H, H1), 1.49 and 1.45 
(m, 9H, H-tBu) 
13
C NMR (100 MHz, CDCl3): δ 172.3, 155.3, 132.9, 130.6, 127.5 (x2), 
115.7, 53.8, 52.6, 37.2, 34.4, 28.6 LRESI-MS: m/z 466 [M+Na]
+
 HRESI-MS: m/z 465.1997 
(calcd. for C24H30N2O6Na 465.1996 [M+Na]
+
) m.p. 48-50°C 
 




















Trifluoroacetic acid (19.5 mL, 40.0 equiv.) was added dropwise to a solution of 4.13 (2.90 g, 
6.60 mmol) in CH2Cl2 (70 mL) at 0°C. After 30 minutes at 0°C, the solution was stirred for a 
further 2 hours at room temperature and then cooled to 0°C. After neutralisation with a 
saturated solution of NaHCO3, the mixture was extracted with a CHCl3/iPrOH (3/1, v/v) 




H NMR (400 MHz, CD3OD): δ 7.69 (d, 2H, J = 8.0 Hz, H4), 7.37 (d, 2H, J = 8.0 Hz, H3), 
7.02 (d, 2H, J = 8.4 Hz, H7), 6.65 (d, 2H, J = 8.4 Hz, H8), 4.73 (dd, 1H, J = 9.2 Hz, J = 6.0 
Hz, H5), 3.76 (bs, 2H, H2), 3.67 (bs, 3H, OMe), 3.14 and 2.98 (dd, AB system, 2H, J = 14.0 
Hz, J = 6.0 Hz, H6), 2.37 (s, 3H, H1) 
13
C NMR (100 MHz, CD3OD): δ 173.8, 169.9, 157.4, 
143.3, 134.4, 131.3, 129.8, 129.1, 128.8, 116.3, 56.2, 55.5, 52.8, 37.4, 35.2 LRFAB-MS (3-
NOBA matrix): m/z 343 [M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 343.1645 (calcd. for 
C19H23N2O4 343.1652 [M+H]
+






























To a solution of 4.12 (2.00 g, 1.2 equiv.) and 4.14 (1.20 g, 4.80 mmol) in DMF (26 mL) was 
added EDC (1.20 g, 1.2 equiv.). After stirring overnight at room temperature the solution was 
concentrated under reduced pressure. The resulting oil was extracted with ethyl acetate, 
washed with water, brine, dried (MgSO4) and concentrated. Purification by column 
chromatography over silica gel (petroleum ether/ethyl acetate: 50 to 100% ethyl acetate) 
yielded 4.15 as a white solid (2.10 g, 3.70 mmol, 77%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.71 (d, 2H, J = 8.0 Hz, H11), 7.39 to 7.20 (m, 6H, H6+7+10), 
6.94 (d, 2H, J = 8.0 Hz, H15), 6.75 (d, 2H, J = 8.4 Hz, H16), 6.63 (bs, 1H, H12), 5.94 (bs, 1H, 
CHAPT. 4 | TOWARDS A SYNTHETIC MOLECULAR PEPTIDE SYNTHESISER 
157 
 
H2), 5.33 to 5.21 (m, 2H, H3), 5.02 (dd, 1H, J = 13.2 Hz, J = 5.6 Hz, H13), 4.77 to 4.50 (m, 
4H, H5+9), 4.63 (bs, 2H, H1), 3.76 (s, 3H, OMe), 3.20 and 3.12 (dd, AB system, 2H, J = 14.0 
Hz, J = 5.6 Hz, H14), 3.06 to 2.88 (m, 6H, H4+8) 
13
C NMR (100 MHz, CDCl3): δ 172.3, 
166.8, 155.8, 141.0, 139.5, 134.9, 133.3, 132.9, 130.5, 128.4, 127.9, 127.7, 127.6, 127.5, 
127.2, 126.9, 117.7, 117.6, 115.8, 66.5, 55.1, 53.8, 52.6, 52.4, 52.2, 50.9, 37.5, 37.1, 34.7, 
33.9 LRESI-MS: m/z 575 [M+H]
+
 HRESI-MS: m/z 574.2548 (calcd. for C32H36N3O7 
574.2548 [M+H]
+






























To a solution of 4.15 (3.10 g, 5.40 mmol) in MeOH (50 mL) - H2O (20 mL) cooled in an ice-
water bath was added dropwise a 0°C solution of NaOH (1.10 g, 5.0 equiv.) in MeOH (15 
mL). Stirring was continued for 30 minutes at 0°C then the solution was allowed to reach 
room temperature and stirred for 4 hours. MeOH was then evaporated under reduced pressure 
and the resulting mixture extracted with CHCl3. The aqueous layer was acidified with 1N HCl 
and then extracted with a CHCl3/iPrOH (3/1, v/v) mixture, dried (MgSO4) and evaporated to 
give 4.16 (3.00 g, 5.40 mmol, quant.) as a white solid. 
 
1
H NMR (400 MHz, CD3OD): δ 8.41 (d, 0.5H, J = 8.0 Hz, H12), 7.76 to 7.23 (m, 8H, 
H6+7+10+11), 7.09 (d, 2H, J = 8.4 Hz, H15), 6.69 (d, 2H, J = 8.4 Hz, H16), 5.96 (bs, 1H, H2), 5.34 
to 5.14 (m, 2H, H3), 4.79 to 4.52 (m, 7H, H1+5+9+13), 3.24 (dd, 1H, J = 14.0 Hz, J = 4.8 Hz, 
H14), 3.05 to 2.88 (m, 7H, H4+8+14) 
13
C NMR (100 MHz, CD3OD): δ 174.2, 173.7, 173.5, 
169.6, 169.5, 158.2, 157.7, 157.3, 142.2, 141.8, 141.1, 136.0, 134.5, 134.3, 134.2, 134.1, 
131.2, 129.1, 129.0 (x2), 128.8, 128.5, 128.2, 127.9, 117.9, 117.8, 116.3, 67.4, 56.1, 55.8, 
53.0, 52.8, 51.6, 49.9, 38.0, 37.3, 35.1, 34.3, 34.0 LRFAB-MS (3-NOBA matrix):  m/z 560 
[M+H]
+
 HRFAB-MS (3-NOBA matrix): m/z 560.2391 (calcd. for C31H34N3O7 560.2391 
[M+H]
+
) m.p. 76-78°C 
 




















Compound 4.20 (585 mg, 3.30 mmol), N-hydroxyphthalimide (589 mg, 1.1 equiv.) and PPh3 
(1.10 g, 1.3 equiv.) were dissolved in THF (30 mL) and cooled to 0°C. DIAD (0.84 mL, 1.3 
equiv.) was then slowly added and then the reaction mixture was allowed to reach 
temperature. After overnight stirring, the solution was concentrated and purified by column 
chromatography over silica gel twice (first: DCM/MeOH: 2% to 20% MeOH, second: 
DCM/MeOH/Et3N: 2% to 3% MeOH, 0.5% Et3N) yielding 4.21 as a white solid (735 mg, 
2.28 mmol, 69%). 
 
1
H NMR (400 MHz, CDCl3): δ  8.15 (d, 2H, J = 6.4 Hz, H1), 7.82 to 7.70 (m, 4H, H8+9), 6.36 
(d, 2H, J = 6.4 Hz, H2), 4.25 (dd, 1H, J = 9.2 Hz, J = 6.4 Hz, H7), 4.15 (dd, 1H, J = 8.8 Hz, J 
= 7.6 Hz, H7), 3.58 (dd, 1H, J = 10.0 Hz, J = 7.6 Hz, H6), 3.43 to 3.35 (m, 1H, H3), 3.31 (dd, 
2H, J = 10.0, J = 6.8 Hz, H3+6), 2.88 to 2.77 (m, 1H, H5), 2.28 to 2.20 (m, 1H, H4), 2.00 to 
1.91 (m, 1H, H4) 
13
C NMR (100 MHz, CDCl3): δ  163.5, 151.7, 149.1, 134.7, 128.8, 123.6, 





m/z 324.1343 (calcd. for C18H18N3O3 324.1343 [M+H]
+















Compound 4.21 (155 mg, 0.48 mmol) was dissolved in EtOH (4 mL) and hydrazine hydrate 
(0.026 mL, 1.1 equiv.) was added. The mixture was heated at 50°C for 4 hours and then 
filtered through cotton wool. The filtrate was then concentrated under reduced pressure and 
the resulting mixture purified by column chromatography over silica gel (DCM/MeOH: 5 to 
15% MeOH then DCM/MeOH/Et3N: 5 to 15% MeOH, 1% Et3N) yielding 4.E as a colourless 
oil (76 mg, 0.39 mmol, 81%). 
 




H NMR (400 MHz, CDCl3): δ  8.10 (d, 2H, J = 6.4 Hz, H1), 6.29 (d, 2H, J = 6.4 Hz, H2), 
5.38 (bs, 2H, NH2), 3.67 (dd, 1H, J = 10.0 Hz, J = 6.4 Hz, H7), 3.58 (dd, 1H, J = 9.6 Hz, J = 
7.6 Hz, H7), 3.38 (dd, 1H, J = 9.6 Hz, J = 7.6 Hz, H6), 3.34 to 3.20 (m, 2H, H3), 3.03 (dd, 1H, 
J = 9.6 Hz, J = 6.8 Hz, H6), 2.68 to 2.58 (m, 1H, H5), 2.12 to 2.04 (m, 1H, H4), 1.81 to 1.68 
(m, 1H, H4) 
13
C NMR (100 MHz, CDCl3): δ 151.7, 149.1, 106.9, 77.5, 50.0, 46.3, 37.4, 27.9 
LRESI-MS: m/z 194 [M+H]
+












Peptides unambiguously represent expanding therapeutic targets and are likely prone 
to become the drugs of choice for the treatment of many important diseases such as cancer. 
Most of the biological processes in life are tightly controlled by peptides in an extraordinarily 
selective fashion. Therefore molecular diversity along with high selectivity constitute the 
cornerstone of peptide drug development. Despite such potential, a limited number of 
peptides are currently approved because pre-systemic degradation and poor membrane 
penetration restrict their use. In spite of the many advances reached in improving peptide oral 
administration, few approaches retain the integrity of the peptide molecular structure. The 
peptidomimetic approach rationally imitates bioactive peptides and integrates their 
pharmacophoric elements into rigid structures, the final resemblance of which to the original 
peptide is hardly distinguishable. The prodrug approach represents a more versatile strategy 
since the peptide is only temporarily modified to enhance its pharmaceutical profile. The 
more promising targeted prodrugs additionally allow the controlled and selective delivery of 
drugs to specific organs, which is essential in the case of anticancer chemotherapy. Another 
encouraging alternative is the derivatisation of peptides into rotaxane architectures. In this 
approach the physicochemical properties of a peptide thread are remarkably modified by its 
encapsulation within a macrocycle.  
 
During this PhD thesis we tried to design, synthesise and study some novel innovative 
devices aiming at protecting, targeting and delivering peptides to tumour cells. This project 
has been conducted as a collaboration between the Gesson group (Poitiers, France) and the 
Leigh group (Edinburgh, Scotland) specialised in glycosylated prodrugs for anticancer 
chemotherapy and peptide rotaxane assembly respectively. Therefore based on the knowledge 
acquired by the two universities we attempted to construct some enzyme-activated peptide 









Towards a model rotaxane-based peptide prodrug 
 
First of all we focused on the preparation of a simple model rotaxane-based prodrug. 
We constructed threads consisting of a trigger, a self-immolative spacer and a model 
stoppered glycine-based peptide which has commonly been used for the templated assembly 
of peptide rotaxanes. However the construction of such threads has to provide the essential 
features required for rotaxane synthesis. Indeed in the clipping approach the thread has to 
present final bulky stoppers indispensable for the mechanical lock of the macrocycle unit. As 
a consequence, modification of the classic prodrug design was necessary to access the 
interlocked device. Therefore we examined some of the spacers developed by Gesson et al. 
and found that the nitro-arylmalonaldehyde was a good candidate. Thus associating this 
spacer with the stoppered glycylglycine model peptide furnished the crucial elements to 
assemble the first model rotaxane (Scheme 1). Unfortunately we found difficulty in isolating 
































Scheme 1 | The first model rotaxane prodrug incorporating the arylmalonaldehyde spacer 
 
Among the self-immolative spacers developed within Gesson group, the benzyloxycarbonyl 
one is quite attractive. Indeed a glucuronylated prodrug incorporating this motif (HMR 1826) 
has demonstrated valuable results in vivo. Accordingly, we concentrated our efforts on 
derivatising this spacer to obtain an effective stopper for this side of the molecule. Spacers are 
crucial units in prodrugs: they move the drug away from the trigger for efficient enzymatic 
recognition and release the drug after activation of the prodrug. Therefore careful 






The “allyl spacer” was the first solution we explored. Simply derived from HMR 1826, this 
new spacer appeared to completely inhibit the recognition of the glucuronide motif (Scheme 
2). Therefore a galactoside derivative was synthesised and proved to be hydrolysed by E. coli 
β-galactosidase, albeit with prolonged reaction time. This provided the starting point of our 




















Scheme 2 | Preliminary evaluation of the “allyl spacer” 
 
Accordingly we prepared the galactosylated prodrug thread and its corresponding rotaxane for 
use in an ADEPT protocol. However while the prodrug thread released the model peptide, the 
rotaxane proved to be insoluble in water thus preventing its enzymatic activation. As a result 
we explored the functionalisation of the macrocycle unit in order to tune the solubility of the 
model rotaxane prodrug. In this direction, two PEG-grafted rotaxanes were successfully 
synthesised and evaluated (Scheme 3). Enzymatic studies with E. coli β-galactosidase 
revealed that while the machine liberates the peptide, the release is significantly slowed down 
in comparison with the non-interlocked prodrug. This can be explained by the fact that the 
supplementary allyl group still hinders the glycosidic bond. Moreover its position on the 
spacer allows the macrocycle to shuttle close to the carbohydrate moiety resulting in a 






















































































































Scheme 3 | The water-soluble PEG-grafted rotaxane 
 
In the light of these results we decided to construct a new model rotaxane. The bis-
galactosylated system appeared quite interesting in two respects. Indeed the supplementary 
galactose unit is placed one position away from the o-nitro galactose and the presence of two 







































Scheme 4 | The bis-galactosylated model rotaxane prodrug 
 
Nevertheless it appeared that such modifications tend to complicate the enzymatic release of 
the model peptide where compared with the non-interlocked prodrug. Unfortunately the 
rotaxane, even though flanked with two galactose units, is once again insoluble in water. 








Protection and targeted delivery of Met-enkephalin 
 
On the other hand, we concentrated our efforts on applying our concept to the 
anticancerous Met-enkephalin pentapeptide (H-TyrGlyGlyPheMet-OH). Indeed the opioid 
peptide displays the essential glycyl residue for templating the assembly of peptide rotaxane 
and CPK models demonstrated that its C-terminal amino acids (PheMet) constitute a natural 
stopper for the amide-based macrocycle. In addition the models also showed that the simplest 
non-modified HMR 1826 spacer along with the adjacent tyrosine residue effectively block the 











































Scheme 5 | The galactosylated Met-enkephalin rotaxane prodrug 
 
Hence we prepared the Met-enkephalin rotaxane prodrug along with its non-interlocked 
derivative. Enzymatic studies revealed that the rotaxane efficiently and rapidly releases the 
peptide after the action of E. coli β-galactosidase. This finding reinforces the idea that 
confining the macrocycle far away from the trigger results in enhanced recognition and 
delivery kinetics of the encapsulated peptide. Moreover the solubility of the rotaxane was 
assured by the presence of the C-terminal carboxylic acid, suggesting that glucuronylated 
rotaxane should present satisfying water solubility. The protective effect of the macrocycle 
was also demonstrated with two different proteases which are largely responsible for the poor 
bioavailability of Met-enkephalin. Moreover, experiments conducted in human plasma 
provided evidence for the high stability of the rotaxane in comparison with Met-enkephalin 







Overall, these studies evidenced that rotaxane-based peptide prodrugs represent a 
valuable innovative concept for the delivery of bioactive peptides. We demonstrated that, in a 
simple rotaxane system, the device efficiently protects and delivers a peptide following 
specific enzyme-mediated activation.  However to reach a generally applicable device, several 
points have to be considered. On one hand, a crucial prerequisite is that the peptide has to 
possess at least one glycine residue and present a natural C-terminal stopper. Furthermore 
another stopper has to be constructed on the prodrug thread. While we focused in the model 
study on adding a hindering component on the spacer unit, the Met-enkephalin rotaxane 
demonstrated that locking the macrocycle away from the trigger-spacer conjugate results in 
increased performance of the rotaxane. Over and above the considerations above, the 
hydrophilic character of the rotaxane has to be finely tuned since good water solubility is 
essential for enzymatic activation.  
 
Consequently an efficient prodrug thread can be rationally devised considering the 
preliminary results presented in this thesis to efficiently reach a rotaxane-based delivery 
















Scheme 6 | Enhanced design of the prodrug thread 
 
Alternatively (if the N-terminal amino acid is not as bulky as necessary), modification of 
HMR 1826 spacer in the m-positions or in the benzylic position should contain the 
macrocycle away from the glycosidic bond. Furthermore, 2
nd
 generation rotaxanes can be 
devised from that point. Indeed we demonstrated with the “allyl based” models that the 
macrocycle can be easily functionalised. As a consequence supplementary tools can be 
grafted on the rotaxane to reach multifunctional advanced materials (e.g. labels, ligands, drugs 




A glucuronic acid should favour 
enhanced water solubility SPACER 
 
HMR 1826 spacer 
* fast release of the peptide 
PEPTIDE 
 
* one Gly residue at least 
* C-terminal natural stopper 
* one N-terminal bulky amino acid 
Alternative modifications to access  






























Scheme 7 | 2
nd
 generation rotaxane-based delivery devices 
 
The toxicity of the macrocycles (functionalised or not) must also be evaluated. If their toxicity 
is proved against cancer then our devices can present combined toxicity or simply be used to 
target and deliver a cytotoxic macrocycle to tumour cells. Therefore in this case the thread 
could be easily devised and incorporate additional functions. 
 
Toward a molecular peptide synthesiser 
 
In the final part of this PhD thesis we described the design of a rotaxane-based 
machine that, following the information carried on its thread, would in principle be able to 
processively assemble a sequence-specific peptide oligomer.  While we successfully 
synthesised a one-station model rotaxane (Scheme 8), the first experiments we conducted did 
not result in the expected outcomes. However the study is only at an early stage and many 































Incorporation of additional tools 
(e.g. labels, ligands, drugs) 
